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Neutrophils constitute a significant proportion of recruited immune cells in many tu-
mours. While activated neutrophils are able to exert robust anti-tumoural effects, more
often they provide growth and survival signals that promote tumour progression. The
mechanisms by which neutrophils impact tumours are unclear.
The relationship between the immune system and cancer is particularly evident
in cutaneous squamous cell carcinoma (CSCC). To investigate the role and potential
prognostic value of neutrophils in CSCC, neutrophil numbers in circulation and in the
tumours of non-therapeutically immuno-suppressed individuals was examined for asso-
ciations with markers of increased risk of metastasis and overall survival. A circulating
neutrophil count of >3.5×109/L was associated with decreased overall survival. More-
over, three out of the four patients that developed metastases in the study cohort had
circulating neutrophil counts above this threshold. When tumour tissue was exam-
ined for CD66b+ and myeloperoxidase (MPO)+ neutrophils, there was a significantly
higher number of neutrophils in tumours with a thickness ≥ 5mm. Although there
were no significant associations with the number of MPO positive cells or levels of ex-
tracellular MPO and high-risk tumour characteristics, MPO was present in all CSCC
tumours, particularly in necrotic core regions. This suggests that neutrophils could
have a role in the progression of CSCC. It also highlights that MPO from activated or
dead neutrophils was present in the CSCC tumour microenvironment, and could have
a functional role in promoting tumour development.
Neutrophils can undergo necrotic cell death, which promotes tissue damage and an
acute inflammatory response. There is considerable interest in neutrophil extracellular
trap (NET) release in cancer, as there is mounting evidence to suggest that NETs can
facilitate tumour metastasis. NET formation is a regulated event, and while some of
the molecular mechanisms that lead to NET extrusion are known, others, such how the
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membrane becomes permeabilised, are still unclear. Necroptosis is a form of regulated
necrosis that depends on mixed lineage kinase domain like pseudokinase (MLKL) form-
ing an oligomeric complex at the plasma membrane. This study showed that TNF-α
induces necroptosis in human neutrophils. Pre-treatment of neutrophils with an MLKL
inhibitor impeded TNF-α-mediated necroptosis and decreased NET release in phago-
cytic neutrophils, but not in PMA-stimulated neutrophils. These findings could not be
corroborated by using the peripheral blood neutrophils of MLKL knockout mice, due
to challenges encountered with their stimulation and assessment of cell death. Further
research is required into the emerging roles of MLKL as well as the potential impact
of oxidants on the molecular players of this pathway.
Activated neutrophils produce hydrogen peroxide (H2O2) and hypochlorous acid
(HOCl) that can impact neighbouring cells and contribute to oxidative stress. Oxida-
tive stress is considered a common feature of inflammation-driven cancers, and pro-
motes genomic instability and aggressive tumour phenotypes. Altered DNA methyla-
tion can modify gene expression and cell function and can be influenced by environ-
mental factors. DNA methyltransferases (DNMTs) and levels of the methyl donor,
S -adenosyl methionine (SAM) can be regulated by oxidative stress. The effect of H2O2
and glycine chloramine (a product of the reaction of HOCl with glycine) exposure on
short-term and heritable methylation patterns in proliferating T-lymphoma cells were
investigated. Using bead chip array technology, differential methylation was assessed
at 850,000 individual methylation sites (CpGs) across the human genome. Glycine
chloramine and H2O2 exposure resulted in large genome-wide decreases in methyla-
tion after completion of replication, but most of these changes were corrected during
subsequent rounds of cell division. However, many smaller methylation changes were
conserved. The failure to restore correct methylation patterns could lead to the prop-
agation of aberrant patterns and abnormal gene transcription. Notably, exposure to
oxidants resulted in increased variability of methylation patterns in the cell population,
indicating that not all methylation sites were affected in the same way. This finding
may have important implications for cancer therapies, as genetic diversity is at the root
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Tumours are predominantly composed of cancer cells growing in an uncontrolled man-
ner. However, they also include a range of normal cells that influence the growth rate
of the tumour and its ability to spread through the body. An exciting area of cancer
research is focused on the role of immune cells in tumours. The immune system has
the potential to eradicate tumours, but if unsuccessful it can also promote survival and
spread.
Our most abundant white blood cells, neutrophils, accumulate in tumours, and
their presence is typically associated with poor patient prognosis. However, neutrophils
are capable of inhibiting or promoting tumour development, and signals from cancer
cells appear to influence their phenotype and fate. Neutrophil-derived oxidants, while
essential for host defense against infection, can also directly damage host tissues during
chronic inflammation. These oxidants have the potential to directly damage DNA
and/or modify epigenetic pathways that can lead to deregulation of gene expression
and abnormal cell division.
Neutrophils are generally short-lived cells, and their clearance from an inflammatory
site can occur via apoptosis, which ensures a tidy disposal, or by an explosive necrotic
process that involves the release of their intracellular contents to the local environment.
Numerous new modes of cell death have recently emerged, but few have been fully
characterised in the neutrophil. It is not known whether the way in which a neutrophil
dies can influence tumour progression. Drugs that modulate the immune system have
shown promise in the treatment of cancer. To this end, the characterisation of the
functional properties and lifespan of tumour-associated neutrophils and their effects on
the function and survival of neighbouring cells within the tumour is important for the
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development of new treatments for cancer.
The following sections provide an overview of the neutrophil’s role in cancer, reg-
ulation of novel cell death pathways that could potentiate the release of intracellular
constituents and the effects of neutrophil oxidants on epigenetic pathways.
1 Neutrophils and cancer
Every day, an estimated 5×1011 mature neutrophils emerge from human bone marrow
terminally differentiated, circulate in the bloodstream and if not exposed to inflam-
matory stimuli will die by spontaneous apoptosis. Neutrophils are our most abundant
leukocytes and are best known for their anti-microbial action.
Neutrophils migrate in response to a variety of chemoattractants which can originate
from injured tissue, other immune cells, pathogens or tumours. Neutrophils respond to
four main categories of chemical chemoattractants; N-formylated peptides, complement
anaphylotoxins, lipids and chemokines. Once a chemoattractant binds to G-coupled
protein receptors on the neutrophil cell surface, cytoskeleton changes occur that enable
the neutrophil to move down a chemical concentration gradient towards the target site
(chemotaxis)[1].
When the neutrophil arrives at its destination, it adheres to blood vessel walls by
activating its secretory vesicles to extrude β2-integrins to the cell surface [2]. Once the
neutrophil is tethered, it secretes matrix metalloproteinases as well as oxidants which
degrade the endothelial wall to allow passage into inflamed tissues [3].
Neutrophils are phagocytes and contain powerful chemicals and proteins housed
in their azurophilic (primary), specific (secondary), gelatinase (tertiary) granules and
secretory vesicles and can internalise microbes into membrane-bound killing vacuoles
called phagosomes (phagocytosis). When the neutrophil becomes activated at an in-
flammatory site it can degranulate which involves the secretion of cytokines, defensins
and stimulatory factors extracellularly which can modulate local tissue but also recruit
other immune cells [3].
In response to activation, the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase complex assembles and associates with the phagosomal membrane [4]. An “ox-
idative burst” ensues whereby the NADPH complex (NOX2) transfers electrons from
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2 dismutates into hydrogen peroxide
(H2O2) [5]. H2O2 reacts with thiols and transition metal centres, such as iron. Reac-
tions with transition metal centres can give rise to hydroxyl radicals (·OH) and other
radical species [5], with significant biological effects. Physiologically relevant concen-
trations of H2O2 are cytotoxic to many cell types as well as directly damaging DNA
through the oxidation of nucleic bases [6; 7; 8]. In addition, radical species can oxidise
lipids producing cytotoxic metabolites such as malonyldialdehyde [9].
Given its strong affinity for transition metals, H2O2 is rapidly utilised by the iron-
containing granule enzyme, myeloperoxidase (MPO). MPO uses H2O2 to oxidise an-
ionic halides such as Chloride (Cl– ), Bromide (Br– ), and Iodide (I– ) or the pseudo-
halide anion thiocyanate (SCN– ) into highly reactive, cell-permeable, hypohalous acids.
Hypochlorous acid (HOCl), also known as chlorine bleach, is the strongest and most
abundant antimicrobial hypohalous acid produced by the neutrophil. HOCl targets
cysteine and methionine residues in proteins [5].
Many enzymes containing cysteine residues in their active sites are particularly
vulnerable to oxidation and inactivation from HOCl [10]. HOCl readily oxidises the
nucleophilic thiol side chain in these enzymes causing the formation of disulfide bonds
and altered tertiary protein structures [11; 5].
Chloramines (produced by the reaction of HOCl with amines) represent another
abundant source of methionine and cysteine oxidising species produced by the neu-
trophil [12]. Despite being slower to react with these groups than HOCl, chloramines
are cell permeable [13; 14] and capable of inactivating transcription factors in vitro
[15]. For example, both HOCl and glycine chloramine (GlyCl) were able to oxidise a
methionine residue in the inhibitory protein Iκ-Bα. This allowed for nuclear factor-κB
(NF-κB) to be released and translocate to the nucleus where it could then initiate
transcription of a broad range of genes coding for immunomodulatory cytokines and
survival factors [15]. Sustained activation of NF-κB is a characteristic of many types of
cancer and there are numerous links between inflammation and its regulation [16; 17].
Methionine is not only essential as an initiating amino acid for protein synthesis
but it also acts as an oxidant scavenger; crucial for oxidation-reduction (redox) home-
ostasis in the cell [18]. Fortunately, the cell has several antioxidant systems that can
counteract oxidative stress. Methionine sulfoxide reductase A is an antioxidant enzyme
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that maintains intracellular methionine levels [19]. However, if oxidative stress is not
controlled, many tumourigenic processes may occur. For instance, when methionine
sulfoxide reductase A was down-regulated in a mouse model of breast cancer, a more
aggressive phenotype was produced [20]. Furthermore, deregulation of cellular methio-
nine levels may contribute to DNA methylation changes which will be discussed in
further detail in section 4. A graphical summary of some of the neutrophil’s defenses
is depicted in Figure 1.1.
Figure 1.1: Neutrophil oxidative response to pathogens. When exposed to pathogenic stimuli,
the neutrophil will phagocytose the invader in its phagosome where the NADPH oxidase (NOX2)




2 then dismutates to hydrogen peroxide (H2O2) and
is converted to hypochlorous acid (HOCl) by the heme-containing enzyme myeloperoxidase (MPO).
HOCl can react with amines to produce chloramines and hydroxide. These reactive oxidant species
(ROS) can damage bacterial cell walls but also damage non-pathogenic cells and tissue. H2O2, HOCl
and chloramines can freely diffuse into cells and can oxidise protein thiols causing conformational
changes and often inactivation. These oxidants can also cause DNA strand breaks, lesions and form
adducts. Figure adapted from [21] and [22]
1.1 Immunosurveillance and inflammation
We rely on our immune systems to protect us from daily exposure to pathogens that
could harm us. In most healthy individuals, cells of our innate and adaptive im-
mune systems work together to keep the body free from disease and maintain tissue
homeostasis. At times of acute infection, the members of our innate immune system
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which include dendritic (DC), natural killer cells (NK), eosinophils, basophils, mast
cells, macrophages and neutrophils mount an initial defense by recognising pathogenic
molecules, attempting to destroy them and signalling danger to other cells and tissues.
Innate immune cells, while rapid and effective at destroying invaders, lack any memory
of antigenic signatures [23; 24]. In contrast, adaptive immune cells, which comprise T
and B lymphocytes, are presented with an antigen by a professional antigen-presenting
cell (such as a DC), and commit to clonal expansion of a single unique specific antigen.
While the primary response by the adaptive immune system can be much slower than
that of the innate immune system, some T-cells will differentiate into memory T-cells,
which persist in circulation and ensure a swifter and more robust immune response
should the host encounter the same antigen again [25].
Of course, during an inflammatory response, cytotoxic chemicals cannot always be
directed uniquely to their target and there is often substantial death and damage to
bystander non-pathogenic tissues, the extracellular matrix (ECM) and immune cells.
Resolution of inflammation post-infection is therefore essential to ensure normal tissue
function is restored. Long term failure to restore tissue homeostasis can result in
aberrant immune signalling, extensive tissue damage, gene and protein modifications
and ultimately carcinogenesis [26].
1.2 Inflammation is an enabling characteristic of cancer
Cancer occurs when normal cells acquire functional properties that alter their inherent
function and enable neoplastic disease. These traits, termed the “hallmarks of cancer”,
were first presented by Hanahan and Weinberg in 2000 as a way of conceptualising
tumourigenic characteristics [27]. The six hallmarks were: sustaining proliferative sig-
naling, evading growth suppressors, resisting cell death, enabling replicative immortal-
ity, inducing angiogenesis, and activating invasion and metastasis. A decade later, the
same authors expanded on these initial hallmarks by describing genomic instability and
tumour-promoting inflammation as “enabling characteristics” that facilitate the acqui-
sition of hallmark features by normal tissue [28]. While it has been argued that many
hallmarks are also traits of benign tumours and some non-cancerous conditions such as
endometriosis [29; 30], the hallmarks are widely accepted as a series of transformational
events ultimately leading to tumour progression and spread.
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Whilst immune cells are attracted to sites of tissue injury or infection by damage-
associated molecular patterns (DAMPS) or pathogen-associated molecular patterns
(PAMPS) they can also respond to signals from abnormal host cells and tumours
[31]. For decades, researchers have observed immune cells infiltrating tumours and
this was regarded as a normal inflammatory response, or “immunosurveillance”, the
host’s way of fighting off cancerous cells [32; 33; 34; 35]. However, an overwhelming
amount of research now indicates that signals from the tumour and other cells of
the tumour-microenvironment (TME) are capable of reprogramming immune cells to
enable tumours to grow [36].
1.3 How cancer evades the immune system
The immunoediting concept describes three successive scenarios of immune response
to the tumour, termed the three “E’s” [37; 38]. The elimination stage consists of
immune cells of both the innate and adaptive branches coming together to destroy
cancer cells. If the immune response fails to completely eradicate the tumour, then
the equilibrium stage begins where the dormant tumour cells continue to receive an
onslaught of immune defenses but manage to survive in a dormant state. These cells
become increasingly unstable genomically, lose antigens that mark them as abnormal,
which leads to the acquisition of a certain tolerance from immune cells. The tumour
is then permitted to grow, giving off growth signals and cytokines which suppress
immune cells even further, precipitating the final phase of escape of transformed and
immunoevasive tumour cells.
In this way, a Darwinian selection process occurs, whereby the TME “selects for” a
chronically activated inflammatory state, as opposed to an acute inflammatory state,
as the former is more conducive for growth [39]. In tumours, chronically activated
leukocytes have been shown to produce several growth factors which promote tumour
proliferation, including; tumour necrosis factor alpha (TNF-α)[40; 41], transforming
growth factor β (TGF-β) [42], epidermal growth factor (EGF)[43] as well as histamine
and heparins [44]. In addition to growth factors, activated leukocytes secrete a variety
of proteases that remodel the ECM and stimulate the release of more mitogens, thus
increasing cell division in the TME [45]. Moreover, the overabundance of reactive
oxygen species (ROS) produced by both the tumour and activated leukocytes create a
6
mileu of oxidative stress which can lead to the modulation of key enzymes, transcription
factors and even resistance to anticancer drugs [46]. Indeed, chronic inflammation has
the potential to enable many of the hallmarks of cancer.
The majority of the literature to date has focused on the role of the T-cells in cancer
but interest in the members of the innate immune system is beginning to emerge.
There has been extensive research into macrophage involvement in tumour progression
but neutrophils have often been overlooked due to their presumed short lifespan and
homogeneity [47; 48]. However, while there is still much debate about the life cycle and
death pathways of neutrophils [49], mounting evidence implicates neutrophils and their
diverse subsets as important contributors to ongoing inflammation, tumour initiation
and progression.
1.4 Neutrophil oxidants and tumourigenesis
The neutrophil is a rich source of reactive oxidants, which have genotoxic and cyto-
toxic affects on other cells. Significant increases to oxidative species can disrupt redox
equilibrium and create an environment of oxidative stress. High oxidative stress over
a short period of time generally leads to cell death or apoptosis (Figure 1.2). But
low to moderate levels over perhaps a longer period of time is where mutagenesis and
tumour promotion are more likely to occur. For example, at below genotoxic levels,
ROS have been shown to be mitogenic by stimulating oncogenes [50; 51], while higher
levels can trigger the cellular DNA damage response mechanism and lead to either cell
cycle arrest and/or death [51; 52].
Genomic instability is one of the enabling characteristics of the hallmarks of cancer
and oxidants derived from neutrophils have been shown to directly damage DNA, create
DNA adducts and alter methylation patterns in non-cancerous cells [53; 54; 55; 56; 57].
One of the first experiments showing that neutrophils contributed to DNA mutage-
nesis was using the bacterial model Salmonella typhimurium(TA100). TA100 that were
exposed to neutrophils had more highly mutated DNA compared to those that were
exposed to neutrophils mixed with other leukocytes or oxidant-deficient neutrophils
(neutrophils from patients with chronic granulomatous disease (CGD))[58]. In a hu-
man model, researchers measured DNA damage in lymphocytes that were exposed to
neutrophils stimulated with phorbol 12-myristate 13-acetate (PMA) to produce H2O2
7
Figure 1.2: Oxidative stress and cancer progression. Levels of oxidative stress favour either
initiation, progression or death of cancer cells. Low to high oxidative stress levels are shown on the
x-axis and how they relate to tumour promotion, mutagenesis and apoptosis or necrosis (cell death).
Figure from Valko et al. 2007 [46].
and HOCl. They discovered that while HOCl did not directly induce DNA strand
breaks, it increased the extent of the damage and lengthened the repair process of
H2O2-induced DNA strand breaks [6]. This was also confirmed in a lung cancer model
which found that a single acute exposure to sublethal doses of HOCl inhibited nu-
cleotide excision repair enzymes for up to 24 hrs [59].
Gungor et al. also used in vitro and in vivo lung inflammation models to show that
HOCl contributes to gene mutagenesis indirectly by forming promutagenic exocyclic
DNA adducts [59; 56]. Similarily, PMA stimulated neutrophils in the presence of
polycyclic aromatic hydrocarbons created DNA adducts that mutated TA100 through
a process that was negated by MPO and SOD inhibitors [60]. Simply damaging DNA
can be carcinogenic in itself but tumour formation and progression is a multi-factorial
process and requires a favourable environment to thrive and spread.
1.5 How tumour-neutrophil crosstalk promotes cancer pro-
gression and metastasis
Neutrophils, like all other immune cells are produced in the bone marrow. During differ-
entiation from a hematopoietic stem cell to mature neutrophil, myeloid cells undergo
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distinct morphological, proteomic, surface marker and granule composition changes,
which enables the characterisation of developmental stage [61]. For example, the mor-
phology of the neutrophil changes dramatically, going from a banded nucleus in young
myelocytes, metamyelocytes and band cells to its trademark segmented formation in
mature and hyper-segmented neutrophils [62]. Furthermore, granule formation occurs
in numerical order at specific stages of maturation, meaning that more immature neu-
trophils do not possess the full set of granules, and cannot execute multiple effector
functions [63](Figure 1.3).
Figure 1.3: Neutrophil maturation and granule and surface marker acquisition. Neu-
trophils mature in the bone marrow from hematopoietic stem cell through to promyelocyte, myelocyte,
metamyelocyte, band cell (not pictured) to mature and hypersegmented neutrophils. At each stage
the neutrophil will develop granules from azurophilic (primary), specific(secondary), gelatinase (ter-
tiary) and finally secretory vesicles. Each granule houses specific enzymes and cytokines that perform
different functions. Similarly, as it matures the neutrophil will acquire more or stronger expression of
cluster of differentiations (CD) surface markers which allow for distinction between subsets. Figure
adapted from [61] and [62].
The current paradigm is that, under normal conditions, neutrophils will only enter
into circulation when fully developed, and will not differentiate any further. During
inflammation, and particularly in cancer states, emergency myelopoiesis occurs due to
diffusible signals from the tumour or other immune cells that summon immature mye-
locytes from the bone marrow into the blood. [64; 63]. Tumours and immune cells can
secrete granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage
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colony stimulating factor (GM-CSF) which are regulatory haematopoiesis glycopro-
teins that instruct the bone marrow to increase production of myeloid cells and pro-
genitors [65; 66]. The result of this massive recruitment from the myeloid compartment
is the presence of a broad range of myeloid cells in the TME that possess varying de-
grees of tumour-suppressor and immunostimulatory abilities. The characterisation of
these populations and their role in tumour progression is complex and is a topic of
considerable interest in the current literature.
1.5.1 Neutrophil polarisation in tumours
Neutrophil function in cancer is a highly debated field of research. Extensive evi-
dence demonstrates context-specific plasticity resulting in both tumour-promoting and
tumour inhibiting populations of immune cells. These polarised phenotypes of tumour-
associated neutrophils (TAN) are often referred to as N1 (potent anti-cancer agents)
or N2 (tumour-promoting)[67]. Neutrophils are not alone in this phenotypic polarisa-
tion, macrophages and T-regulatory cells have also been categorised in a similar way,
displaying both pro and anti-tumoural functions [68; 69]. It is therefore important to
define the potential causes of this divergence with the aim of devising new therapeutic
targets to promote a shift to a dominant N1 anti-cancer phenotype.
1.5.2 N1 anti-cancer phenotype
Although much of the current literature depicts neutrophils in a pro-tumoural role,
there is also evidence that neutrophils can kill tumours and prevent relapse (reviewed
in [70; 71; 72]). For example, a large colorectal cancer tissue micro array analysis
revealed that a high density of MPO+ cell infiltrate was an independent favourable
prognostic factor of survival [73]. The N1 phenotype delivers its effective tumouricidal
activity by increasing oxidant production [74; 75]. Within the tumour, N1 TAN also
recruit and stimulate CD8+ T-lymphocytes by secreting more TNF-α and IL-10 and
less arginase [76] (Figure 1.4).
In order to effectuate a successful anticancer response neutrophils have several re-
quirements; there must be a clear recruitment and localisation signal from the tumour
and direct contact must be established [77; 78; 79], the neutrophil needs to be permit-
ted to activate, and the target tumour type needs to be susceptible to its oxidants [80].
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Figure 1.4: Polarised neutrophil phenotypes in cancer. In the tumour microenvironment
neutrophils can exert a strong anti-cancer response (N1) or a pro-tumour response (N2). The N1
neutrophil is fully mature with densely packed granules. These neutrophils establish contact with
tumours, and increase oxidant production to cytotoxic levels. They stimulate CD8+ T-cells by in-
creasing their production of IL-10 and TNF-α and decreasing their arginase production. They can also
travel to the lymph and present antigens to dendritic cells, stimulating adaptive immunity. Finally,
once activated and degranulated, they will form apoptotic bodies which keep their cellular contents
inside the cell until they can be engulfed and cleared by macrophages. The N2 neutrophil can be either
immature or mature with low granularity. They are less mobile and although the genes that regulate
oxidant production may be upregulated, they show reduced tumour cytotoxicity. The oxidants they
produce inhibit T-cell proliferation and activity as well as activate tumour promoting cytokines such
as MMP-9, VEGF and TGF-β. They also upregulate their TGF-β receptors which may be a polari-
sation switch, further promoting pro-tumoural neutrophil activities. They secrete oncostatin M which
has been shown to promote macrophage polarisation to M2 phenotype. They also produce NETs and
elastase which may escort tumour cells to distal sites and degrade the extracellular matrix allowing
for escape into the blood stream.
One study used a modified colon adenocarcinoma (C-26) cell line to produce sustained
G-CSF and transplanted these cells along with unmodified C-26 cells into a mouse.
Using electron microscopy (EM) and in vitro assays they found that there was a strong
neutrophil recruitment to the G-CSF producing cells and that these neutrophils inhib-
ited their growth, while the unmodified C-26 cells were not contacted and remained
unharmed [81]. Co-culture experiments have shown that circulating neutrophils taken
from breast cancer bearing mice are highly cytotoxic to tumour cells compared to
neutrophils from non-tumour bearing mice, but only when they came into direct con-
tact. This effect was abrogated by the addition of catalase, suggesting H2O2-mediated
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cytotoxicity [79]. Similarly, pre-activated neutrophils that came into contact with a
hepatoma cell line in vitro caused injury after 15 minutes of exposure and complete
lysis after 45 minutes. The amount of killing corresponded to the extent of oxidant
production and was attenuated with the addition of SOD, suggesting the involvement
of O –2 and H2O2 [82]. Further research into specific mechanisms of H2O2 cytotoxicity
revealed that murine breast cancer cells were killed by a lethal influx of Ca +2 ions trig-
gered by H2O2 exposure. Cancer cells deficient in the TRPM2 Ca
+
2 channel showed
resistance to neutrophil killing [83]. It remains unclear how much exposure cancer cells
would receive from H2O2 produced by from neutrophils in vivo, as in theory, the ma-
jority of H2O2 would be captured and transformed into HOCl by MPO. In a murine
macrophage cancer cell line, HOCl at low doses (10-20 µM) was shown to cause the
oxidation of plasma membrane sulfydryls, resulting in the disruption of potassium ion
levels [84]. At higher doses (>50µM), HOCl treatment led to oxidation of methionine
and tryptophan residues and formation of protein carbonyls, and ultimately cell lysis
[84]. HOCl may be involved in the signalling pathway that controls apoptosis as HOCl
stimulated apoptosis of human acute myeloblastic leukemia cell line (HL-60) 24 hours
after exposure [85; 86].
Neutrophil anti-cancer response requirements appear to be achievable during the
early of stages cancer [87], and in the premetastatic niche [88], but there is little evi-
dence showing non-manipulated neutrophil anti-cancer response in later stages of cancer
where inflammation may already be established.
1.5.3 N2 pro-tumour phenotype
While there is general consensus on what traits constitute a N1 neutrophil, the ori-
gins and attributes of the N2 phenotype have been more challenging to characterise.
Some features of the N2 phenotype include increased arginase and oxidant production
(leading to T-cell inactivation), reduced cytotoxic capabilities, secretion of metallopro-
teinases (i.e. MMP-9) and pro-angiogenic cytokines (i.e vascular endothelial growth
factor (VEGF))[89; 90], and release of the elastase protease [91].
TGF-β, an immunosuppressive cytokine that can be secreted by both tumours
and immune cells, appears to be the major polarising factor in modulating neutrophil
phenotype in a cancer setting. Tumour-secreted TGF-β generally exists in an inactive
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[92; 93]. N2 neutrophils in a fibrosarcoma mouse model were found to upregulate TGF-
β receptors in response to circulating TGF-β, however, a robust neutrophil-mediated
anti-tumoural response was observed when these receptors were blocked [94]. Several
other studies have also supported the inhibitory effects of TGF-β on degranulation and
cytotoxicity in non-small cell lung cancer (NSCLC) and mesothelioma cancer models
[95; 96].
A convincing study by Sagiv et al. has recently described increased numbers of
a subpopulation of mature neutrophils that had a lower density (LDN) than nor-
mal density mature neutrophils (NDN) in the blood of murine and human cancer
patients[97]. They showed that these LDN neutrophils had reduced degranulation and
H2O2-mediated cytotoxic capacities. When the NDN were incubated with TGF-β ex
vivo and in an in vivo mouse model, the NDN converted to LDN. Importantly, these
authors made two propositions based on their work; firstly, that these LDN were not
immature or degranulated neutrophils but functionally impaired mature neutrophils.
Secondly, that mature neutrophils are not terminally differentiated upon exit from the
bone marrow but can be dramatically modified whilst in peripheral circulation [97].
Prior to this study, it was more widely believed that neutrophil plasticity in response
to tumour signals was a trait reserved mainly for immature myeloid populations.
The term myeloid derived suppressor cells (MDSC) describes a group of immature
cells of myeloid lineage unified by their ability to suppress T-cells. They can be divided
into two subcategories based on their nuclear morphology. M-MDSC are mononuclear
and PMN-MDSC or G-MDSC are polymorphonuclear/granulocytic [98]. MDSC can be
subdivided further based on their surface markers and functional capabilities. MDSC
are produced excessively in individuals with cancer and are now widely regarded as
a major source of anti-cancer immuno-suppression [99; 100; 101]. MDSC have been
shown to suppress T-cell activity by producing large amounts of arginase 1 and ROS
[102; 103].
It remains challenging to distinguish between PMN-MDSC and N2 TAN as these
groups share similar surface markers and immuno-suppressive functionalities. How-
ever, several robust transcriptomic comparisons of PMN-MDSC, N2 TAN and naive
neutrophils have shown that there are definitive protein expression differences between
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these groups. Comparisons of the mRNA profiles in neutrophil populations from non-
tumour bearing or mesothelioma tumour-bearing mice revealed that genes involved in
cytoskeletal reorganisation, respiratory burst, granule proteins (including MPO) and
apoptosis were down regulated in N2 TAN, while genes involved in proinflammatory
cytokine production and antigen presentation were upregulated compared to naive and
PMN-MDSC. These authors also noted that protein expression in PMN-MDSC were
more closely related to naive neutrophils than to N2 TAN [104].
In contrast, another study compared mature neutrophils from tumour-free mice to
PMN-MDSC from tumour-bearing mice and showed that PMN-MDSC had impaired
phagocytosis, secreted lower levels of TNF-α and similar levels of nitric oxide (NO) to
naive neutrophils. As expected, PMN-MDSC displayed increased arginase, MPO and
ROS activity. Furthermore, quantitative real-time PCR (qPCR) revealed that MPO
transcripts were more than 50 times more highly expressed in PMN-MDSC compared
to naive neutrophils [105].
MPO has an important role in potentiating the effects of metalloproteinase MMP-
9; an enzyme secreted by MDSC and TAN in substantial amounts [106; 107]. Active
MMP-9 is a gelatinase that degrades ECM proteins and activates the important angio-
genic factor VEGF. Pro-MMP-9 is the inactive form of MMP-9 which can be activated
by the oxidation of its sulfur-containing amino acids. MPO-derived HOCl oxidises the
pro-MMP thiols resulting in a conformational change and active MMP-9 [108]. By the
same mechanism, HOCl inhibits the tissue inhibitor of metalloproteinases 1 (TIMP-
1)[109], thus freeing sequestered MMP-9, enhancing ECM break down and facilitating
tumour escape [110]. MMP-9 has been shown to be a critical component of metastasis,
as inhibiting MMP-9 early in the metastatic cascade prevented metastasis in a murine
metastatic breast cancer model [111].
Caution must be used when interpreting the results from studies using mouse models
of neutrophils in cancer, as there are not only substantial species differences between
mouse and human neutrophil numbers, function and populations, but also in the way
cancer progresses [112]. It is also worth considering that cancer is often referred to as
a disease of the aged and many studies have utilised mouse models that are often not
age-appropriate [113].
In light of this, additional work is required to characterise the increasing numbers
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of human neutrophil subsets present in cancer. Interestingly, it has been argued that
all these neutrophil categories do not represent distinct subsets but rather the dynamic
activation states and ages of conventional neutrophils [114; 115]. Complicating the
resolution of these subsets even further, is the notion that certain subsets may be unique
to the type and stage of the cancer [114]. Regardless of the nomenclature of emergent
neutrophil phenotypes, there have been numerous reports demonstrating correlations
with circulating and tumour-localised neutrophil numbers and poor patient outcomes.
For instance, one study implanted benign murine fibrosarcoma cells (QR-32) into mice
to show how the sheer presence of neutrophils in the tumour infiltrate permitted the
acquisition of a metastatic phenotype. In mice that were either neutrophil deficient or
depleted, a metastatic phenotype was not observed [116].
Many studies have used MPO expression as a marker for neutrophils in immuno-
histochemical analyses of tumour tissue. Increased MPO+ cell infiltrate has correlated
with increased stage, increased secondary primary tumours, and higher mutagenicity
in many different types of cancer, showing promise as a marker of disease progression
[117; 118; 119; 120; 121].
1.5.4 Neutrophil-lymphocyte interactions
In addition to its role as a cytotoxic agent, the neutrophil also displays immunoregula-
tory functions. Activated neutrophils are an important source of cytokines, chemokines
and angiogenic factors which can modulate the activity of other neutrophils, leukocytes
and stromal cells at inflammatory sites [122; 123; 124].
The neutrophil-T-lymphocyte relationship is complex, as there is evidence for mu-
tual activation and inhibition by both cell types [125]). Interleukin-8 (IL-8 or CXCL8) is
a well characterised neutrophil cytokine which is involved in the recruitment and stim-
ulation of other neutrophils, but is also chemotactic for basophils and T-lymphocytes
[89; 126]. Neutrophils can contribute to adaptive immunity by the presentation of
antigens to memory CD4+ T-cells [127; 128; 129]. This may also occur in cancer, as
TAN upregulate gene pathways for antigen presentation as well as many chemokines
and cytokines that regulate lymphocytes.[76]. Neutrophils also stimulate T-cells indi-
rectly by migrating to the lymph and interacting with dendritic cells [130]. Neutrophils
have proven helpful in early cancer by decreasing tumour production of IL-17 which
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indirectly stimulated T-cell infiltration and tumour death [131].
However, T-lymphocytes that enter the TME often encounter both inhibiting sig-
nals from the tumour but also first responder neutrophils which can decrease their
proliferation and anti-tumour activities [132]. Neutrophil secretion of MMP-9 in col-
orectal tumours activated latent TGF-β which in turn effectively suppressed effector
T-cell function [133].
T-lymphocyte function is particularly sensitive to oxidative stress. Evidence from
our research group and others have shown that stimulated neutrophils and PMN-MDSC
can suppress T-lymphocyte activation and proliferation through an oxidant and CD11b-
contact dependent mechanism [134; 135; 136; 137; 138]. T-lymphocytes taken from ad-
vanced cancer patients that were treated with anti-oxidants ex vivo showed an increased
ability to proliferate compared to untreated T-lymphocytes [139]. T-cells co-cultured
with activated neutrophils became hyporesponsive due to alterations in the T-cell re-
ceptor (TCR) signalling pathway [140]. These alterations have been directly related
to the production of ROS by PMN-MDSC and impacted cancer-antigen recognition in
CD8+ T-cells resulting in immune tolerance [141].
However, lymphocytes have shown proliferative resilience to exposure from H2O2
from activated neutrophils in vitro. Lymphocytes that survived a first exposure to
oxidants built a greater resistance to a second exposure and phenotypic alterations were
observed in their progeny [142]. These results indicate that H2O2 from neutrophils can
produce short-term changes to lymphocyte cellular processes and these alterations can
be passed on through subsequent cell division. Possible mechanisms for this will be
discussed in more detail in Section 4.
Cytotoxic T-lymphocytes are thought to be the most important agents in the host
tumour defence through the action of IFNγ and perforins [143; 144]. The presence
of CD8+ cytotoxic T-lymphocytes at the tumour site has been by far the strongest
observable predictor of good overall survival in a large range of different cancers and is
being evaluated as a prognostic tool in histopathological settings [145; 146; 147]. It is
therefore pertinent to study the impact of neutrophils and their oxidants on lymphocyte
survival and function.
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2 Neutrophils and non-melanoma skin cancers
Non-melanoma skin cancer (NMSC) is the most common form of cancer affecting pale-
skinned individuals in the world [148]. NMSC are most commonly found on the skin of
the head and neck as these regions the most frequently exposed to ultra-violet radiation
(UVR) through sunlight. While increased awareness of the risks of recreational sun
exposure is the likely cause of slowed NMSC incidence rates in Canada and Australia;
Germany, China and the U.S.A have reported significant increases [149; 150; 151]. In
New Zealand, the per capita mortality rates from skin cancer are among the highest in
the world [148; 152].
As its name suggests, non-melanoma skin cancer refers to any skin cancer that is not
melanoma. The most common forms of non-melanoma skin cancers are those effecting
the keratinocytes of the epidermis; basal cells and squamous cells. Of the keratinocyte
carcinomas (KC), basal cell carcinoma (BCC) is more common, comprising about 80%
of presenting cases. Despite cutaneous squamous cell carcinoma (CSCC) being less
prevalent in the general population, it is significantly more likely to recur and metas-
tasise [153]. Studies into the epidemiology of UVR exposure in KC reported that BCC
is strongly linked to intermittent UVR exposure while CSCC was most strongly asso-
ciated to life-long exposure to UVR [154]. Although sun exposure is the primary cause
of the development of NMSC, chronic skin ulcerations, human papilloma virus (HPV)
infection, carcinogenic chemicals and the use of immuno-suppressive medications are
also risk factors [153; 155].
There is now substantial evidence to suggest that the development of keratinocyte
carcinoma in itself could be a marker of increased risk for other malignancies [156;
157; 158; 159]. This is particularly so if a KC presents at a young age [160]. KC
may be predictive of a high cancer-risk phenotype which may be linked to immune
dysregulation.
2.1 Cutaneous squamous cell carcinoma (CSCC)
While the majority of CSCC are successfully treated by surgical excision, it is esti-
mated that approximately 5% of CSCC will metastasise [153]. There is therefore much
interest into refining CSCC classification in order to aid clinicians in the recognition
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of high-risk patients. There are several histological and clinical features of CSCC that
determine tumour stage. These features include; diameter > 20mm, perineural inva-
sion, poorly or undifferentiated histological characteristics, thickness > 2mm, invasion
into subcutaneous fat, and Clark’s level ≥ 4 (a surrogate marker of thickness), and ear
and lip location. Although several different staging systems have been proposed, the
best predictors of high-risk tumours are tumour thickness [161; 162; 163; 164] and the
Brigham and Women’s Hospital (BWH) tumour (T) staging system [165](Figure 2.1).
However, the effectiveness of these staging systems is the subject of ongoing debate

































































































































































































































































































































































































































































































































































CSCC is one of the cancers with the highest UVR-induced mutation rates with
notable defects in numerous oncogenic pathways including the inactivation of the tu-
mour suppressor gene p53 [167]. Interestingly, genetic analyses into non-cancerous sun-
exposed epidermal keratinocytes have shown that these cells carry many of the same
mutations as CSCC cells. This finding suggests that mutations alone are not sufficient
to promote tumour progression and that other factors such as the microenvironment
may be involved [168; 169].
2.2 Immuno-suppression and CSCC
Exposure to UVR not only initiates cancer but can also induce both local and sys-
temic immuno-suppression. Early studies used chronic UVR exposure to induce CSCC
tumours in mice. It was observed that the UV-irradiated host’s immune system was
unable to contain the tumour growth but when the tumour was transplanted to a
genetically identical mouse, the tumour was destroyed. When the UVR-induced tu-
mour was transplanted into a immuno-suppressed mouse, the tumour grew progres-
sively. The researchers concluded that this was due to a highly antigenic phenotype
of UVR-induced tumour combined with an UVR-induced immuno-suppressive state
[170; 171; 172]. Another study showed that UVR not only initiated tumours but the
damaged keratinocytes produced cytokines that resulted in a high neutrophil influx.
These recruited neutrophils were shown to promote tumour escape into the vasculature
and dissemination of metastases to the lung [173].
CSCC has an intriguing relationship with therapeutic immuno-suppression. In or-
gan transplant recipients (OTR), who receive immuno-suppressive medications, mor-
tality due to skin cancer is higher than any other factor [174]. OTR present with
rapidly growing, invasive, aggressive phenotype CSCC, prone to metastasis. Incidence
of CSCC in OTR is estimated to be up to 250-fold increased compared to the general
population [175]. Skin cancer in OTR has been most extensively studied, however in-
dividuals with other immuno-compromising conditions such as HIV, autoimmune and
lymphocytic leukemia have also shown a huge increased risk of NMSC particularly
CSCC [176]. As stated above, the occurrence of BCC versus CSCC in the general
population is about 3:1 but in immuno-suppressed individuals the incidence is reversed
[176]. It appears that the additive effect of immuno-suppression due to UVR expo-
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sure along with therapeutically-induced immuno-suppression combine to promote an
internal environment conducive to the growth of aggressive CSCC.
Analysis of the circulating and tumour-localised immune phenotype of immuno-
suppressed individuals should therefore provide some insights into what immune con-
text allows for aggressive CSCC progression. The majority of research conducted on
the immune cell populations of immuno-suppressed and OTR patients with cancers has
focused on the decreased numbers and altered balance of circulating T-cell populations,
specifically CD4+, CD8+ and regulatory T-cells (T-regs) [177; 178; 179]. However, pre-
vious work by our research group has shown that in CSCC patients, OTR have higher
circulating frequencies of MDSC compared to non-OTR. This study also revealed that
the development of CSCC in both OTR and immunocompetent individuals was mainly
associated with increases in the PMN-MDSC subset [99]. In line with this, it has been
shown that immuno-suppressive medications such as glucorticosteroids stimulate the
release of granulocytes from the bone marrow into circulation and delays their apopto-
sis [180; 181; 182]. This raises the possibility that increased frequencies of granulocytic
MDSC and/or neutrophils could be markers of systemic immune suppression in CSCC.
2.3 Neutrophils in CSCC
Combining the evidence that immuno-suppression and the tumour microenvironment
play a role in CSCC progression along with the observations that increased frequencies
of neutrophils are found in UVR damaged skin and in circulation of patients with
progressive CSCC, it is surprising that very few studies have investigated the potential
of neutrophils as biomarkers of high-risk CSCC.
There has been much interest in the impact of systemic inflammation in cancer
patient prognosis. In particular, total circulating neutrophil counts and the neutrophil
to lymphocyte ratio have been extensively studied in colorectal, naspharyngeal, breast
and gastric cancers as markers of disease progression [183; 184; 185; 186; 187]. However,
the use of these quantitative measures as biomarkers has had mixed prognostic value
(reviewed in detail by [188]). At present, no studies have analysed circulating neutrophil
number or the neutrophil to lymphocyte ratio with respect to survival or high-risk
tumour features in CSCC.
High neutrophil frequencies and elevated neutrophil/lymphocyte ratio in the tu-
21
mours of head and neck (HNSCC) and cervical SCC, have been associated with poor
prognosis [189; 190]. However, these parameters have not been assessed in CSCC.
One study has looked at the frequencies of MPO+ cells in human CSCC tumour tis-
sue. Their results showed that MPO+ cells were present in all their samples but
in lower abundance than T-cells and macrophages. In contrast, they used a mouse
model to show that in an acutely induced tumour, neutrophils comprised the highest
immune infiltrate and produced Oncostatin M, which promoted tumour proliferation
and impacted macrophage polarisation to an M2 phenotype [123]. Notably, this study
analysed a mixed population of human patients, which included several OTR. This
study also did not compare numbers of MPO+ cells with markers of metastatic risk.
The numbers of granulocytes (CD66b+) along with their most potent effector enzyme
MPO, could represent potential biomarkers of disease progression as well as clues into
the mechanism behind neutrophil-mediated tumour progression.
In summary, a challenge of contemporary oncoimmunology is to better understand
the factors that influence the balance between a dominant versus tolerant immune sys-
tem in cancer. To date, neutrophils have been implicated in the initiation, progression
and spread of cancer cells and have shown promise as potential biomarkers of high-risk
cancers. There is a need for more information about the immune contexture that en-
ables the aggressive nature of normally benign forms of cancer such as CSCC. By using
information about the immune systems of therapeutically immuno-suppressed individu-
als that permit aggressive phenotype CSCC, and comparing this to non-therapeutically
suppressed individuals who present with CSCC, an immune phenotype biomarker could
emerge to aid in predicting which CSCC could kill.
22
3 How neutrophil survival and death pathways in-
fluence inflammation and cancer
Cell death is a fundamental activity in the development of almost all organisms [191;
192]. It is an essential event in embryonic development and in the maintenance of
normal tissue homeostasis, but also occurs in pathological contexts as a result of injury,
infection and cancer, enabling the clearance of unwanted or damaged cells.
The way in which a cell dies has important immunological consequences. The
immune system has to gauge its response to dead cells by either evoking a strong,
adaptive immune attack (immunogenic response) or allowing for normal cell death
to occur quietly, producing a negligible immune response (tolerogenic response)[193].
Signals that immune cells receive from dying and dead cells can help it to discriminate
between responses, and these signals often depend on the mode of cell death.
Mammalian cells are genetically encoded to undergo a type of programmed cell sui-
cide called apoptosis. Apoptosis has distinct morphological traits characterised by cell
shrinkage and nuclear fragmentation, the formation of intact nodules called apoptotic
bodies and the exposure of surface markers that promote clearance through phagocy-
tosis (i.e phosphatidylserine (PS)). This is in contrast to lytic cell death, or necrosis,
which results in a substantial amount of cellular debris and can occur as a result of
environmental injury or chemical damage [194].
For many years it was assumed that apoptosis led to immunologically silent death,
and necrosis to a pro-inflammatory state. However, it now appears that immune re-
sponses to dead cells are much more complex and depend on numerous factors such as:
cell type, current or past activation, cell contents, where in the body the death occurs,
the type of death pathway that is triggered, and what immune cells are in the vicinity
to respond [195].
In the case of the neutrophil, the way in which it dies is of particular importance. At
an inflammatory site, activated neutrophils produce diffusible oxidants and degradative
enzymes, release cytokines and other inflammatory mediators, and extracellular traps
(NETs)[5; 196; 197]. Given the arsenal of cytotoxic chemicals and pathogenic materials
neutrophils house, it is critical that after serving their purpose, they are removed from
the body in a controlled way, such that their contents do not cause excessive damage
23
to surrounding tissues and/or exacerbate the inflammatory response. In their death,
neutrophils can effectively dictate the course of the inflammatory response by either
triggering its resolution or sparking its perpetuation.
The study of cell death has undergone a major transformation in recent years, with
a number of new forms of regulated cell death described [198]. However, the regulation
of neutrophil death pathways and the effect of dying neutrophils on neighbouring cells
remain poorly characterised. Considering the evidence for neutrophil involvement in
cancer biology, unearthing the molecular death pathways that occur in neutrophils is
important not only in understanding the underlying pathology of inflammatory disease
but also in the discovery of novel therapeutic targets.
The following sections provide an overview of current knowledge of cellular death
pathways and investigations of these pathways in the neutrophil.
3.1 Regulated cell death
Regulated cell death (RCD), is a biologically controlled process that involves intricate
signalling cascades and key effector molecules. In addition to cell death induced by
extrinsic sources, the term regulated cell death encompasses programmed cell death,
which refers exclusively to genetically encoded physiological programs during develop-
ment or tissue homeostasis that are not set in motion by any external stimuli [194].
Up until recently, necrosis was thought to only occur through physical, chemical or
mechanical damage to the plasma membrane. However, it is now known that necrosis
can also be a regulated event. Although the final morphological state remains the
same (plasma membrane rupture), there are clearly defined molecular players involved
in regulated necrosis which can be modulated to alter cell fate [199].
The different RCD pathways can be categorised by their dependance on a family
of cysteine–aspartate proteases (caspases) for execution. Caspase-dependent pathways
include apoptosis and pyroptosis while caspase-independent pathways include (but are
not limited to), necroptosis and NETosis [200] .
3.2 Caspase-dependent cell death
Caspases are proteolytic peptidases which exist initially as inactive monomeric procas-
pases. Caspases are activated by dimerization and/or cleavage facilitated by specific
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adaptor proteins [201]. Active caspases contain cysteine residues in their catalytic do-
main which hydrolyze peptide bonds situated after certain aspartic acid residues in
a substrate. Ultimately, caspases activate key downstream enzymes, including other
caspases, to coordinate the systematic destruction of structural proteins in the cell,
resulting in apoptotic cell death [202].
In mammalian cells, caspases can be classified into several groups: initiator cas-
pases (CASP2, CASP8, CASP9, and CASP10) and executioner caspases (CASP3,
CASP6, and CASP7) which are key in the apoptosis pathway and inflammatory cas-
pases (CASP1, CASP4, CASP5, CASP11, and CASP12) which regulate pyroptosis
[198].
3.2.1 Apoptosis
Apoptosis is a caspase-mediated programmed cell death characterised by morphological
and molecular changes distinct from necrosis. An apoptotic cell will undergo nuclear
condensation (pyknosis) and fragmentation (karyorrhexis), a characteristic blebbing
of the outer membrane and cell shrinkage with no loss of membrane integrity [203].
Phosphatidylserine (PS) will also become exposed on the surface of the plasma mem-
brane acting as an “eat me” signal for phagocytes to engulf the apoptotic bodies,
whilst not generally triggering an intense inflammatory response. Apoptosis occurs
through two major pathways either initiated by the cell itself (intrinsic) or death re-
ceptor mediated (extrinsic) mechanisms. Intrinsic apoptosis is activated in response to
DNA damage, absence of growth factors, metabolic stress or other cytotoxic stimuli
by mitochondrial outer membrane permeabilisation (MOMP). Mitochondrial proteins
such as cytochrome c and second mitochondria-derived activator of caspases (SMAC)
are released and interact with apoptotic protease-activating factor 1 (APAF1) form-
ing the “apoptosome”. This complex recruits and activates the initiator procaspase-9
[204; 205]. In addition, SMAC inhibits inhibitor of apoptosis proteins (IAP) which
bind and repress procaspase-9 and other active caspases [206; 207]. Liberated CASP9
then activates the executioner caspases (CASP3, CASP6, and CASP7) which direct
protease and endonuclease activation, cytoskeleton and nuclear protein degradation
events leading to an apoptotic cell death [202].
The initiation of MOMP is controlled by a family of B-cell lymphoma 2 (Bcl-2)
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proteins which regulate the formation of the Bax/Bak lipid pore in the outer mito-
chondrial membrane. The Bcl-2 family is made up of pro- and anti-apoptotic members.
Pro-apoptotic Bax and Bak are constitutively expressed but only associate to induce
MOMP upon direct activation through Bid, Bim and p53 proteins following exposure
to apoptotic stimuli [208]. Anti-apoptotic Bcl-2 family members including, Bcl-2, Bcl-
xL and induced myeloid leukemia cell differentiation protein (Mcl-1) block Bax/Bak
pore formation but can be sequestered by “de-repressor” proteins such as Bad, Noxa,
Blk and Puma [209].
Apoptosis through the extrinsic pathway can occur in response to binding of death
receptor ligands or by withdrawal of dependence receptor ligands. When a death re-
ceptor ligand such as TNFα binds to tumour necrosis factor receptor (TNFR) it asso-
ciates with Fas-associated via death domain (FADD) which activates initiator caspases
CASP8 and CASP10 [202]. These activated caspases simultaneously activate both exe-
cutioner caspases as well as Bid which leads to MOMP. The withdrawal of dependance
receptor ligands leads to the activation of CASP9 and other downstream executioner
caspases [202].
3.2.2 Pyroptosis
In response to DAMPS and PAMPS members of the innate immune system (and some
endothelial cells) will form multiprotein signalling complexes called inflammasomes
[210]. Inflammasomes assemble in the cytosol and mediate the activity of inflamma-
tory caspases (CASP1, CASP4, CASP5, and CASP11(mice)) and some types of inflam-
matory cell death. There are five sensor/receptor proteins that form inflammasomes,
the most extensively studied being nucleotide-binding oligomerization domain (NOD),
leucine-rich repeat (LRR)-containing protein (NLR) family members NLRP1, NLRP3
and NLRC4 [211]. In the “canonical” pathway, upon ligand binding to the sensor, adap-
tor protein (ASC) is recruited which contains a caspase recruitment domain (CARD)
and a pyrin domain (PYD). ASC binds and activates procaspase 1 which then initiates
subsequent inflammatory processes. “Non-canonical” inflammasome pathways refer
to activation of inflammatory responses effectuated by CASP4, CASP5 and CASP11
[212].
Pyroptosis is a gasdermin-mediated form of RCD usually involving caspases, that
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is innately inflammatory [213]. Morphologically, pyroptosis is characterised by cell
flattening and rapid plasma membrane rupture. It often results in the CASP1 mediated
secretion of the cytokine IL-1β, also known as leukocytic pyrogen, an important pro-
inflammatory factor [214]. Pyroptosis was originally thought to occur only in immune
cells of monocytic lineage in response to bacterial stimuli [215]. The pathway allows
the cell to release bacteria that replicate in the intracellular niche into the extracellular
space, thereby exposing the pathogens to neutrophil killing and clearance. However, it
is now evident that pyroptosis occurs in other cell types and neutrophils [215; 216].
On a molecular level, pyroptosis is initiated in response to certain pathogenic mate-
rials, particularly lipopolysaccharides (LPS) and DAMPs, by the assembly the NLRP3
inflammasome [217]. Procaspase-1, activated by ASC, goes on to cleave and activate
IL-1β and IL-18 as well as gasdermin D. Alternatively, LPS can also activate pro-
caspases 4, 5 and 11 which can cleave and activate gasdermin-D proteins through a
“non-canonical” inflammasome pathway [218; 215; 212]. Gasdermin-D proteins accu-
mulate at the plasma membrane and form large pores, which disrupt ionic gradients
leading to the influx of water, osmotic lysis and release of pro-inflammatory contents
[219].
3.3 Caspase-independent cell death
3.3.1 Necroptosis
Necroptosis is a regulated form of cell death that is morphologically similar to necrosis
and is thought to occur as an alternative to apoptosis in instances when caspases
are inhibited [220]. Necroptosis is an important process in the host defense against
pathogens by killing infected cells and is therefore also associated with inflammatory
diseases and the release of DAMPs [221; 222; 223; 224].
Similarly to extrinsic apoptosis, necroptosis that can be triggered by the binding of
stimuli such as TNF-α, IFN-γ, lipopolysaccharides (LPS) or viral double stranded RNA
or DNA to cell surface death receptors including TNFR1, FAS and PRRs such as TLRs
[200; 225]. However, necroptosis is caspase-independent and controlled by key down-
stream mediators; receptor interacting serine-threonine 3 (RIPK3) and mixed lineage
kinase domain-like pseudokinase (MLKL). Upon activation by TNF-α, TNFR1 will
form Complex I which consists of the adaptor protein TRADD, ubiquitylated receptor
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interacting serine-threonine 1 (RIPK1), TNF receptor associated factor 2 (TRAF2) and
cellular inhibitor of apoptosis protein-1 (cIAP1) which initially activates the transcrip-
tion factor NF-κB to upregulate survival factors such as cellular FLICE-inhibitory pro-
tein (FLIP) [226]. Deubiquitinilation of RIPK1 through inhibition of IAP family pro-
teins initiates the assembly of a second cytosolic complex, Complex II or DISC (cytoso-
lic death-inducing signalling complex), which includes FADD, TRADD, procaspases-8
and RIPK1 [227]. At this point, apoptosis may occur due to the activation of CASP8
or the failure of Complex I to initiate transcription of anti-apoptotic factors [228]. If
CASP8 is inhibited, RIPK1 recruits RIPK3 through their RIP-homotypic interaction
motif (RHIM) domain, and causes RIPK3 to oligimerize and autophosphorylate [229].
The RIPK1 and RIPK3 complex (the necrosome) is an amyloid-like fibrillar structure
which initiates the necroptotic pathway [230; 231]. Caspase inhibition is critical for
necroptosis to proceed as caspases can cleave the kinase domain of both RIPK1 and
RIPK3 which inhibits subsequent phosphorylation events [232; 233]. Phosphorylation
and activation of RIPK1 and RIPK3 is essential for the formation of the necrosome,
and while there is evidence that RIPK1 and RIPK3 auto-phosphorylate, and trans-
phosphorylate, other kinases as well as mitochondrial oxidants may also be involved
[234; 235; 236; 237]. Phosphorylation of RIPK3 likely creates a favorable binding sur-
face for the recruitment of the executioner protein mixed lineage kinase domain like
pseudokinase (MLKL) [235]. Upon phosphorylation of its activation loop by RIPK3,
MLKL oligomerises and localises to the plasma membrane. MLKL is thought to con-
tribute to plasma membrane perforation by forming pores that induce lytic cell death
[238; 239; 240; 241] (Figure 1.5).
3.3.2 Regulation of necroptosis
Although necroptosis is an event associated with immunity and the inflammatory re-
sponse against pathogens, not all of the major effector proteins are conserved across
the species. For example, RIPK3 and MLKL are absent from several species in the
animal kingdom [243]. Genetic knockout of either RIPK3 and/or MLKL in mice are
developmentally viable and show no major phenotypic differences compared to wild
type mice, other than resistance to necrosis [244; 245; 246].











































Figure 1.5: Death receptor stimulation of the necroptotic cellular death pathway,
formation of the necrosome and MLKL-dependent cell lysis. Upon binding of TNF-
α its receptor (TNFR1), complex I is formed consisting of adaptor proteins TRADD and
TRAF2 as well as the E3 ligase cIAP1 and RIPK1. When IAP is inhibited RIPK1 can be
ubiquitinilated and form the cytosolic Complex 2 with FADD, TRADD and CASP8. Acti-
vated CASP8 can initiate activation of the extrinsic apoptosis pathway and the activation
of CASP3 which will execute downstream events such as the fragmentation of DNA and mi-
tochondrial outer membrane permeabilisation (MOMP). When CASP8 is inactive, RIPK1
recruits RIPK3 to form the necrosome which in turn phosphorylates and activates MLKL.
Phosphorylated MLKL oligimerises and translocates to nuclear, vesicular and plasma mem-
branes, causing ruptures and ultimately cell lysis. Figure adapted from [242; 199]
RIPK1 knockout mice survive embryogenesis but die shortly after birth [243; 247].
RIPK1 can promote survival or cell death depending on its activation state. In its
ubiquitylated form its acts as a scaffold for the induction of pro-survival and inflamma-
tory genes, but in its activated kinase form, it can promote CASP8-dependent apoptosis
or necroptosis [230; 198]. The IAP family which include cIAPs and X-linked inhibitor
of apoptosis protein (XIAPs), are recruited to the TNF receptor domains upon stimu-
lation and contribute to RIPK1 regulation. IAP proteins are RING domain ubiquitin
E3 ligases that mark proteins for degradation through ubiquitylation [248]. In addi-
tion to their role directly inhibiting executioner caspases (CASP3 and CASP7) as well
as the initiator caspase (CASP9), XIAP and cIAP proteins have also been shown to
29
ubiquitylate RIPK1 [228; 249; 250].
It was recently shown that mitochondria play an essential role in TNF-α-induced
necroptosis by influencing RIPK1 kinase activity. Oxidants cause RIPK1 to autophos-
phorylate through the modification of three redox sensitive cysteine residues, enabling
interaction with RIPK3 [236]. Degterev and colleagues discovered that the small-
molecule inhibitor of necroptosis, necrostatin-1, specifically targeted RIPK1 [251].
Necrostatin-1 (Nec-1) is an allosteric inhibitor of RIPK1 kinase activity and pre-
vents the interaction between RIPK1 and RIPK3 and TNF-α-induced necroptosis
[251; 252; 253].
RIPK1 and RIPK3 activation are essential for necroptosis initiated by many death
receptors and PPRs, however, in certain settings, RIPK3 can trigger necroptosis inde-
pendently of RIPK1 and is considered the determining factor of the onset of necroptosis.
Newton and colleagues showed that RIPK3 dictates the cell death path triggered in ge-
netically engineered mice [254]. Mice expressing catalytically inactive RIPK3 induced
RIPK1 and CASP8 dependent apoptosis and also showed resistance to TNF-α-induced
necroptosis [254]. In contrast, mice expressing inactive RIPK1, although also resistant
to TNF-α-induced necroptosis, retained gene transcription abilities and did not acti-
vate CASP8 [254]. Several other studies have shown in in vitro human and murine cell
lines that RIPK3 overexpression increases susceptibility to TNF-α-induced necropto-
sis, further defining RIPK3 as a “molecular switch” between apoptosis and necroptosis
[255; 252]. RIPK3 can also induce necrosis independently of RIPK1 in mice murine
cytomegalovirus infection [256]. It has been reported that cytomegalovirus encodes
a structural protein that selectively inhibits the RHIM-binding domain and induces
RIPK3-dependent, RIPK1 independent necrosis [256]. Furthermore, a recently pub-
lished study discovered a molecule that can block the oligimerisation of RIPK3 and
simultaneously inhibit both necroptosis and apoptosis [257].
RIPK3 may also have a role in regulating mitochondrial-derived oxidants, which
impact cell death pathways. Mitochondrial oxidant production has been reported to
be an essential requirement in TNF-α-induced caspase-independent cell death in a
mouse fibroblast cell line (L929), mouse embryonic fibroblasts (MEF), and macrophages
[258; 259; 260]. RIPK3 has been shown to interact with several metabolic enzymes in
L929 cells, and increases the availability of glucose and glucose consumption enzymes.
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This increase in cellular metabolism may lead to the increased oxidant production
and subsequent necrosis [255]. However, the extent of the role of mitochondria in
necroptosis is debated, as cells lacking mitochondria are still able to undergo necroptosis
[261; 241; 253; 262]. Under certain conditions, RIPK3 has been reported to favour
apoptosis and NLRP3 inflammasome activation, often depending on the availability of
its downstream effector molecule MLKL [254; 263; 264].
The formation of the necrosome was shown to be key for the induction of necropto-
sis, however, how this complex could induce plasma membrane rupture was unknown
until the discovery of MLKL pseudokinase. Sun and colleagues first described a small
molecule inhibitor called necrosulfonamide (NSA) that blocked necroptosis downstream
of RIPK3 [239; 265]. The authors identified MLKL as the target of NSA and found
that it disabled its function by covalently binding to a cysteine residue (Cys86) found
in its effector region [239]. These authors also showed that RIPK3 bound and phospho-
rylated MLKL at its threonine 357 and serine 358 residues, and that these phospho-
rylation events were critical for necroptosis to occur. As a pseudokinase, MLKL lacks
the full set of the catalytic residues required for phosphoryl transfer [266]. MLKL’s
crystal structure revealed the presence of an N-terminal four helix bundle, and a C-
terminal pseudokinase domain joined by a two-helix linker or brace. It was shown that
phosphorylation of the activation loop helix (which forms part of the N-lobe of the
pseudokinase domain) by RIPK3 changes the protein’s conformation and enables its
necroptotic effector function [241]. MLKL forms homotrimers and translocates to the
plasma membrane where the positively charged amino acids on its four helix bundle
bind to phosphatidylinositol phosphates and induces leakage of liposomes and Ca +2
influx leading to necrosis [240; 267].
There are a number of interacting protein partners that may enhance and/or mod-
ify MLKL’s behaviour. The anti-oxidant enzyme, thiol oxidoreductase thioredoxin-1
(Trx1) has been shown to preferentially bind the monomeric form of MLKL, block-
ing disulfide bond formation and oligomerisation [268]. This finding suggests that
MLKL activity can be regulated by its redox state. Heat shock protein (Hsp90) has
been reported to stabilize both RIPK3 and MLKL translocation to the membrane,
preventing their proteasomal degradation [269; 270]. Furthermore, MLKL interacts
with the non-voltage-sensitive channel transient receptor potential melastatin related
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7 (TRPM7) that has been reported to be essential for MLKL’s pore forming capacity
[267]. Moreover, MLKL appears to regulate PS exposure on the outer leaflet of the
plasma membrane prior to necrosis, as well as the formation of “necroptotic bodies”
- two traits which were previously thought to be hallmarks of apoptosis [271; 272].
Apart from its role in necroptosis, MLKL may also be involved in facilitating endo-
somal trafficking and extracellular vesicle generation [273]. This constitutive role of
MLKL was shown to occur independently of RIPK1 and RIPK3, although its activity
was enhanced by RIPK3 phosphorylation.
Whilst retaining much of the molecular machinery required for death pathway ac-
tivation, there are many unique properties of the neutrophil which can modify conven-
tional execution of regulated cell death pathways.
3.4 Neutrophil lifespan
Although generally considered to be short-lived cells, the average lifespan of the neu-
trophil in the absence of proinflammatory signals remains unclear. Pillay and colleagues
carried out an in vivo heavy water (2 H2O2) neutrophil labelling experiment in humans
and reported the lifespan of the neutrophil in the absence of infection to be approxi-
mately 5 days [274]. This was in stark contrast to all previous reports which estimated
neutrophil half-lives between 24-36 hours [47; 275; 276; 277; 278], and was critically
received [279; 280; 281]. The authors conceded that the data from their experiment was
subject to limitations due to the lack of information about neutrophil transit time in
the bone marrow, which may have impacted their mathematical modelling. A more re-
cent study, using a similar method, employed a two-compartment mathematical model
that accounted for bone marrow and circulating blood neutrophil pools and determined
unstimulated neutrophil half-lives to be between 13-19 hours [282].
Further complicating measurements of neutrophil lifespan is the evidence that a
substantial amount of aged neutrophils can reside much longer in peripheral tissues
such as the liver and spleen (marginated pool) and can be stimulated to return to
circulation by the injection of steroids [278; 283; 284]. Furthermore, there are challenges
associated with the interpretation of lifespan data associated with in vitro experiments.
There have been reports of neutrophils becoming activated during isolation and culture
procedures that can artificially prolong lifespan and confound measurements [277; 285].
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Nevertheless, mature neutrophils are arrested in G0/G1 phase of the cell cycle, and
this low transcriptionally active state further supports the notion of a short lifespan
[286; 287; 288]. The following section will discuss several fundamental features of the
neutrophil that predispose it to more easily follow the pathway to apoptosis.
3.5 Anti-inflammatory death pathways in neutrophils
Apoptosis is the most common form of death in neutrophils. The act of efferocytosis
of apoptotic neutrophils by macrophages promotes the anti-inflammatory phenotype
of the macrophage, stimulates tissue repair and aids in the resolution of inflammation
[124; 289; 290].
Under non-pathological conditions, mature, terminally differentiated neutrophils
are released from the bone marrow into the bloodstream and are programmed to die
by spontaneous apoptosis shortly thereafter. However, there are several fundamen-
tal physiological idiosyncracies of neutrophils which result in subtle deviations in the
regulation of their apoptotic pathway.
Neutrophils have low levels of mitochondria and appear to rely predominantly on
glycolysis for metabolic requirements [291; 292; 293; 294]. Neutrophils also express
low quantities of the mitochondrial protein cytochrome c [291]. Whilst cytochrome c
normally plays a role in the electron transport chain in mitochondria, in the neutrophil,
its major function is in the assembly of the apoptosome and is essential in the activation
of caspases [295]. Furthermore, neutrophils express high levels of APAF-1 and low
levels of both X-linked inhibitor of apoptosis protein (XIAP) and cellular inhibitor of
apoptosis protein 1 (cIAP1) which further favours an apoptotic fate [295].
The balance of expression of pro- and anti-apoptotic proteins involved in neutrophil
apoptosis may support the hypothesis that neutrophils have shorter life cycles. Ma-
ture neutrophils express negligible levels of anti-apoptotic Bcl-2 protein [296]. Instead,
Mcl-1 appears to be the major regulator of survival in the neutrophil [297; 298]. Mcl-
1 binds pro-apoptotic Bcl-2 family members, and sequesters Bak and Bax, however,
Mcl-1 has a much shorter half-life (3 hours), compared to its pro-apoptotic equiva-
lents [298]. Furthermore, neutrophils express myeloid nuclear differentiation antigen
(MNDA) which is localised to the nucleus in young and activated neutrophils. In aged
neutrophils, MNDA is released into the cytosol where it is activated by caspases and
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associates with Mcl-1, accelerating its degradation [299].
Another factor influencing neutrophil apoptosis is the production of oxidants by the
NADPH oxidase complex NOX2 [300]. In resting cells, components of NOX2 exist in
the cytosol and membranes, only assembling upon activation. It has been proposed that
oxidant production is a critical factor in the activation of executioner caspases during
phagocytosis [301]. Upon phagocytosis of microorganisms, oxidants are produced along
with the release of cytotoxic proteases from granules in order to kill the pathogens. It
has been claimed that this process induces phagocytosis induced cell death (PICD),
where certain bacterial strains, accelerate apoptosis in neutrophils through a process
dependent on the production of oxidants [302; 301; 303; 304]. PICD is classically driven
by the upregulation of Bax leading to MOMP and the oxidant-dependant activation of
caspase-8 [305]. In contrast, several other reports have shown that phagocytosis and
subsequent oxidant production inactivates caspases and prevents caspase-dependent
classical apoptosis [300; 306; 307]. Oxidants produced by NOX2 also stimulate the
activation and/or granule release of proteases such as calpains and cathepsins which
in turn influence protein degradation events downstream of caspase activation during
apoptosis [308; 309; 310; 311; 312]. Neutrophils undergo death receptor mediated apop-
tosis [313]. Neutrophils express Fas, TNF and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) cell surface receptors [314] and several studies have reported
that ligand binding to these receptors leads to accelerated classical apoptosis under non-
inflammatory conditions [300; 315; 296; 316]. However, the effect of TNF-α binding on
neutrophil death is variable, as a range of outcomes after exposure have been reported
[317; 318; 319]. One study has shown that TNF-α could induce apoptosis in a subpop-
ulation of neutrophils between 2-8 hours after exposure, but this effect was abrogated
if the neutrophils were primed or aged prior to exposure [320]. In contrast, another
study showed that TNF-α treatment can confer a protective effect by stimulating the
transcription factor NF-κB to upregulate anti-apoptotic proteins [321]. Van den Berg
and colleagues confirmed that neutrophils exposed to low doses of TNF-α (<1ng/mL)
were protected against apoptosis which depended on the synthesis of de novo proteins.
However, exposure to TNF-α at concentrations over 10ng/mL did induce apoptosis in
neutrophils, which could not be overcome by the addition of anti-apoptotic cytokines
and was dependent on NOX2 activation [322]. A mechanistic link explaining the di-
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vergent effect of TNF-α was uncovered by Cross and colleagues who reported that low
concentrations stimulated transcription of anti-apoptotic Bcl-2 family member A1/Bfl-
1 (A1) while higher concentrations accelerated Mcl-1 degradation [323; 324]. Apoptosis
due to death ligand binding is more likely to occur in an inflammatory context, where
the molecular players involved can receive function-modifying signals and be steered
off their course, leading to alternative pathways and pro-inflammatory outcomes [283].
3.5.1 Factors influencing apoptotic pathways
During inflammation, granulocyte colony stimulating factor (G-CSF) and granulocyte
macrophage colony stimulating factor (GM-CSF) released by immune cells and tumours
not only simulate the release of neutrophils from the bone marrow [325], but can also
increase the life span of neutrophils already in circulation [326; 327; 328]. This combined
effect may contribute to deregulation of neutrophil homeostasis and the neutrophilia
observed in many cancers related to inflammation [28].
GM-CSF delays apoptosis in neutrophils by increasing the expression of Mcl-1,
allowing it to exert its inhibitory effect on pro-apoptotic Bax [297; 329; 330; 331]. G-
CSF has been shown to stimulate the production of proliferating cell nuclear antigen
(PCNA). PCNA is a factor typically involved in DNA synthesis in repair, and resides
in the nucleus in most cells. However, in neutrophils, high levels of PCNA are found in
the cytosol where it associates with and prevents activation of executioner procaspases
and prolongs neutrophil lifespan [332]. PCNA levels decline naturally with the onset
of apoptosis [332].
Interleukin-8 (IL-8), also known as neutrophil chemotactic factor, is secreted by
macrophages, endothelial cells and neutrophils, and not only causes neutrophil mi-
gration but also stimulates the secretion of more IL-8 [126; 333]. IL-8 secreted by
neutrophils has been shown to favour metastasis in melanoma studies by enabling pas-
sage through the endothelium [126; 334]. IL-8 has been reported to prolong the lifespan
of neutrophils by delaying both spontaneous [335; 336] and TNF-α-induced apoptosis
[336; 337]. However, other studies have shown IL-8 to have no effect on spontaneous
apoptosis [327; 338]. IL-8 has also been shown to stimulate non-apoptotic pathways in
neutrophils which will be discussed in Section 3.6.1.
While the engulfment of certain pathogens can promote neutrophil apoptosis, other
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strains can delay neutrophil apoptosis and PICD [339; 340; 305; 341]. For example,
phagocytosis of Francisella tularensis has been shown to interrupt the assembly of
NOX2, stabilise mitochondria and reduce Mcl-1 expression which combine to prolong
the life of the neutrophil significantly compared to other pathogenic stimuli [342; 305].
Pattern recognition receptors (PRR), such as the toll-like receptors (TLR) and
NOD-like receptors (NLR), on the neutrophil cell surface enable it to detect PAMPS
such as LPS [343], peptidoglycans and flagellins [344]. Activation of the TLR path-
way leads to the translocation of nuclear factor-κB (NF-κB), mitogen-activated protein
(MAP) kinases and interferon regulatory factors to the nucleus that activate transcrip-
tion of several effector cytokines and chemokines which can modify neutrophil function
and fate [345]. Exposure to LPS has been shown to activate neutrophils and inhibit
apoptosis at early time points [327; 346], but can promote necrosis at later time points
[347; 344]. These variable outcomes may indicate that LPS exposure can activate
multiple death pathways.
In instances of serious infection or inflammation, neutrophils can become over-
whelmed with signals and undergo necrosis or activate other pro-inflammatory path-
ways to cell death.
3.6 Pro-inflammatory death pathways in activated neutrophils
Our understanding of the immune response to cell death was once based on the di-
chotomy of anti-inflammatory programmed cell death versus lytic, pro-inflammatory
necrotic cell death. A new approach centers on predicting inflammatory response from
the recognition of damage-associated molecular patterns (DAMPS) from dying cells
[193]. This approach stems from observations that apoptotic cell death can still be
pro-inflammatory and immunogenic based on the cell surface exposure and/or release
of particular DAMPS [348]. DAMPs, also called alarmins, include cell surface ex-
posed proteins such as calreticulin [349], heat shock proteins (HSP)[350], adenosine
triphosphate (ATP) and PS, as well as discharged cell degradation products such as
high-mobility group box 1 protein (HMGB1)[351; 352], nucleic acids and urate [353].
When DCs encounter DAMPs they can prime helper and cytotoxic T-cells, triggering
an adaptive (immunogenic) response.
It has also been reported that while both DCs and macrophages can present antigens
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from apoptotic cells to T-cells [354; 355], only DCs are able to trigger a response [355].
Furthermore, DCs that have engulfed apoptotic cancer cells can prime cytotoxic T-cells
to elicit a sustained tumour-specific immune response in mice [356; 357].
However, there is evidence that DAMP release does not automatically provoke an
adaptive immune response [358]. Yatim and colleagues proposed that DAMPs should be
classified as either inducible or constitutive. Constitutive DAMPs are the constituents
of a cell, that are present regardless of the mode of cell death, and are passively released
upon membrane damage. Constitutive DAMPS can be sensed by DCs and trigger an
inflammatory response by innate immune cells, but not necessarily the adaptive branch.
Inducible DAMPs occur through NF-κB activation associated with the type of death
pathway launched in the cell. T-cell priming and subsequent adaptive immune response
appears to be dependent on these inducible DAMPs [359].
In response to DAMPs and PAMPS neutrophils assemble inflammasomes upon
stimulation and these complexes are involved in several forms of pro-inflammatory
neutrophil cell death pathways [360]. In the neutrophil, the pathways leading to pyrop-
tosis appear to be altered, and the mechanisms remain ill-defined. Several studies have
shown that while the NLRP3 inflammasome is formed in response to bacterial stimuli
(Salmonella, Streptococcus pneumoniae and LPS) and is responsible for processing sig-
nificant amounts of IL-1β, it is not involved in neutrophil pyroptosis [361; 362; 360].
One study has reported that neutrophils NLRC4-dependent pyroptosis occurs in re-
sponse to P.aeruginosa infection but only when the NOX2 is impaired [216]. Other
reports have demonstrated that NLRC4 activation drives CASP1 dependent IL-1β pro-
cessing and activation, but not cell death in neutrophils stimulated with Salmonella
and P.aeruginosa [361; 363]. Yet another study has claimed that neutrophils do not
express NLRC4 and do not undergo pyroptosis [364].
Neutrophils also differ in their processing of the pyroptosis effector protein gasdermin-
D. CASP1 does not cleave gasdermin-D effectively in neutrophils [365], but it can
be cleaved by the serine protease neutrophil elastase in aging neutrophils and dur-
ing E.coli infection [366]. A recent study has shown that in neutrophils challenged
with LPS, NLR3 inflammasome mediated cleavage of gasdermin-D does not result in
its trafficking to the plasma membrane but rather to the azurophilic granules [367].
Gasdermin-D permeabilised the granules and facilitated the release of NE into the
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cytosol [367]. Other studies have suggested that gasdermin-D activity overlaps with
other forms of cell death. Chen and colleagues reported that neutrophils exposed to
LPS or gram-negative bacteria, activated the CASP4/11 pathway leading to a type of
gasdermin-D-dependent and caspase-independent lytic cell death [365]. Moreover, this
type of cell death did not occur when inhibitors of gasdermin-D were used [368].
3.6.1 Neutrophil extracellular traps
A novel trait of neutrophils was discovered by Brinkmann et al. in 2004 called neu-
trophil extracellular trap (NET) formation [197]. NET formation is a process in which
the neutrophil decondenses its DNA and ejects it to the exterior of the cell. The
purpose of this apparently suicidal function appears to be trapping microbes in the
extruded DNA thus preventing their spread. NETs are composed of chromatin and
citrullinated (post-translationally modified arginine) histones (H3Cit) as well as sev-
eral active granule components including MPO and elastase which may contribute to
killing of invaders [197; 369; 370]. Following neutrophil stimulation, a series of molec-
ular events occur including, superoxide O ·–2 production, mitochondrial depolarisation,
vacuolisation and chromatin decondensation. Extranuclear DNA mixes with neutrophil
granule components and following the break down of the plasma membrane, is released
extracellularly, often resulting in a regulated neutrophil death called NETosis.
Phorbol 12-myristate 13-acetate (PMA) is a potent non-physiological inducer of
NETs and is widely used as a trigger for NET release in in vitro experiments. PMA tar-
gets protein kinase C (PKC) which initiates the assembly and activation of the NADPH
oxidase complex NOX2 on neutrophil membranes. Diphenyleneiodonium (DPI) inhibits
NOX2 activity and the production of NETs. The production of oxidants is thought to
be essential for the formation of NETs as neutrophils from patients with chronic granu-
lomatous disease (CGD) have a reduced capacity to form NETs [371]. However, it has
been shown that neutrophils can extrude NETs in response to calcium ionophores, in-
dependently of NOX2 in a process that depends on potassium channel protein 3 (SK3)
and mitochondrial oxidants [372; 373].
NETs are pro-inflammatory and have been implicated in inflammatory disease
states such as atherosclerosis, venous thromboembolic disease, gout, cancer and more
recently, coronavirus disease-19 (COVID-19) [374; 375; 376; 377].
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The first study to show evidence of NETs in human cancer tissue was a study
involving Ewing sarcoma patients. Of the eight patients, two patients showed evidence
of TAN and these TAN colocalised with extracellular DNA and MPO. Based on this,
the authors suggested that NETs are associated with cancer progression because these
two patients experienced relapse, while four patients that did not have NETs did not
relapse [376].
Several studies have shown that chemokines known to be upregulated by tumours
and TAN such as IL-8, G-CSF and TGF-β promote NETosis [378; 379; 380]. In mouse
lung and mammary carcinoma models, increased systemic levels of G-CSF was shown
to increase neutrophil counts and prime these neutrophils to produce NETs when chal-
lenged with LPS. The resulting NETosis and increased volume of circulating extracel-
lular chromatin was shown to increase the risk of cancer-associated thrombosis in these
mice [380].
Cools-Lartigue and colleagues published a review on NETs in cancer progression
highlighting that while there is some evidence that NETs are involved in tumour pro-
gression, a great deal more indirect research has been done on neutrophil proteins and
peptides that may be associated with NETs (i.e neutrophil elastase, MMP-9) [381].
Given the adhesive nature of NETs more research has centered on the role of NETs
in promoting metastasis. In vitro and murine models have shown that NETs sequester
circulating tumour cells and promote metastasis by facilitating tumour cell adhesion
to distal sites. Mice treated with DNAases and neutrophil elastase inhibitors did not
develop metastases [382]. In a similar vein, human CD66b+, mature, low density,
NET-producing neutrophils from gastric cancer patients were shown to readily adhere
to gastric cancer cells in co-culture. Again, this effect was abolished by pretreatment
with DNAse [383]. Furthermore, in a recent study in hepatocellular carcinoma (HCC),
neutrophils from patients with HCC, particularly with metastatic HCC, showed in-
creased NET formation. They demonstrated that NETs adhered to HCC cells, made
them more resistant to death and enhanced their invasive qualities. This metastatic
potential was blocked when NET formation was prevented [384]. Furthermore, it was
shown that a metastatic 4T1 breast cancer cell line could induce NET formation in the
lungs of mice [385].
NET components have shown prognostic potential in small study that analysed
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the H3Cit levels in advanced cancer patients compared to severely ill (cancer-free) and
healthy individuals. H3Cit plasma levels were significantly higher in advanced cancer
patients, corresponding with circulating levels of NE and MPO as well as poor clinical
outcomes [386].
NET formation is thought to be a form of necrotic death which is usually results
in lysis of the neutrophil. As we have seen, neutrophil cytolysis leads to the release
of many reactive oxidants and proteases that have inflammatory and cytotoxic poten-
tial. This has lead to some debate as to whether NET formation is simply just the
carcases of dead neutrophils that trap microbes by a passive process, rather than an
active process utilised by neutrophils in response to stimuli [387]. However, there is
some evidence that NETs can be delivered outside of the neutrophil without caus-
ing cell lysis in a process called vital NETosis. Pilsczek and colleagues observed a
rapid onset, oxidant-independent, vesicle-mediated DNA release of NETs in response
to Staphylococcus aureus which did not result in neutrophil death. [388]. Other studies
have suggested that the NETs are composed of mitochondrial DNA [389]. While vital
NETosis has been shown to occur in response to bacterial stimuli, it is unclear if this
process takes place in cancer and requires further research [387; 390].
Studies of the NET release pathway have shown that several critical processes
must occur for it to take place, therefore, NET extrusion can be regulated. How-
ever, the molecular mechanisms behind how neutrophils extrude NETs through the
plasma membrane remain unclear. It has been proposed that the pyroptosis effector
protein gasdermin-D is essential for NET release, by first forming pores in granules
to release NE and then forming pores in the plasma membrane to allow NET extru-
sion [368; 365]. The execution of specific death pathways can depend on the type of
stimuli encountered and the availability of effector proteins in the pathway. It is there-
fore possible there are other pore-forming molecules from other death pathways that
can execute a similar function as gasdermin-D in NET release that have not yet been
uncovered.
3.6.2 Necroptosis effector molecules and regulated necrosis in neutrophils
Necrosis involving the effector molecules RIPK1-RIPK3-MLKL can be induced in neu-
trophils using various stimuli. However, significant knowledge gaps remain in the func-
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tion of the molecular players involved in neutrophil necroptosis and there may be
considerable overlap between other known molecular death pathways.
3.6.3 TNF-α-induced necroptosis
Tumour necrosis factor alpha (TNF-α) is an important inflammatory cytokine which
has significant roles in both immune homeostasis and in inflammatory disease. TNF-
α is predominantly secreted by macrophages, but lower levels are also secreted by
endothelial cells and neutrophils [391]. In pathological conditions, TNF-α can also be
expressed by a range of human cancers, and contrary to what its name suggests, it is
associated with resistance to apoptosis, proliferation, recruitment of myeloid cells and
ultimately poor patient outcomes [392; 393; 394].
Furthermore, neutrophil oxidants, such as HOCl, are known to promote the pro-
duction of TNF-α by T-cells, macrophages and B-cells [395; 396; 397; 398]. The in-
flammatory tumour microenvironment is therefore, likely to be an area of high TNF-α.
Since neutrophils accumulate in tumours and their N2 phenotype shows resistance to
apoptosis, it is important to clarify the effect of TNF-α on neutrophil lifespan.
To date, only one published study has shown that neutrophils undergo TNF-α-
induced necroptosis through the RIPK1-RIPK3-MLKL pathway [399]. Wicki and col-
leagues showed that the murine neutrophil pathway to necroptosis or apoptosis was
dependent on the activity of XIAP [399]. They showed that wild type murine neu-
trophils as well as XIAP -/- mice exposed to TNF-α were susceptible to apoptosis,
which could be blocked when the pan-caspase inhibitor benzyloxycarbonyl Val-Ala-
Asp (OMe) fluoromethylketone (zVAD-FMK) was used in the wild type mice but not
in the XIAP -/- mice. Instead, in the XIAP -/- mice, the use of zVAD-FMK induced
translocation of MLKL to the plasma membrane and necroptotic cell death, an effect
that was negated by inhibitors of RIPK1 or MLKL. Necroptosis could be induced in
the wild type mice by using a combination of zVAD-FMK and IAP inhibitor SMAC
mimetic (AT-406) in combination with TNF-α. At present, whether human neutrophils
are susceptible to necroptosis through the use of these protypical necroptosis inducers
remains to be shown.
As discussed in Section 3.5, low levels of TNF-α generally prolong neutrophil lifes-
pan and higher levels promote death through apoptosis, however, alternative outcomes
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have been observed. Early reports have shown that TNF-α exposure induced both
apoptotic and necrotic cell death in neutrophils independently of activated caspases
through the use of the zVAD-FMK [400; 401; 402]. Several of these reports indicated
that the presence of intracellular oxidants were essential for the cell death observed
[400; 402].
A prerequisite for necroptosis is the inactivation of caspases, and caspase-independent
cell death has been shown to be dependent on mitochondrial derived oxidants. How-
ever, in activated neutrophils, NOX2 would be the prominent source of oxidants, and
would likely obscure any contribution from the mitochondria. While there appears to
be a regulatory relationship between caspases and the production of oxidants through
NOX2, how this interaction is mediated is debated. One report has shown that TNF-α
stimulation of neutrophils pre-treated with zVAD-FMK reduced levels of extracellu-
lar oxidants [403], suggesting that caspase function is upstream of the NOX2 and can
impact its activity. However, under similar conditions, other studies have shown that
caspase inhibition increases oxidant production [404; 401; 405]. The role of NOX2 and
its oxidants in neutrophil TNF-α-induced necroptosis remains unclear.
3.6.4 Adhesion receptor-induced necroptosis
A study by Wang and colleagues showed that neutrophils can undergo necroptosis when
primed with GM-CSF by the ligation of adhesion molecules to several cell surface pro-
teins [406]. The cell surface proteins CD44, CD11b, CD15 and CD18 all mediate neu-
trophil adhesion to endothelial surfaces and are involved in neutrophil migration and
functional activities [407; 408; 409; 410]. The authors observed necrotic death in the
absence of any pharmacological inhibitors of caspases or IAPs that was dependent on a
pathway involving the RIPK3-MLKL-dependent activation of p38 mitogen-activated
protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K). Interestingly, while
MLKL involvement was a critical factor in triggering necroptosis, they did not find
that it was responsible for plasma membrane rupture. Rather, in this system, it took
on a role of a signalling molecule responsible for NOX2 activation. They showed that
oxidant production was essential for membrane rupture as both neutrophils from CGD
patients (who have impaired NOX2 activity) and neutrophils with pharmacologically
inhibited NOX2 could not undergo adhesion receptor-induced necroptosis [406].
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3.6.5 Pathogen-induced necroptosis
Neutrophil engulfment of pathogens can lead to phagosomal killing by means of the
cytotoxic oxidants produced by NOX2 and apoptotic death. However, some microbes
can alter neutrophil death pathways causing necrosis.
The first study to suggest that pathogen-induced necroptosis occurs in neutrophils
showed that neutrophils underwent a RIPK1-dependent necrosis upon phagocytosis
of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The
authors showed that the lytic death observed was dependent on RIPK1 by using large
doses (50-500µM) of Nec-1 [411]. Several years later, the authors revised this claim
showing that the lytic death observed by ingestion of CA-MRSA in neutrophils was
independent of RIPK1 and MLKL activity but was dependent on RIPK3 activity,
suggesting that a new cell death pathway was invoked by these bacteria [412]. Fur-
ther research showed that CA-MRSA promoted secretion of IL-1β in a non-pyroptotic
pathway independent of NLRP3 inflammasome and CASP1 activation [413]. The in-
volvement of neutrophil oxidants in this pathway were not assessed.
A clear example of necroptosis in human neutrophils in response to pathogens is
during infection with the protozoan parasite Leishmania infantum. It was reported
that when CASP8 was inhibited L. infantum exposure caused RIPK1-RIPK3-MLKL
dependent necroptosis [414; 415]. The role of oxidants produced by NOX2 in necrop-
tosis were not explored in this study.
A summary of the regulated cell death pathways in the neutrophil are presented in
Figure 1.6.
3.6.6 The potential overlapping molecular players in neutrophil necropto-
sis and NETosis
Neutrophil necroptosis and NETosis are two forms of regulated necrosis that rely on
membrane permeabilisation for execution. MLKL has been shown to contribute to
extensive membrane remodelling events in necroptosis, such as PS exposure [271] and
pore formation [267], but has also been reported to be involved in endosomal trafficking,
extracellular vesicle generation and nuclear membrane translocation in other cells [419;




































































Figure 1.6: Overview of regulated cell death pathways in neutrophils. Regulated cell death
can result in a immunologically tempered apoptotic cell death or a pro-inflammatory necrotic cell
death. Apoptosis (far left) is an intrinsically wired pathway in most cell types involving the release
of mitochondrial effector proteins but can also be triggered by extrinsic stimuli. Both extrinsic and
intrinsic pathways involve the activation of caspases. These cysteine-dependent proteases catalyse a
cascade of events leading to the destruction of vital cell components and their packaging into intact
apoptotic bodies for clearance by other phagocytes. Pyroptosis (far right) is also a caspase-dependent
form of cell death but results in plasma membrane lysis and the release of pro-inflammatory cytokines.
In response to PAMPS, DAMPS or LPS the cell will form protein complexes called inflammasomes
which activate CASP1 and stimulate the release of inflammatory cytokines (IL-1β and IL-18). Ulti-
mately, Gasdermin D is cleaved by either CASP1 or neutrophil elastase (NE) and forms pores in the
plasma membrane leading to cell lysis. Non-canonical pathways which bypass the inflammasome can
activate CASP4 and CASP5 also leading to Gasdermin D mediated cell death. Necroptosis is a form
of caspase-independent cell death that results in membrane lysis and is mediated by RIPK1, RIPK3
and MLKL. Necroptosis can occur in response to death receptor ligand or adhesion molecule binding,
certain pathogens and some interferons. It is dependent on the inhibition of both CASP8 and IAPs
as well as the availability of proteins in the RIPK1/3-MLKL pathway. Cell lysis due to neutrophil
extracellular trap (NET) extrusion (NETosis) is another form of regulated cell death that results in
an inflammatory response. NET release can be triggered by PMA, MSU, adhesion receptor ligation
and some pathogens and leads to the production of oxidants by either the NADPH oxidase complex
NOX2 or mitochondria. Nuclear and granule membranes are degraded, and their contents mix in the
cytoplasm prior to release. Pores form in the plasma membrane to allow for release of extracellular
traps which are composed of double stranded DNA decorated with MPO and NE as well as other bac-
tericidal molecules. The characterisation of the molecular players involved in each of these pathways
as well as their interconnectivity is a rapidly expanding field. Figure adapted from [200; 416; 417; 418]
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Two independent papers exploring associations of the RIPK1-RIPK3-MLKL path-
way in NET formation were published in the same journal issue and presented conflict-
ing results. Desai and colleagues used PMA (25nM) or monosodium urate crystals as
stimuli for NET release and measured NETs by quantifying the fluorescence of sytox
green (a cell-impermeable DNA binding dye) after 2 hours [420]. The authors showed
that pre-incubation with Nec-1 or NSA significantly decreased NET release under both
conditions. Furthermore, they showed that with both stimuli, levels of phosphorylated
MLKL increased incrementally over 3 hours post-stimulation [420]. Since NET release
is dependent on the activation of NOX2, the authors next examined the effect of Nec-1
and NSA on oxidant release. They found that there was no significant inhibition of
oxidant release with either inhibitor in both the PMA and MSU stimulated neutrophils.
Furthermore, they showed that CGD patient neutrophils stimulated with PMA demon-
strated significantly less MLKL phosphorylation compared to control. Finally, bone
marrow derived neutrophils from RIPK3 -/- mice exposed to MSU, LPS and PMA
showed significantly less NET release and cell death overall compared to controls [420].
In contrast, Amini and colleagues reported that there were no significant decreases
in NET formation when neutrophils were treated with LPS, PMA or E.coli, in RIPK3
-/- compared to wild type mice. Furthermore, there were no significant differences
in neutrophil oxidant production and bacterial killing between the species. In hu-
man neutrophil experiments, there were no significant differences in human neutrophils
pre-incubated with NSA in NET formation, oxidant production and bacterial killing
compared to control [421].
In the wake of these opposing reports, Naccache and Fernandes published a com-
mentary outlining the challenges with working with NETs in the laboratory [422]. The
authors noted that the methodologies utilised to analyse NET release are often incon-
sistent between studies. For example, plating neutrophils on glass slides (as performed
in the Amini study) may lead to pre-stimulation. Furthermore, fluorescent dyes that
are normally used to visualise NETs (such as sytox green or picogreen) do not distin-
guish between mode of cell death, they simply bind to extracellular DNA. Also, NETs
are generally quantified using microscopy by reporting the “NETs per field of view” or
“NET forming neutrophils”, however these methods are highly subjective. Based on
these points, the authors highlighted that the major differences between the Desai and
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Amini papers could be attributed to; the stimulation time (2 hours by Desai versus 1
hour by Amini), and the differing methods of cell isolation and microscopic analysis
[422].
In spite of these challenges, further evidence has emerged linking MLKL to NET
extrusion. D’Cruz and colleagues showed that IFN-γ-primed bone marrow mouse neu-
trophils with pharmacologically inhibited IAPs and caspases underwent a necropto-
sis that was morphologically similar to NETosis [423]. They detected extracellular
citrullinated histones (H3Cit) and double stranded DNA co-localized to necroptotic
neutrophils in wild type mice but not in RIPK3 -/-, MLKL -/- or kinetically inactive
RIPK1 -/- mice. They also determined that necroptosis in this system required the
presence of NOX2-independent oxidants, as pre-treatment with the oxidant scavenger
N-acetyl-L-cysteine (NAC) but not DPI inhibited this process [423]. Using immunogold
electron microscopy, the authors showed that MLKL localised to both the plasma and
nuclear membranes and was also found on extracellular double stranded DNA in IFN-
γ-primed necroptotic neutrophils. This effect was not observed when the neutrophils
were pre-treated with the Nec-1 [423]. Interestingly, IFN-γ-primed human neutrophils
did not produce NETs or undergo necroptosis when treated with the combination of
Biranapant (IAP inhibiting compound) and Z-VAD-fmk (caspase inhibitor). However,
the neutrophils did respond when pre-treated with an alternative IAP inhibiting com-
pound that they claimed more effectively inhibited both XIAPs and cIAPs. NET
formation and cell death using this system was blocked by Nec-1. In addition, they
investigated the necroptotic pathway in PMA stimulated human and mouse neutrophil
NET extrusion, and noted that it was dependent on NOX2 and neither the inhibition
of RIPK1 nor deficiency of RIPK3 or MLKL negatively impacted on NET formation
[423].
Phosphorylated MLKL has been detected on NETs associated with venous throm-
boembolic disease [424]. Mice pre-treated with Nec-1 or deficient in MLKL prior to
inferior vena cava ligation were less prone to clot formation in vivo. In vitro experi-
ments showed neutrophils treated with thrombin-activated platelets died by NETosis
whereas neutrophils pre-treated with Nec-1 remained viable [424].
In line with the finding of Desai and colleagues, a recent study showed that PMA
treatment increased levels of phosphorylated MLKL and induced NET formation in
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human neutrophils [425]. The authors showed that NET formation was inhibited by
pre-incubation with high doses (50-100µM) of Nec-1. However, this finding was not
validated by using any other inhibitor such as NSA (MLKL inhibitor) or DPI (NOX2
inhibitor)[425]. Further work has used HL60 cells (a human cell line that can be
matured into neutrophil-like cells by treatment with dimethyl sulfoxide (DMSO)) to
show that MLKL-dependent NET formation occurs in response to PMA [426].
The necroptosis death pathway has an important role in inflammation and disease
pathogenesis. Dead neutrophils, particularly necrotic neutrophils can release cytotoxic
oxidants and proteases into the local microenvironment. Such a death can inflict local
tissue damage, alter molecular pathways, exacerbate the inflammatory response and
potentially cause carcinogenesis. It is therefore important to characterise the death
pathways of neutrophils. Cellular death pathways are complex, and the interconnec-
tivity between molecular players are challenging to define. The role of necroptotic
effector proteins in neutrophil fate and function remains unclear as numerous conflict-
ing reports exist. It remains unknown if human neutrophils can undergo necroptosis
using the classical inducers of the pathway (TNF-α+ZVAD-fmk+IAP inhibitor (TSZ)).
Furthermore, while MLKL appears to play a role in NET formation as well as other
death and signalling pathways, the exact mechanisms require further research.
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4 Neutrophils and epigenetic pathways in cancer
Epigenetics is the study of how environmental factors produce heritable changes in
cellular gene expression without modifying the primary genetic code [427; 428]. Dis-
turbances to gene transcription lead to modified protein expression and altered cell
function. While changes to gene expression can enable short-term adaptations to en-
vironmental stressors, they can also induce longer term changes leading to disease and
cancer.
Tumour progression is not solely driven by genetic mutations to key genes that
control cell proliferation and survival pathways, but is also affected by environmental
factors in its growth niche [429]. Research into the epigenetic pathways in cancer such
as histone protein modifications, chromatin remodeling, non-coding micro RNA and
DNA methylation have revealed mechanisms which enable aberrant gene expression
and tumourigenesis.
Chronic inflammation is considered to be one the most influential environmental
factors contributing to the initiation and progression of cancer and has been connected
to epigenetic changes in tumours [430; 431]. The following sections will examine current
literature on epigenetics in cancer with a focus on how inflammation could impact DNA
methylation.
4.1 Epigenetic pathways
In order for the cell to function, molecular transcriptional and translational machinery
must be able to access the codes for proteins written in the DNA. DNA is packaged
into chromosomes that keep it tightly compacted within the nucleus. Chromosomes
are made up of chromatin that is composed of DNA and protein histones wound into
compact spools called nucleosomes [432]. At the core of the nucleosome structure is an
octameric complex comprised of four pairs of histone proteins; H2A, H2B, H3 and H4.
Adjacent nucleosome cores connect through a section of DNA bound to linker histone
protein (H1 or H5), which allows for the formation of higher-order compact structures
[433]. Chromatin exists in either a tightly compressed closed state (heterochromatin)
preventing gene expression, or in a less condensed open state (euchromatin) allowing
for the binding of transcription factors and the downstream translation of proteins.
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Despite each cell sharing identical genetic information, multicellular organisms are
composed of many different cell types with specialized forms and functions. This di-
versity is possible because epigenetic marks are used to coordinate gene expression or
repression in specific cell types. The majority of these marks are assigned during the
process of differentiation in early development, however, this process continues long
into adult life via the differentiation of tissue stem cells. To maintain a differentiated
state, each cell must preserve its specific pattern of epigenetic marks and gene expres-
sion throughout DNA replication and cell division [434]. Histone modification and
DNA methylation are two epigenetic mechanisms that protect against untimely gene
expression, by regulating the availability of gene transcription from euchromatin until
required [435].
4.2 Histone protein modifications
Protein histones have amino acid tails, that protrude from the nucleosome and carry
many reversible post-translational modifications, including: methylation, acetylation,
phosphorylation, ubiquitinylation and deamination. These modifications influence
transcription by recruiting or blocking effector proteins [436; 437], and also modify levels
of chromatin compaction by interfering with sister nucleosome interactions [438; 439].
Of the post-translational histone tail modifications, the acetylation of ε-NH2 lysines
has been the most extensively studied and is most commonly associated with tran-
scriptionally active euchromatin [440]. Acetylation is regulated by histone deacetylases
(HDAC) which are ubiquitously present in cells, but simply unraveling the chromatin
is often not sufficient to activate genes, as the presence of methyl groups bound to
DNA nucleotides provides added stability to gene silencing. In addition, methyl-CpG
binding proteins (MBP), recruit HDAC favouring a closed chromatin state [441; 442].
Thus, histone proteins and DNA methylation have overlapping molecular players that
combine to modify the activities involved in gene activation [435; 443].
4.3 DNA methylation
DNA methylation is an enzymatic process that consists of the covalent addition of a
methyl group (CH3) to the 5-carbon of the cytosine nucleotide ring, resulting in the
formation of 5-methylcytosine (5-mC). The distribution of 5-mC in the human genome
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is so common that it is often referred to as the fifth base [444]. The formation of 5-mC
is mediated by a family of DNA methyltransferases (DNMT) that catalyse the transfer
of methyl groups from S -adenosyl methionine (SAM). The transferred methyl group
extends into the major groove of the DNA helix, rendering the base inaccessible to
transcription factors [442].
In the mammalian genome, approximately five percent of cytosines are methylated
[445], and the vast majority are located in regions of DNA where the cytosine is directly
adjacent to a guanine (connected by a phosphate group), called CpG sites [446]. This
specificity for CpG sites allows for symmetrical addition of methyl groups to both
parental DNA strands ensuring that methylation patterns can be maintained on the
nascent strand during replication [447; 448] (Figure 1.7).
Over half of the genes in the mammalian genome contain short CpG enriched re-
gions called CpG islands. Approximately 60% of CpG islands are located at promoter
regions of transcriptional start sites and methylation in these regions can effectively
repress gene transcription [449]. However, CpGs islands can also occur outside of a
promoter region and methylation of CpGs islands along the gene body do not gener-
ally interfere with elongation of the transcript [450; 451]. Moreover, methylation can
occur outside of CpG islands, which can lead to the silencing of transposons [452], as
well as influence promoter enhancers [453] and insulators (which modify enhancers)
[454]. The methylation of CpG islands in intragenic regions may regulate alternative
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Figure 1.7: Activated and deactivated transcriptional states of DNA and Chromatin. In
each cell of the human body, 22 homologous chromosomes and a pair of sex chromosomes (typically
either XX (females) or XY (males)) house the entire genetic code written in the DNA. Each highly
compacted chromosome consists of hundreds of thousands of nucleosome structures which are made up
of DNA wound around protein histones. The chromatin can be in either a condensed, heterochromatin
state where transcription is silenced (red box), or, a transcriptionally active, open euchromatin state
(green box). Euchromatin has the potential to be transcriptionally active, however, this depends on
additional factors including transcription factor (TF) availability. Heterochromatin has deacetylated
histones and methylated DNA which together with its conformationally unfavorable state prevent the
binding of transcriptional machinery such as RNA polymerase and transcription factors, which blocks
the production of protein transcripts. The catalytic addition of a methyl group (CH3) by DNMT from
SAM to cytosine (5-mC) at CpG sites can inhibit gene expression. When histones are acetylated and
the DNA is unmethylated, transcription enablers may access the DNA freely and gene expression is
favoured. Adapted from [457]
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4.3.1 DNA methyltransferases
DNMTs are enzymes responsible for the establishment and maintenance of 5-mC in the
genome. DNMT1, DNMT3a and DNMT3b have enzymatic activity and associate with
DNA, whereas DNMT2 is inactive. Initially, DNMT1 was considered to be the sole
overseer of maintenance methylation with DNMT3a and DNMT3b encoding exclusively
the de novo methylation required to establish genomic methylation in embryogenesis
[458]. However, there is now clear evidence that DNMT3a and DNMT3b also assist
in the maintenance of methylation and all three DNMTs are essential for mammalian
development [459; 460].
DNMT1 is the most abundant methyltransferase in differentiated mammalian cells,
and is the largest in size with a molecular mass of 1̃80 kDa [461]. DNMT1 associates
with the replication fork [462], ensuring methylation patterns are reinstated in the
daughter strand during DNA replication [463]. A number of proteins have been shown
to form complexes with DNMT1 to guide and enhance its activity during the S-phase
of the cell cycle [464; 465]. Ubiquitin-like, containing PHD and RING finger domains 1
protein (known as UHRF1, ICBP90 and NP95) binds to hemimethylated DNA, recruits
DNMT1 and participates in the eversion of cytosines for methylation [466; 467; 468;
469; 470]. Proliferating cell nuclear antigen (PCNA), a key scaffolding factor for DNA
replication and DNA repair, has also been shown to bind DNMT1 and amplify its
activity [464]. While the interaction of these proteins with DNMT1 has been reported,
it is a matter of debate as to whether they are vital to the methylation process [471; 472].
DNMT1 contains an amino-terminal regulatory domain, and a proline-cysteine
dipeptide active site in it’s catalytic C-terminal domain [473]; with both domains es-
sential for activity [474]. The C-terminal region also contains ten essential domains
required for interaction with the methyl donor SAM. The N-terminal region contains
the replication foci targeting sequence that enables the enzyme to associate with the
replication fork, as well as an allosteric site that can bind 5-mC and improve the en-
zyme’s positioning with both DNA and SAM [475; 476; 477]. When a mutation to the
DNMT gene was introduced in an in vivo mouse embryogenesis model it resulted in
embryonic lethality and dramatic global demethylation [478]. However, the discovery
that knocking out DNMT1 in embryonic stem cells in vivo did not cause cell death
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nor disrupt de novo methyltransferase activity, prompted the search for other DNMTs
[479]. Okano et al. first described the existence of the de novo methyltransferases
DNMT3a and DNMT3b in mammals [480]. DNMT3a and DNMT3b are smaller in
size ( 120kDa) compared to DNMT1, and have a shorter N-terminal region, but the
catalytic domain is conserved amongst all DNMTs [481].
The major difference between DNMT1 and DNMT3a/DNMT3b is its preferential
methylation of asymmetrically methylated DNA. In vitro experiments comparing the
rates of methylation of unmethylated versus hemimethylated oligonucleotdes showed
that while DNMT1 strongly favoured the methylation of hemimethylated oligonu-
cleotides, DNMT3a and DNMT3b readily methylated hemimethylated and unmethy-
lated oligonucleotides equally [480].
DNMTs can associate with each another through their N-terminal regions, which
can lead to a five-fold increase in methylation rates [482]. DNMT1 can be stimulated
to participate in de novo methylation by DNMT3a both by direct association, and
indirectly, by increasing its activity at DNMT3a methylated sites [483]. Knocking out
both DNMT1 and DNMT3b in a colorectal cancer cell line led to the demethylation
of key tumour progression genes, an effect that was not observed when they were
knocked out individually, suggesting that these two methyltransferases are capable of
maintaining the silence of tumour suppressor genes [459]. There is also some evidence
that DNMT1 may play a regulatory role in the DNA damage repair response as it has
been shown to be recruited by and associate with PCNA and RAD9 at sites of DNA
double strand breaks [484; 485].
4.3.2 S -adenosyl methionine and the methionine cycle
The methylation of DNA by DNMTs relies on a methyl transfer reaction which depends
on S -adenosyl methionine (SAM) as a cofactor. Although other methyl donors do exist,
such as folate, DNMTs have a strong preference for SAM due to its highly favorable
reaction thermodynamics [486]. The availability of SAM is dependent on the delicate
interplay of several key enzymes and their reaction products in the methionine cycling
pathway.
Methionine is an essential amino acid and insufficient dietary intake has been linked
to modified gene expression and oncogenesis [487; 488]. SAM is generated through
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the reaction of methionine adenosyltransferase (MAT) with methionine and adenosine
triphosphate (ATP). DNMTs transfer the methyl group to the 5-carbon ring of the
cytosine nucleotide and SAM is converted to S -adenosylhomocysteine (SAH). SAH
is the substrate for SAH hydrolase (SAHH), a NAD+-dependent enzyme, which hy-
drolyses SAH to adenosine and homocysteine. Homocysteine is then converted either
into glutathione (a ubiquitous cellular antioxidant) or is methylated to produce me-
thionine by the enzyme methionine synthase (MS) or enzymes involved in the folate
cycle. Homocysteine levels are depleted through reactions with folate/B12-dependent
methionine synthase and/or betaine-homocysteine methyltransferase which catalyse
the production of or tetrahydrofolate (THF), a key methyl group donor/acceptor in
the folate cycle. Cystathionine β-synthase (CBS) uses homocysteine as a substrate
for the formation of cystathione, a critical precursor in the transsulfuration pathway
leading to glutathione synthesis. Adenosine deaminases or adenosine kinases can react
with adenosine to keep adenosine concentrations favorable and keep the cycle flowing
forward (Figure 1.8) [489; 490; 491].
4.3.3 Passive demethylation
Processes surrounding the demethylation of DNA are as critical as their methylation.
This is particularly the case in early mammalian development. Monk et al. first
observed a genome-wide demethylation in mouse development at the zygote stage, prior
to uterine implantation [493]. After implantation, DNMT3a and DNMT3b mediate de
novo methylation and the previously absent DNMT1 maintains this methylation as the
cell continues to divide [493; 494].
The failure of DNMT1 to methylate a daughter strand of DNA during replication
results in a passive DNA demethylation process [495]. This phenomenon has been
described in cells that exhibit high proliferation rates. A recent study showed that
suppression of DNMT1 expression in highly proliferative mouse embryonic fibroblasts
(MEF), passively and preferentially demethylated genes involved in pluripotency. This
lead to the increased expression of these genes and induced a more stem-like phenotype
[496].
Passive demethylation can also occur by disruptions to the pathways involved in the
























Figure 1.8: The methionine cycle. Cellular methionine is converted to S -adenosylmethionine
(SAM) by the methionine adenosyltransferase (MAT) and ATP. A methyl group is transferred from
SAM to cytosine by DNMT which generates 5-mC on the DNA and S -adenosylhomocysteine (SAH).
SAH hydrolase (SAHH) converts SAH to homocysteine and adenosine. Homocysteine and adenosine
levels must be adequately depleted in order to favor the reaction of SAH with SAHH. Homocysteine is a
substrate for methionine synthase (MS) which, in conjuction with vitamin B12, regenerates methionine
as well as tetrahydrofolate (THF) (a key molecule in the folate cycle). Homocysteine is also a substrate
for cystathionine β-synthase (CBS) which converts it to cystathionine. The transsulfuration pathway
continues and generates cysteine, the precursor for glutathione synthesis. Adapted from [486] and
[492]
of SAM to SAH has been called the “methylation index” as an indicator of methylation
status in the cell [497]. The formation of SAH is much more favorable in equilibrium
dynamics than that of its products, therefore, levels of SAH will increase if adenosine
and homocysteine are not effectively cleared [498]. DNMTs have been shown to bind
SAH with a higher affinity than SAM, thus a build up of SAH results in significant
inhibition of DNMTs as well as decreasing levels of SAM [498; 499; 500]. Yi et al.
showed that even a modest increase in homocysteine levels was sufficient to produce
an increase in SAH levels as well as global hypomethylation in primary lymphocytes
[501]. Another study showed that depleted SAM levels alone was not enough to affect
methylation levels and only increased SAH levels and/or a decreased SAM:SAH ratio
was correlated with hypomethylation [502]. Not only are the reaction thermodynamics
unfavorable, but cysteines in the active site of SAHH are capable of forming disul-
fides which inactivate its catalytic activity [503]. When recombinant human placental
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SAHH was exposed to a panel of thionucleoside derivatives that targeted its cysteine
at position 195, all caused enzymatic inactivation and one was shown to be partially
dependant on the redox activity of the enzyme [503].
Several studies have looked at the effect of a low oxygen environment on SAM and
SAH levels with perplexing results. Under hypoxic conditions, SAM and SAM:SAH
levels increased in a HEPG2 hepatoma cell line [504], however, the opposite effect was
observed in a cervical cancer cell line (HeLa) under the same conditions [505]. These
authors also noted that increased cell density was positively correlated with decreased
SAH levels, concluding that SAM and SAH regulation under hypoxic conditions may
depend on tumour types as well as density or cell contact related factors [505; 506].
All mammalian cells contain MAT and it is particulary active in the liver. MAT
is encoded by three genes; MAT1A, MAT2A and MAT2B. MAT1A gene expression is
found predominantly in the liver where it encodes for an α-1 subunit forming the MATI
(tetramer) and MATIII (dimer). The α-1 subunit contains ten cysteines in its active
site and these isoenzymes can be regulated post-translationally by either nitrosylation
or oxidation of a cysteine at position 121, which leads to inactivation [507; 508; 509].
In contrast, MAT2A and MAT2B are expressed in most tissues. MAT2A encodes for
the catalytic subunit α-2 and MAT2B encodes for the regulatory subunit MATβ of
the MATII enzyme. The MATII enzyme contains half as many cysteines in its active
site as MATI/MATIII and lacks the redox sensitive cysteine 121. Although it has been
shown that MATII may not be sensitive to inactivation by H2O2 exposure [510], its
inactivation was reported in human alcoholic liver cirrhosis by means of oxidative stress
and/or an unvalidated post-translational modification [511; 512].
Under hypoxic conditions, HIF-1α induced an increase in MAT2A mRNA expres-
sion as well as MATII activity but a decrease in SAM levels which led to hypomethyla-
tion in hepatoma cells [513]. In contrast, in a model of high oxidative stress (alcoholic
rat liver), an increase in MATII enzyme, decreased SAM and subsequent hypomethy-
lation was also observed [514]. This is intriguing since MATII is responsible for SAM
production and its increased activity has traditionally been associated with increases
in SAM levels. Possible explanations have been proposed for this including; redirection
of SAM to the polyamine pathway and/or the build up of homocysteine levels due to
increased activity of betaine homocysteine transferase and decreased activity of MS
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[513; 514].
These studies suggest that the activity of MATII as well as other members of the
methionine cycle may be regulated by an oxidative mechanism that is not yet fully
understood. Notably, many of these enzymes contain critical cysteine residues in their
active sites, and could therefore be susceptible to inactivation through oxidation.
4.3.4 Active demethylation
While the mechanisms of passive demethylation and DNMT inhibition have been the
subject of substantial research, active demethylation pathways are more obscure.
Given the strength of the carbon-carbon bond present in 5-mC, it was once thought
that passive demethylation was the only plausible explanation for what was deemed
an irreversible modification. However, it has now been shown that active demethyla-
tion does occur. Active demethylation can occur by base excision repair mechanisms
driven by base modification through hydroxylation of 5-mC by ten-eleven translocation
(TET) enzymes and/or deamination by activation induced deaminase (AID) enzymes
[495]. These modified bases contribute to demethylation either by preventing DNMT
maintenance methylation on the parental strand during replication because the base
is no longer recognised as methylated [515], or by base replacement by base excision
and/or mismatch repair processes [516; 517].
The AID enzyme was initially identified in B-cells contributing to antibody diver-
sification through its ability to convert cytosines to uracils in regions of the Ig loci
[518].AID can deaminate either cytosine or 5-mC yielding uracil or thymine, respec-
tively. These mismatched bases are recognised by thymidine DNA glycosolase (TDG)
and methyl-CpG-binding domain protein 4 (MBD4) and removed from the DNA, lead-
ing to replacement at the abasic site by an unmethylated cytosine by base excision
repair enzymes [519]. However, attributing a major role to AID in active demethyla-
tion is controversial, due to the fact that it is rare in tissues apart from lymphoid and
cancer cells [520], and the high error rate involved in uracil excision repair [521; 522].
The family of TET enzymes (TET1, TET2 and TET3) are 2-oxoglutarate and iron-
dependent dehydroxylases that use molecular oxygen to convert 5-mC to 5-hydroxymethyl
cytosine (5-hmC). TET can also react with 5-hmC to produce 5-formylcytosine (5-fC),
and 5-carboxylcytosine (5-caC) through subsequent iterative oxidative reactions [523].
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The TET family’s active site is highly conserved and contains a cysteine rich region
adjacent to the 2-oxoglutarate-Fe(II) dioxygenase domain that is involved in chromatin
targeting and is essential for TET function [524; 525]. TET1 and TET3 also contain a
CXXC zinc finger domain which enables CpG binding [526]. 5-hmC is abundant in the
genomic DNA of all mammals and is thought to be an intermediate of demethylation.
However, there is also evidence to suggest that it is not a transient species and could
represent a new epigenetic marker, or a “sixth base” [527; 528; 528].
TET oxidation of 5-mC is thought to modulate gene activity by three different path-
ways. Firstly, it removes the methyl mark from cytosines, thus entraining replication-
dependent demethylation. Secondly, 5-hmC may attract alternate proteins modifying
normal processes at the base. For example, MBDs do not recognise 5-hmC and there-
fore cannot provide their level of protection against transcription and recruitment of
deacetylases [441]. Furthermore, UHRF1 (a known DNMT1 regulator) also binds hemi
or fully 5-hmC CpGs, therefore suggesting its involvement in the regulation of TET
[529]. Thirdly, 5-hmC can be converted to 5-hydroxymethyluracil (5-hmU) by AID or
5-fC and 5-caC by TET, all of which are recognised by DNA glycosylases, ultimately
leading to regeneration of unmethylated cytosines [530]. It is currently unknown what
consequence the oxidation of 5mC or other TET-mediated oxidative derivatives on
promoters or other regulatory regions has on the translation of proteins.
TET enzymes may have more complex functions outside of their role in demethy-
lation as its activity has been associated with both upregulation and downregulation
of gene expression in embryonic stem cells [531]. Mutations to the TET2 gene is one
of the most frequently reported in blood cancers [532]. Decreased expression of TET
enzymes and 5-hmC is also common in other malignancies such as gastric, lung and
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Figure 1.9: Passive and active demethylation. Passive demethylation (green box) can occur
when either TET enzymes generate 5-hmC from 5-mC or when DNMTs are inhibited directly or
indirectly by limiting levels of SAM. If 5-hmC is present then DNMT will not recognise the base as
methylated and not methylate the newly synthesized DNA at the appropriate site. If the DNMT or
SAM levels are inhibited the DNMT may fail to bind with the hemi-methylated parental strand. In
this example, at subsequent replications, the absence of methylation in the nascent strand will be
amplified leading to the dilution of the 5-mC signal at these cytosines. During active demethylation
(red box) TET enzymes generate 5-hmC from 5-mC but can also react with the 5-hmC to produce
5-fC and 5-cAC. These products are recognised by thymidine DNA glycosolases (TDG) which will
excise these cytosine bases leaving an abasic site. Base excision repair enzymes will recognise these
sites and insert unmethylated cytosines. If the unmethylated cytosines are not recognised by DNMTs
during replication, the 5-mC signal will be diluted in newly replicated DNA. Adapted from [527] and
[534].
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4.4 Altered DNA methylation in cancer
Whilst an altered genetic profile is an established hallmark of tumour progression, aber-
rant epigenetic modification patterns are now recognised as an important collaborator
in enabling genomic instability [535; 536]. Hypermethylation within the promoter re-
gions of tumour-suppressor genes leads to gene silencing and tumour progression in
many different cancer types [537; 538; 539; 540; 541]. In tumour progression, the most
advantageous gene regions to become hypermethylated are those involved in the regula-
tion of cell survival and proliferation. Hypermethylated cell cycle control genes such as
p16 have been observed in human leukemia-lymphoma cell lines resulting in a distinct
growth advantage and immortalisation [542]. Cell adhesion genes such as cadherins are
also often hypermethylated in certain cancers, a trait linked with tumour metastasis
[543]. Other tumour suppressor genes such as the well-known BRCA1, a gene involved
in DNA repair, is often silenced through hypermethylation in breast and ovarian can-
cers [544]. Apart from p16 hypermethylation which has now been observed in many
cancers [545], patterns of methylation may be unique to the cancer type and/or its stage
[535]. In contrast, global decreases in methylation are widespread in numerous cancers
[546; 547; 548]. Hypomethylation can lead to chromosomal instability, increased tu-
mour frequency and to the reactivation of previously silenced oncogenes [549; 550]. One
of the first studies to investigate methylation states in human cancers discovered that
at several gene loci, tumour DNA was significantly hypomethylated compared to nor-
mal adjacent tissue from the same patient [546]. Several in vivo experiments showing
connections with cancer induction and hypomethylation have used DNMT knock down
models to induce the hypomethylation [551; 549], however, many cancer cell types ex-
hibit increases in DNMT expression, particularly DNMT3b [538; 539; 540; 541]. Ostler
et al. reported that cancer cell lines expressed at least 20 different forms of truncated
DNMT3b transcripts that lacked their catalytic domain [552]. These truncated forms
are thought to compete for binding to DNA with active DNMT forms or with its bind-
ing partners to modulate DNMT activities [552]. The mechanisms leading to DNMT
inactivation and hypomethylation require further research.
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4.5 Inflammation, neutrophil oxidants and DNA methylation
Oxidative stress occurs when the generation of oxidants in a cell exceeds the ability
of antioxidant defenses to neutralise them. Genetic mutations caused by oxidative
DNA damage can lead to the initiation of cancer and other diseases, with 8-hydroxy-
2’-deoxyguanosine (8-OHdG) is the most frequently observed DNA modification asso-
ciated with oxidative stress [553]. 8-OHdG is abundant in mammals, and has been
used as a biomarker for oxidative DNA damage and carcinogenesis [554; 555; 556]. 8-
OHdG is promutagenic because it can cause base pairing mismatches, random adenine
insertions, misreading of adjacent pyrimidines and eventual GC to TA transversion
mutations [557; 553]. In addition, the presence of 8-OHdG within a one or two nu-
cleotide proximity on the same strand was shown to inhibit maintenance methylation
by DNMT in the nascent DNA strand [558]. The formation of the oxidative product
8-OHdG can occur from exposure to carcinogenic substances and endogenous cellular
sources, but it can also be formed from oxidative stress brought on by inflammation.
However, the frequency of 8-OHdG has been estimated at less than 10,000 per cell, and
it is unclear how often this modification would occur at a CpG site [559]. Therefore,
8-OHdG is unlikely to account for major global changes in methylation.
As we have discussed in section 1.4 activated neutrophils are a major source of
oxidants during inflammation [118]. One in vivo mouse model study found a positive
correlation between MPO levels and tumours with higher mutagenicity [121]. H2O2 and
hypohalous acids produced by MPO can all react with DNA producing adducts which
can either cause damage to the strand or lead to base substitutions and mutagenesis
[560]. The hypohalites OCl– and OBr– formed by the reaction of H2O2 and halide ions
with MPO have been shown to form 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG)
which directly damages DNA [561]. Promutagenic DNA lesions due to the formation
of 8-chloroguanine through exposure to HOCl causes G to C transversions during DNA
synthesis [562].
In addition to promoting direct DNA damage, there is evidence that neutrophil
oxidants can also modify epigenetic pathways. Weitzman et al. reported alterations
to the methylated regions of oncogenes in bacterial and mammalian cells treated with
activated neutrophils [563]. Several studies have found aberrant methylation patterns in
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patients that have chronic inflammatory diseases of the gastrointestinal tract associated
with increased cancer risk [564; 565; 566]. Interestingly, the analysis of cells in both
mice and humans with chronic inflammation has revealed that about 60% of genes that
were methylated in cancer were also methylated in chronically inflamed non-cancerous
tissue prior to tumour formation; suggesting that hypermethylation is a predisposing
feature of carcinogenesis [564; 567].
The effect of H2O2 on methylation patterns remains unclear, and may be concen-
tration dependent. At high concentrations of H2O2 (500µM), significant increases in
methylation were observed at targeted sites in an osteoblast cell line. At lower con-
centrations H2O2(100µM), this change was not observed [568]. This is in agreement
with a study showing that treatment of a colon cancer cell line with H2O2(1mM to
8mM) stimulated recruitment of DNMT1 to its protein binding partners and this com-
plex localised preferentially to CpG rich promoter regions of DNA. This resulted in
hypermethylation and gene silencing [569]. Interestingly, it’s recently been shown that
acetylated (activated) TET2 enzymes can form a complex with DNMT1 and TDG and
protect against abnormal methylation during H2O2 treatment [570].
In the search for a compound that inhibited DNMT activity one group serendipi-
tously discovered that several candidate compounds containing quinone cores effectively
inhibited DNMT by a mechanism dependent on their production of H2O2(100µM). This
suggested inhibition of DNMT by inactivation of its core cysteines in its active site [571].
These compounds were not tested further in in vitro models.
Molecular chlorine produced by neutrophil MPO can react with cytosine to produce
5-chlorocytosine (5-cC) [572]. A series of experiments from Valinluck et al. showed that
neither MBPs nor DNMTs can differentiate between 5-cC and 5-mC. Therefore, MBPs
and DNMTs can bind to 5-cC and bring about de novo methylation [573; 574; 575].
Since there are no known glycosylases that can remove 5-cC, it can be incorporated
into DNA causing heritable abnormal methylation patterns in nascent DNA. One study
showed that while the incorporation of 5-cC did result in gene silencing, there was no
significant change in global methylation levels. It is also unclear, how often 5-cC
would occur under physiological conditions, and would depend on the proximity and
abundance of more favorable HOCl or chloramines reaction partners within the cell
[5; 576; 577]. However, these results do suggest that the incorporation of 5-cC over an
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extended period of time (due to chronic exposure to oxidants through inflammation),
could have an accumulative effect, and contribute to longer-term changes in methylation
patterns [578].
Neutrophil oxidants could also effect the epigenetic pathways of other immune cells
found at an inflammatory site. Inflammatory states can give rise to populations of
neutrophils that are chronically activated and produce increased amounts of oxidants,
which are known to interfere with T-lymphocyte function [579] (section 1.5.1). Follow-
ing activation, T-lymphocytes rely on epigenetic pathways in order to proliferate and
produce differentiated memory or effector subsets [580; 581]. Furthermore, the release
of cytokines such as IFN-γ is dependent on rapid demethylation of its gene [582]. There
are relatively few studies that have explored the epigenetic impact of neutrophil derived
oxidants on T-lymphocytes. However, two studies have shown that CD4+ T cells that
were treated with 20-50 µm H2O2 showed reduced DNMT1 levels and demethylation
of key genes involved in lupus disease progression [583; 584].
Previous work by our research group has used a mass spectrometry approach to show
that a single sub-lethal exposure to the neutrophil oxidant glycine chloramine (GlyCl),
impaired cytosine methylation on newly replicated DNA in a Jurkat T-lymphoma cell
line [585]. This was associated with inhibition of DNMT1 and depletion of methionine
and occurred at doses that had minimal effect on proliferation. There was no significant
reduction in global methylation levels when a single exposure of H2O2 was used in
this model. Analysis of global methylation was assessed between 2 and 6 hours post-
treatment, therefore it was not determined if the demethylation observed was heritable
in subsequent generations of cells. Due to the methods used, this work did not give
any insights into the specific genes affected by demethylation by GlyCl and potential
enabling pathways. Furthermore, DNMTs have been shown to be most active in the
S-phase of the cell cycle [586]. It would therefore be interesting to investigate what
impact oxidative treatment would have on methylation during this time period.
Understanding how DNA methylation changes are rewritten in the methylome, and
the implications of these changes to cell function is fundamental to understanding
the aetiology and successful treatment of disease. There is evidence to suggest that
methylation processes are influenced by oxidative stress, due in part to the susceptibility
of DNMT and SAM levels to redox regulation. At present no studies have investigated
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how neutrophil oxidants can influence the methylation patterns of T-lymphocytes at
a nucleotide resolution and if these patterns can become established in the genome in
subsequent generations.
5 Summary and Research aims
The influential role of the immune system in cancer is becoming increasingly clear.
Chronic inflammation, often even at subclinical levels, increases cancer risk substan-
tially, and has been implicated in the initiation, progression and spread of neoplastic
disease. Immune cells are attracted to tumours and can initiate both pro- and anti-
tumour responses depending on the signals they receive. Neutrophils, as the most
abundant leukocyte in the body, are often the first to respond to inflammatory signals.
They can be directly cytotoxic to tumours and promote an adaptive response, but can
also encourage tumour growth through the release of cytokines, proteases and oxidants.
Furthermore, tumours can secrete cytokines that illicit the recruitment of circulating
immune cells as well as the precipitous release of populations of immature myeloid cells
from the bone marrow. These myeloid derived suppressor cells (MDSC) have altered
functional capacities compared to their mature counterparts and have been shown to
enable tumour growth. Research into how neutrophils contribute to cancer progression,
not only as biomarkers, but mechanistically, is now a field of considerable interest.
Cutaneous squamous cell carcinoma (CSCC) is a skin cancer that is strongly influ-
enced by the immune system. Therapeutically immuno-suppressed individuals (TII)
have a significantly higher propensity to develop an uncommonly aggressive phenotype
of CSCC which can lead to poor patient outcomes. The underlying aetiology behind
this phenomenon is unclear. However, previous work by our research group has shown
that higher levels of neutrophil-like granulocytic MDSC are present in the blood of
TII presenting with aggressive phenotype CSCC [99]. Moreover, a subset of patients
not receiving immuno-suppressive medications (non-TII) also develop aggressive CSCC
and we have shown higher levels of granulocytic MDSC in the blood of patients pre-
senting with CSCC tumours with high metastatic risk [587]. Although there has been
increasing evidence highlighting the potential functional role and/or prognostic value
of neutrophils in disease progression in other cancers, these parameters have not been
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assessed in CSCC. The specific objective of Chapter 3 was therefore to analyse asso-
ciations between circulating and tumour-infiltrating neutrophil numbers, the presence
of MPO in tumours and clinical markers of high risk CSCC.
Another important aspect of inflammation is cell death. While apoptosis generally
results in a silent, anti-inflammatory response, an explosive, lytic necrotic cell death
is pro-inflammatory with tumour-promoting potential. Damage-associated molecular
patterns (DAMPS) and other pro-inflammatory signals released from necrotic cells
results in a rapid response from immune cells which respond to local tissue damage
and clear cellular debris. However, this process can result in immune responder cells
secreting factors that promote angiogenesis, growth and proliferation of surrounding
cells. Cell death in the tumour microenvironment is therefore an important aspect to
consider in the progression of cancer. In the absence of survival signals, neutrophils
commonly die by apoptosis, but when they are activated, they produce oxidants and
secrete cytokines that enable them to live substantially longer. Bearing in mind the
associations between neutrophil infiltrate in tumours and cancer progression, it is per-
tinent to consider modes of neutrophil death that require further characterisation and
their ensuing effects in an inflammatory milieu. Although several types of regulated
necrosis in the neutrophil have been reported, the specific functions of the effector
molecules involved remain poorly defined. In Chapter 4, the role of the key necroptosis
pathway proteins will be explored in the context of neutrophil function and death in
response to TNF-α and other conventional neutrophil stimuli.
As mentioned above, one of the consequences of a lytic cell death is the release of
intracellular contents into the local environment. The cells in the vicinity of a lytic
neutrophil would therefore suddenly have to cope with a variety of stimuli including
strong diffusible oxidants and proteases. Oxidative stress can be substantially increased
following the death of activated neutrophils, and while cells can adapt to short-term
exposure to oxidative stress, high levels of oxidation can result in extensive and irre-
versible damage to membranes, proteins, lipids and DNA. However, sublethal levels
of oxidants can have more subtle effects on cells by altering enzymatic activities and
inducing stress responses leading to changes in gene expression, metabolic activities
and/or death pathways. One of the hallmarks of cancer is genomic instability and
mutation, which lead to altered gene expression and tumour promotion. However, it
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is now clear that the atypical gene expression observed in cancer may also be due,
in part, to modifications to the epigenome as a result of environmental factors. The
methylation of cytosine in DNA is an epigenetic mark that leads to gene silencing, and
methylation patterns are often transformed in human cancers. While there appears
to be an association between inflammation and epigenetic changes in cancer cells, the
mechanisms behind how this could occur are yet to be defined. Since the molecular ma-
chinery responsible for the faithful transfer of methylation to nascent strand cytosines
are sensitive to oxidation, research into the effects of neutrophil derived oxidants on
methylation is worth investigating. Chapter 5 will explore the effect of exposure to
neutrophil oxidants on DNA methylation patterns in T-lymphoma cells, whether or
not these changes can be inherited by subsequent rounds of cell division and what
functional pathways could be affected by these alterations.
The main aim of this thesis was to assess the effects of neutrophil function and fate
in the context of cancer by investigating their role in:
 cutaneous squamous carcinoma disease progression and outcome (Chapter 3)
 pro-inflammatory cell death and the molecular players involved (Chapter 4)




1 Cell culture reagents
RPMI, fetal calf serum, penicillin and streptomycin were from Invitrogen (Auckland,
NZ) and Endotoxin-Free Dulbecco’s phosphate buffered saline (PBS) (1X) was from
Sigma-Aldrich (Steinheim, Germany).
2 Methods applicable to Chapter 3
2.1 Clinical audit selection criteria
Records from the Department of Plastic and Reconstructive Surgery, Christchurch
Hospital, New Zealand were searched to locate all individuals with excision of primary
CSCC between January 1, 2009 and December 31, 2011, preoperative complete blood
cell counts (CBC) and comprehensive pathology reports, including all tumour charac-
teristics (n=332). Further data were retrieved from medical records, including survival
time since diagnosis (date last seen or date of death).
Case exclusion criteria included in situ CSCC lesions, recurrent or metastatic
CSCC, incomplete histopathology reports or medical records, and presence of diseases
that modulate circulating leucocyte numbers (HIV, haematological malignancy, recent
(<2 years) exposure to chemotherapy). Cases remaining were defined as the ‘Initial
Cohort’ (n=282).
Because a proportion of the patients presented with multiple tumours removed by
one or more operations over a short period (<3 months), further selection criteria were
applied to restrict case inclusion from that period to a single, representative CSCC
tumour per patient. These tumours were identified as having, firstly, the highest BWH
67
T stage, and, secondly, the greatest tumour thickness. If a patient presented with a
new primary CSCC more than three months after the previous CSCC, the tumour was
included in the study as an independent incidence.
Patients that were currently taking immunosuppressive medications (Prednisone,
Azathioprine, Cyclosporine, Tacrolimus or mycophenolate mofetil) were defined as
‘therapeutically immuno-suppressed individuals’(TII) and were excluded from the study.
Patients not currently taking any immunosuppressive medications were defined as ‘non-
therapeutically immuno-suppressed individuals’(non-TII) and were included in the final
cohort(n=129).
2.2 Prospective study of matched circulating and tumour-
localised immune cell populations
Twenty eligible non-TII (selection criteria as per “Final cohort”) donated preoperative
fresh blood and a primary CSCC tumour sample to the Cancer Society Tissue Bank
Christchurch (CSTBC) in 2013. For each patient, a routine CBC was performed by
the Canterbury District Health Laboratory, and the results were retrieved from the
Christchurch Hospital online patient medical record database. Patients provided in-
formed, written consent for use of tissue and permission to access medical records.
Ethical approval was granted by the Upper South Island Regional and University of
Otago Human Ethics Committees.
2.3 Immunohistochemistry
Of the tumour samples in the prospective study, 20 were available for immunostaining.
Formalin fixed paraffin embedded tumour sections (2µm) were prepared and immunos-
tained. Double immuno-labelling was performed manually according to the manufac-
turer’s protocol using EnVision G—2 Doublestain System Rb/Mo DAB+/Permanent
Red (Dako, Carpinteria, CA, USA). Primary antibodies were against the neutrophil, G-
MDSC and eosinophil specific antigen CD66b (1:1000,clone GF10F5; BD Biosciences,
San Diego, California) and the cytotoxic T-lymphocyte specific antigen CD8 (1:50,
clone C8/144B, Dako). Rabbit polyclonal antibody against human myeloperoxidase
(1:1500, A398, Dako,Carpinteria, CA). For antigen retrieval, slides were incubated in
Tris-EDTA (pH 9.0) for 3 min in a pressure cooker, then cooled for 40 min at room
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temperature.
Immunohistochemical quantification of the CD66b and CD8 positively stained cells
was carried out by the student and confirmed by an anatomical pathologist (Dr. An-
drew Miller), blinded to clinicopathological information. Immunohistochemical quan-
tification of the number of MPO stained cells was carried out by the student and
unconfirmed by an independent assessor. The number of CD66b, CD8 or MPO stained
cells observed in peritumoural and intratumoural locations were enumerated in three
randomly selected high-powered fields (HPF, 400x, 0.23 mm2) in areas with high im-
mune cell infiltration (excluding areas of tissue necrosis and ulceration). Numbers of
cells in each location were expressed as the average number of cells per HPF.
The levels of extracellular MPO was determined by attributing a score of ‘low’ or
‘high’ to the HPF. A score of high was given if the presence of extracellular MPO was
observed in over 50% of the total MPO+ cells.
2.4 Statistical analysis
Categorical variables were compared by the Chi-squared and Fisher’s exact test. Con-
tinuous variables between patient groups were compared using the Kruskal-Wallis test
with Dunn’s post test and Mann Whitney U tests. Survival distributions were plotted
using Kaplan-Meier plots and compared by the log rank test. Univariate and multivari-
ate analysis of prognostic factors was carried out using the Cox proportional hazards
regression model. Survival data for a New Zealand (NZ) population, with the same
age and gender distribution as the patient cohort, were generated using life table data
(years 2010 – 2012) from Statistics New Zealand. These data were based on NZ birth
and death registrations during 2000–2002. The Kaplan-Meier method was used for uni-
variate analysis, and Cox regression (odds ratios with 95% CI) for multivariate analysis.
All significance tests were two-sided, and p values of <0.05 were considered significant.
Statistical analyses were performed using SPSS for Windows version 17 (SPSS Inc.,
Chicago, IL, USA) and PRISM 5.0 software Graph Pad Software Inc. (San Diego,
CA, USA).
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3 Methods applicable to Chapter 4
3.1 Neutrophil isolation
3.1.1 Human
Blood was donated from healthy volunteers. 5% (w/v) dextran (Sigma-Aldrich, Stein-
heim, Germany)) in 0.9% (w/v) NaCl (1x saline) was added to heparinized blood at
a final concentration of 1%. The leukocyte rich upper layer was transferred to a fresh
tube and Ficoll-Hypaque was then underlaid and centrifuged at 1000g for 20 min at
RT with no brake. Following the removal of the peripheral blood mononuclear cells
and plasma layers, the remaining cells were resuspended in PBS and red blood cells
removed using hypotonic water lysis. Following centrifugation (5 min at 400g) the
neutrophil pellet was resuspended in RPMI with 2% fetal bovine serum (FBS) and
cells counted using a haemocytometer. Neutrophil purity was determined using flow
cytometry and was ∼98%. Unless otherwise indicated all experiments were conducted
with neutrophils at a concentration of 1× 106/mL.
3.1.2 Mouse
Blood was extracted from 8 week old wild type (BALB/c) and MLKL knockout (MLKL
-/-) mice by cardiac puncture performed by Dr. Abel Ang, Postdoctoral fellow, Otago
University, Christchurch while the candidate observed, in accordance with Otago Uni-
versity Animal Ethics Committee protocol C8-16. Briefly, the mice were given deep
terminal anaesthesia (2% isoflurane) prior to and during a thoracotomy to expose the
heart. A 23G needle containing 1µL 0.1mM EDTA was inserted into the ventricle
while the heart was still beating and blood was slowly withdrawn. Approximately 1
mL blood was collected per mouse, and the blood was pooled from a minimum of 4-8
mice from the same species.
To lyse red blood cells, whole blood was mixed with 1 part blood to 9 parts am-
monium chloride solution (0.8% + 0.1mM EDTA, pH 7.3) and incubated on ice for 15
minutes. Gentle rotation of the tube was performed every 2-3 minutes. The blood was
centrifuged at 300g for 6 minutes. The supernatant was discarded and the cell pellet
was washed once with media (EasySepTM Buffer containing 2% FBS and 1mM EDTA).
After centrifugation, the cell pellet was resuspended in 500 µL media.
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Neutrophils were purified by a negative selection technique using an EasySep Mouse
Neutrophil Enrichment Kit (Stemcell Technologies, Grenoble, France) as per the manu-
facturer’s specifications. The blood sample was transferred to a 5mL polystyrene round
bottom-tube containing 25µL of rat serum and 25µL enrichment cocktail. The sample
was mixed and incubated at 4◦ C for 15 min. The sample was then washed with 2mL
of media and centrifuged at 300g for 10 min. Supernatant was discarded at cells were
resuspended in 500µL media with 25µL Biotin selection cocktail and incubated for 15
min at 4◦ C. The magnetic particles were vortexed for 30 seconds and then 75µL was
added to the sample and incubated for 10 min at 4◦ C. 500µL media was added to the
sample and the tube was placed (without a lid) into the EasySepTM immunomagnetic
column-free magnet and incubated at room temperature for 3 min. The magnet was
picked up and the sample was inverted briskly into a new sterilised tube. Cells were
counted using a haemocytometer. Purity was determined by cell morphology and was
∼85%. The predominant contaminating cell type were red blood cells.
3.2 Zymosan, PA01 and PAC preparation
All microbial preparations were performed as previously described [588; 589]. Zymosan
A from Saccharomyces cerevisiae (Sigma-Aldrich, Steinheim, Germany))(5 mg/mL)
was opsonized with 20% autologous serum in Hanks buffer for 20 min at 37◦C with
gentle rotation (6 rpm). Opsonized zymosan was then washed twice in PBS (8,000rpm,
2 min) and resuspended in media at a concentration of 3× 108.
Pseudomonas aeruginosa was the strain PA01 or a clinical isolate of unknown origin
(PAC). Bacteria were cultured overnight in 3% Tryptic soy broth (w/v; 37◦C, harvested
by centrifugation (200 rpm), washed in PBS, and suspended in HBSS (10 mM PBS,
pH 7.4, containing 500 µM MgCl2, 1 mM CaCl2 , and 1 mg/ml glucose). Bacteria were
quantified by measuring absorbance at 550nm and determining cell number using a
standard curve based on colony counts. Bacteria were opsonized with 20% autologous
serum in Hanks buffer for 20 min at 37◦C with gentle rotation (6 rpm) immediately
before exposure to neutrophils.
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3.3 Reagents and inhibitors
Where noted, neutrophils were pre-incubated with either with the MLKL inhibitor
Necrosulfonamide (NSA)(Selleck Chemicals, Houston, USA) (5 or 10µM), or RIPK1 in-
hibitor Necrostatin-1 (Enzo Life Sciences, Lorrach, Germany)(Nec-1)(10µM), Diphenyl
eneiodonium chloride (DPI) (Sigma-Aldrich, Steinheim, Germany))(10µM), BV6 (Sel-
leck Chemicals, Houston, USA) 20µM, Birinapant (Selleck Chemicals, Houston, USA)
20 µM, ZVAD-FMK (Abcam, Cambridge, United Kingdom) (10µM) or solvent control
Dimethyl Sulfoxide(DMSO) for 30 mins at 37◦C prior to further treatments.
TNF-α (Gibco, Waltham, Massachusetts, United States) 100ng/mL was used in
viability assays or Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, Steinheim,
Germany) used at 100ng/mL (162nM) in viability assays and 12ng/mL (20nM) in NET
assays.
3.4 TSZ treatment
TSZ treatment refers to the prototypical stimuli for TNF-α-induced necroptosis. Neu-
trophils were pre-incubated with ZVAD-FMK (Z) (10µM) and SMAC mimetic (S) BV6
(20µM) or Birinapant (20µM)(in mice) with or without NSA, Nec-1 or DPI where in-
dicated prior to stimulation with TNF-α (T) (100ng/mL).
3.5 Flow cytometry for AnnexinV-FITC/PI Staining
Neutrophils resuspended in RPMI + 2% fetal bovine serum were pre-incubated with or
without inhibitors for 30 mins at 37◦C and then stimulated with TNF-α (100ng/ml),
PMA (100ng/ml) or zymosan (MOI 5). Neutrophils were then plated (5× 105/mL per
well) on a 12-well plate and incubated at 37◦C for 1, 2 and 3 hours. After incubation,
cells were transferred to microfuge tubes and centrifuged at 400g for 5 mins. The
supernatant was discarded and the cells were resuspended in Annexin-V binding buffer.
5µl of Annexin-V FITC conjugated antibody (Life Technologies, Eugene, Oregon, USA)
added to the suspension and incubated in the dark for 15 mins. After incubation
propidium iodide (PI) was added, and then read on the flow cytometer with FL1
and FL3 detection. Viable cells were considered PI negative and were calculated as a
percentage of viable cells based on 105 events.
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3.6 Lactate dehydrogenase activity assay
The method used in the current study for the lactate dehydrogenase (LDH) release as-
say is described in detail in [590]. All reagents, buffers and solutions were prepared and
used exactly as described. Neutrophils (2 × 106/mL) were pre-treated with inhibitors
and stimulated with TSZ, PMA or zymosan in eppendorf tubes. 200 µL from each
sample were plated in triplicate on a 96-well plate (the sample plate) and incubated for
the indicated time period at 37◦C. After treatment had elapsed, 50 µL from each well
was transferred to a new 96-well plate (the assay plate). The assay reagent was pre-
pared by adding an equal volume of Buffer A (4 mM Iodonitrotetrazolium chloride in
0.2 M Tris–HCl, pH 8.2) to Buffer B (6.4 mM Beta-nicotinamide adenine dinucleotide
sodium salt (NAD), 320 mM lithium lactate, in 0.2 M Tris–HCl buffer) and 0.5 µL of
1-methoxyphenazine methosulfate (MPMS) supplement (150mM MPMS in Tris buffer)
and vortexed for 30 seconds. 50 µL of the assay reagent was added to each well on
the assay plate and was mixed on a orbital shaker (300 rpm) in the dark for 30 mins
at room temperature. 0.5 µL of 1M acetic acid was added to each well to stop the
reaction and stabilize the product. The absorbance of the product was read at 490nm
in a plate reader (Varioskan Flash platereader, ThermoFisher Scientific, Finland). For
each experiment, 2 × 106/mL of neutrophils were lysed in 1% Triton-X on ice for 20
mins and then centrifuged at 14,000 rpm for 15 min, the equivalent volumes were added
to the assay plate in order to quantify the maximal LDH release. The amount of LDH
released was then expressed as a percentage of maximum release.
3.7 Live Cell Microscopy
Time lapse images of CY3, FITC, DAPI and DIC channels were taken every 10 sec-
onds using an Olympus IX81 live-cell inverted microscope equipped with an XM10
monochrome fluorescence charge-coupled device camera and Cell R software (Olympus
Soft Imaging Solutions, Munster, Germany) with 20x or 40x magnification, exposure
100 ms (CY3, FITC) and 10 ms (DIC, DAPI).
The fluorescent dye Hoescht (4ng/mL)(DAPI channel) was used to visualise nuclear
and intracellular DNA and cell impermeable DRAQ7 (1.2µM)(CY3 channel) or sytox




3.8.1 NET plate assay
Freshly isolated neutrophils (1.0 X 106/mL in RPMI + 2% fetal bovine serum pre-
incubated with or without inhibitors. Stimuli were then added to each condition: 10:1
PA01 or PAC or 20nM PMA, plated in triplicate on a 96-well plate and incubated
at 37◦C and 5% CO2 for 4 hours. Sytox Green at a final concentration of 5µM was
added and neutrophils incubated for 5 min in the dark. Fluorescence (excitation 485
nm, emission 520 nm) measured on a POLARstar fluorescence plate reader (BMG
Technologies, Germany), as previously described [197; 588].
3.8.2 R19S fluorescent probe for detection of HOCl
Intracellular levels of HOCl was measured by quantifying the fluorescent intensity of
the R19S fluorescent probe as previously described [589]. Neutrophils were resuspended
in Hanks buffer or RPMI + 2% FBS and preincubated with MLKL inhibitors NSA or
(5 or 10µM), DPI (10µM) or vehicle control (DMSO) for 30 mins. After incubation,
the R19S probe was added at a final concentration of 10µM. Neutrophils were then
stimulated with either 100ng/mL of PMA, or Zymosan (MOI 5) and incubated for 2
hours at 37◦C. Fluorescence was detected on the flow cytometer.
3.8.3 Taurine Chloramine assay
2 x 106 neutrophils were resuspended in 1 ml of 10mM PBS and 5mM taurine with
nutrients (50mM MgCl2, 100mM CaCl2 and 100mg/ml glucose). The suspension was
aliquoted into microfuge tubes in duplicate with or without inhibitors and warmed to
37◦C for 30 mins. PMA (100 ng/ml final concentration) was added to stimulate the
neutrophils and incubated for a further 30mins on a rotating wheel. After incubation
2mg/ml of catalase was added to each tube and the cells were centrifuged at 500g
for 5 mins. 200ul of supernatant from each tube was aliquoted into microtitre wells
in duplicate. 50 µl of tetramethylbenzidine (TMB) developer solution was added to
each well, triturated and absorbance measured at 650nm on the plate reader. (TMB
solution: 24mg tetramethylbenzidine in dimethylformamide, acetic acid and potassium
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iodide.) The amount of HOCl produced was calculated by comparing the absorbance
of each well to an HOCl standard curve carried out on the same day.
3.8.4 MPO activity assay
To test the ability of NSA to directly inhibit MPO, the taurine chloramine assay above
was adapted to a cell-free assay. NSA was added to 95µl of 1.5µM MPO in 0.01%
CETAC and 10mM taurine buffer to each well in duplicate. 50µM of H2O2 was then
added to each well, mixed and left for 4 mins at RT. After incubation catalase (1mg/ml)
was added to scavenge any excess H2O2. Tetramethylbenzidine (TMB) developer so-
lution was added to each well, triturated and absorbance measured at 630nm on the
plate reader after 9 mins. The amount of HOCl produced was calculated by comparing
the absorbance of each well to an HOCl standard curve carried out on the same day.
3.8.5 Cytochrome c assay
5× 105 neutrophils in Hanks buffer that were pre-incubated with inhibitors or control
were added to 1mL plastic cuvettes with 20µg/mL of catalase, 40µM cytochrome c
and with or without superoxide dismutase (20mg/mL). Cuvettes were pre-warmed in
the spectrophotometer at 37◦C for 10min. After blanking the control cuvette, the
neutrophils were stimulated with PMA (100ng/mL) and left to incubate for 1min. The
rate of superoxide production in terms of reduction of cytochrome c was then assessed
by the measuring change in absorbance at 550nm for 3 minutes. The slope of the most
linear part of the graph (absorbance units per minute) was used to calculate the µM
production of superoxide min−1ml−1 with the following equation:
A = εcl where ε = 21.1× 103 M−1 cm−1
c = A min−1/ (21.1× 103 M−1cm−1 x 1 cm)
c = 47.4× 10−6 A (M min−1)
c = 47.4 x A (µM min−1)
3.8.6 β-glucoronidase assay
Freshly isolated neutrophils were resuspended in Hank’s buffer at a concentration of
5 × 106/mL and preincubated with either NSA (10µM)or DPI (10µM) for 30 mins at
37C. Cytochalsin B (5µg/mL) was added to each condition except for controls for 5
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mins. Neutrophils were then stimulated with Formyl-Methionyl-Leucyl-Phenylalanine
(fLMP) (0.5µM) and incubated at 37C for 20mins. Cells were then centrifuged at
1000g for 10min. 100µl of supernatant was combined with 100µl of phenolphthalein-
glucuronide buffer and added to a 96-well plate in triplicate. The plate was then
incubated for 18 hours at 37◦C. After 18 hours, 100µl of glycine buffer was added to
each well and the absorbance was read at 550nm in a plate reader. The concentration
of phenolphthalein was determined by comparison to a standard curve generated from
known concentrations of phenophthalein..
3.9 Western Blotting
For detection of MLKL, neutrophils were pre-incubated with inhibitors or not and left
unstimulated or stimulated with either PMA (100ng/mL) or P.aeruginosa (MOI 10)
or TSZ. HT29 cells stimulated with or without TSZ for 5 hours, were used as a positive
control.
3.9.1 Lysis buffer
Lysis buffer was 0.5% Triton, 0.5% Deoxycholic acid, 150mM NaCl, 20mM Tris (pH 7.5,
Sigma-Aldrich, St. Louis, MO, USA), 10mM EDTA (Sigma-Aldrich, St. Louis, MO,
USA), 30mM Sodium pyrophosphate (Fisons, Ipswich, UK) in ddH2O water. 200µM
of PMSF, 200µM sodium vanadate as well as 1x PhosSTOP phosphatase inhibitor
cocktail and Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland) were
added just prior to use. Cell lysis was performed on ice.
3.9.2 Sample buffer
Sample were diluted in loading buffer at a 5X concentration. Reducing sample buffer
was prepared by adding 12.5mL glycerol, 5g SDS, 50mg bromophenol blue and 5 mL
β-mercaptoethanol to 15 mL 1M Tris-HCl (pH 6.8). The final volume was brought up
to 50 mL with double distilled water (ddH2O). In some experiments, neutrophils were
lysed directly in the assay plate using 1X sample buffer, boiled for 10 min and stored
at -20◦C for future use.
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3.9.3 SDS-PAGE electrode running buffer
SDS-PAGE running buffer contained 192mM glycine, 25mM Tris and 0.1 SDS in
ddH2O.
3.9.4 Transfer buffer
Tris-glycine western blot transfer buffer was prepared by dissolving 25 mM Tris and
192 mM glycine in ddH2O water with 10% methanol and kept at 4
◦C.
3.9.5 SDS-PAGE and protein detection
All cell lysates were separated by SDS-PAGE in 12% Mini-PROTEAN TGX Precast
Protein Gels (BioRad, Hercules, California, USA) and transferred to polyvinylidene
difluoride membrane or nitrocellulose (0.2 µm, GE Healthcare, Chicago, IL, USA),
and blocked with 5% BSA in Tris-buffered saline with 0.05% Tween 20 for 1 hour.
Anti-MLKL (1:3000), rat monoclonal antibody (Millipore, Temecula, USA) and Anti-
phosopho-MLKL (1:1500) (Ser358) rabbit monoclonal antibody (Cell Signaling Tech-
nology,Danvers, MA, USA) were used to detect MLKL and MLKL phosphorylation re-
spectively. Anti-β-Actin mouse monoclonal antibody (Sigma-Aldrich, Steinheim, Ger-
many)) was used as a loading control. The membranes were incubated with antibodies
in 5% BSA in Tris-buffered saline with 0.05% Tween 20 overnight at 4◦C on a rocking
platform. The membranes were then washed in TBST (200ml 10X tris-buffered saline
and 1mL Tween 20 in 1800mL ddH2O) and incubated with secondary antibody diluted
1:10,000 in 5% BSA for 1 hour. Membranes were then washed in TBST and detection
of membrane-bound antibodies was performed using Amersham ECL Select Western
Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA) and visualised using
the Q9 Advanced Chemidoc (UVItec, Cambridge,UK).
4 Methods applicable to Chapter 5
4.1 Tissue culture of Jurkat cells
Jurkat E 6.1 human suspension T-cell lymphoma cells were grown in RPMI 1640
medium supplemented with 10% v/v heat-inactivated FBS, 100 U/mL penicillin and
100µg/mL streptomycin at 37◦C in a humidified incubator with 5% CO2. Cell concen-
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trations were not permitted to exceed 1×106/mL and were not seeded at concentrations
below 2.5× 105/mL. A log phase of growth was maintained by sub-culturing the cells
every 2 to 3 days.
4.2 Cell cycle blocking and oxidant treatment
Cell cycle blocking was performed as previously described [591; 585]. 100 mL of 1 ×
106/mL Jurkat cells were treated with 1 mM thymidine for 18 hours to arrest the cells
in G1 phase of the cell cycle. At 18 hours, the cells were counted and cell death and
cell cycle analysis was assessed by flow cytometry to ensure successful blocking. The
cells were washed twice in PBS and resuspended in fresh media with 50 µM cytidine
to promote release into S-phase. The cells were then split into either a treatment or
control flask and the treatment flask received the oxidant while the control received
the volumetric equivalent of PBS. At each time point, 5× 106 cells were centrifuged at




Hydrogen peroxide (Fluka Analytical, Sigma-Aldrich) was diluted into PBS and the
concentration determined spectrophotometrically (240 = 43.6 M−1 cm−1). Jurkat cells
were treated using 100-fold dilutions of reagent stock solutions.
4.3.2 Glycine chloramine
Glycine Chloramine was prepared fresh on the day of cell treatments by adding hypochlor-
ous acid dropwise to a 10 mM excess of glycine in an equivalent volume of PBS while
gently vortexing. The concentration of glycine chloramine was determined using 5-thio-
2-nitrobenzoic acid (TNB) by measuring the change in absorbance at 412 nm, using
the molar extinction coefficient for TNB (14, 100M−1 cm−1) and adjusting for the 1 : 2
stoichiometry of the reaction (GlyCl:TNB).
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4.4 Cell cycle analysis
4.4.1 DNA staining solution
A stock solution of 2mg/mL of RNAseA (Roche Diagnostics, Mannheim, Germany) was
prepared in water and boiled for 5 min to inactivate any DNAses. After cooling, 1mg
of propidium idodide (ThermoFisher Scientific, Finland) was added to the solution and
vortexed for 1 minute. Stock solution was stored at 4 ◦C in a light-proof microcentrifuge
tube.
4.4.2 Fixation and analysis
Cells were prepared for cell cycle analysis as previously described [585; 592]. 0.5 –
1×106 cells were pelleted, washed once in PBS, resuspended in 100 µL PBS and fixed by
dropwise addition of 900 µL ice cold 70% v/v ethanol while gently vortexing. Fixed cells
were used immediately or kept at 4 ◦C for a maximum of 2 days. Cells were pelleted,
washed twice in PBS, and then resuspended in 250 µL PBS containing 5 µL DNA
staining solution. After 30 minutes incubation in the dark at room temperature, DNA
content for 10,000 cells per sample was determined using a FC500 MPL Flow Cytometer
(Beckman Coulter Inc.) and single-parameter DNA histograms were compared using
CXP software to visualize the progression of cells through the cell cycle.
4.5 Cell viability
200 µL of each sample (treatment or control) was added to a 96-well plate and 1µL of
propidium iodide (PI) 5mg/mL was added, incubated for 5 min and then read on the
flow cytometer with FL1 and FL3 detection. Viable cells were considered PI negative
and were calculated as a percentage of viable cells based on 105 events.
4.6 Cell proliferation assay (CFSE)
Jurkats were labelled with carboxyfluorescein diacetate, succinimidyl ester (CFSE;
Invitrogen, Auckland, New Zealand) by incubation (5 min, room temperature) at
1 × 107/mL in PBS with 1 µM CFSE before washing. Following gating on viable
cells, the proportion of labelled Jurkat cells with a diluted CFSE signal (prolifera-




DNA was extracted from ∼5 × 106 Jurkat cells at 4 and 72 hour time points using
the GeneJet genomic DNA purification kit (Thermo Scientific, Finland) as per the
manufacturer’s protocol for cultured mammalian cells. Cells were pelleted for 5 min
at 250g, the supernatant discarded and washed once in PBS. Cells were resuspended
in lysis and Proteinase K solution, mixed thoroughly and incubated at 56◦C while
vortexing occasionally until the cells were completely lysed. RNAse A solution was
added and incubated for 10 min at room temperature. 50% ethanol was added to
the samples, vortexed and added to the DNA purification columns. The column was
centrifuged at 6000g for 1 min and the flow-through discarded. A wash buffer containing
ethanol was then added and the column centrifuged for 8000g for 1 min and flow-
through discarded. The column was then transferred into a microcentrifuge tube and
the elution buffer was added to the center of the column and incubated for 2 min at
room temperature. The column was then centrifuged at 8000g for 1 min and purified
DNA stored at -20◦C for future use.
4.8 Sodium Bisulfite conversion
Sodium bisulfite conversion of extracted DNA from the 4 and 72 hour time points was
performed using Zymo Research EZ DNA Methylation Kit ((Zymo Research, Irvine,
CA) according to the manufacturer’s specifications. Briefly, DNA was added to the 5
µL of M-Dilution Buffer, made up to a final volume of 50µL with water and incubated
for 15 min at 37◦C. CT conversion reagent was added to each sample and incubated
in the dark at using a thermocycler at 95◦C for 30 sec., 50◦C for 60 min. for 16
cycles, then held at 4°C. Samples were loaded into Zymo-Spin IC columns containing
M-Binding buffer and inverted to mix. The columns were centrifuged at 10,000xg for
30 seconds and the flow-through discarded. Cells were washed once and the incubated
with M-Desulphonation Buffer at room temperature for 20 min. After incubation,
cells were centrifuged and washed twice in wash buffer. Columns were transferred
to a microcentrifuge tube to which M-Elution Buffer was added. The column was




DNA was quantified using a NanoDrop 8000 (ND-8000) UV-Vis Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA), by absorbance at 260 nm. Tris-EDTA
(TE) was used in blank subtraction.
4.10 DNA methylation analysis
DNA methylation profiles were assessed using the Illumina Infinium MethylationEPIC
850K array (Illumina Inc., San Diego, USA) at 4 and 72 hours post synchronization.
Whole genomic bisulfite converted DNA was sent for processing by Agresearch (Inver-
may Agricultural Centre, Mosgiel 9092). Agresearch performed the array analysis and
returned raw unprocessed intensity data as .idat files for bioinformatic analysis.
4.11 Bioinformatic analysis
Data analysis was performed using the Minfi and Limma Bioconductor software pack-
ages within the R statistical program (www.R-project.org). All packages, programs and
pipelines used in this analysis are freely available, and the workflow was based upon
published scripts [593]. All samples passed quality control and were normalised to-
gether using Subset-quantile Within Array Normalisation (SWAN) [594] and variance-
stabilizing transformation [595; 596]. CpG sites containing detection p-values >0.05
for 1% or more samples, were excluded from further analysis. Because the cell samples
were of the same sex, all chromosomes were retained, however, CpG sites identified as
having polymorphic hybridising potential and homology to common SNPs [597] were
removed. Multidimensional scaling of the top 1000 methylation values was performed
using pairwise distance method for gene selection, and normalised, filtered methyla-
tion values. Hierarchical clustering was performed on a “minkowski” distance matrix
calculated using the β-values for all probes, regardless of significance.
4.11.1 Average relative methylation analyses
Average relative methylation analyses for each sample was calculated using the mean
β-values from all probes. The mean difference in methylation between treatment and
control groups was then calculated using paired t-test.
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4.11.2 Differential Variably
Differentially variable positions (DVPs) were identified using the DiffVar algorithm
[598] within the missMethyl package [599]. This analysis used a similar linear model
as below, however, biological replicate was incorporated into the statistical design as a
covariate.
4.11.3 Identification of differentially methylated CpGs
The methylation status of each CpG site was calculated using normalised CpG site
signals represented as methylation values (M-values) and β-values. M-values were
generated within Minfi as the log2 ratio of the signal intensities of methylated CpG site
divided by the unmethylated CpG site
Unless stated otherwise, statistical analyses were performed using the M-values.
β-values (average DNA methylation level for each CpG site) were used for data visual-
ization and range from 0 (unmethylated) to 1 (methylated). β-values were generated
by dividing the methylated CpG site intensities with the sum of the methylated and
unmethylated CpG site intensities [600]. Normalised β-values and M-values were man-
ually assessed for fit using density plots (Figures 2.1 and 2.2).
Differentially methylated positions which correlated with treatment were identified
using a linear regression model within the Limma package, with adjustment for mul-
tiple testing. This was calculated by comparing the methylation measurements of the
control samples with the treatment samples, for each of the two time points (4 hours
post-release, and 72 hours post-release). Samples that originated from the same cell
passage were treated as a biological replicate and the correlation coefficient between
these samples was incorporated into the statistical design using Limma’s duppcorr
function. The top most significant, differentially methylated CpG positions were iden-
tified by log fold change (logFC) weighted functions using Limma’s toptreat algorithm.
Adjustment for multiple correction was performed using the “Benjamini, Hochberg”
method within Limma and quantile-quantile plots for the linear regression model were
assessed at each time point using the observed against expected –log10(p-value) (Fig-
ures 2.3 and 2.4). The observed data show a minor inflation of p-values smaller than
expected by chance. Therefore, the criteria for significance was substantially increased
by excluding CpG sites that displayed less than a 10% mean difference in methylation
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Figure 2.1: Assessment of normalized β-values and M-values for the GlyCl pre-
replication phase dataset. Control samples are represented in dark grey and treatment
samples are represented in light grey. The bump observed at 50% methylation is characteristic
of Jurkat cells, which have a highly duplicated genome.
Figure 2.2: Assessment of normalized β-values and M-values for the H2O2 dataset.
Control samples are represented in dark grey and treatment samples are represented in light
grey. The bump observed at 50% methylation is characteristic of Jurkat cells, which have a
highly duplicated genome.
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between treatment and control samples, and CpG sites that had a mean methylation
value less than 10% or greater than 90% (in the control), as changes within the excluded
ranges are unlikely to be of biological relevance.
A B
Figure 2.3: H2O2 exposure quantile-quantile plot on expected –log(p-values)(x-
axis) vs observed –log(p-values)(y-axis). Under the null distribution, if no significant
associations, all points would be expected to lie on the red line. A) 4 hour time point B) 72
hour time point.
4.11.4 Differentially methylated gene regions and pathway analysis
Differentially methylated gene regions were interrogated within the Minfi package using
the statistical package DMRcate [601]. A methylation differential cut off of 10 was
used, and unless stated otherwise significance was determined using a false discovery
rate (FDR) of 0.05 in conjunction with a p-value cut off of 0.05.
Pathway analysis was performed by comparison with the Kyoto Encyclopedia of
Genes and Genomes (KEGG) [602] and gene ontology databases (GO) [603] using the
missmethyl R package [599], with correction for CpG site bias.
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Figure 2.4: GlyCl exposure quantile-quantile plot on expected –log(p-values)(x-
axis) vs observed –log(p-values)( y-axis). Under the null distribution, if no significant





high-risk cutaneous squamous cell
carcinomas
Results from this chapter were published as part of a paper entitled “Cutaneous squa-
mous cell carcinomas with markers of increased metastatic risk are associated with
elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells”
(Seddon et al. Journal of Dermatological Science, April 2016 (83)124-130 [587].
1 Introduction
Non-melanoma skin cancers, including cutaneous squamous cell carcinoma (CSCC),
are the most common type of skin cancer worldwide. Although metastases are rare,
they are more common in CSCC than with basal cell carcinomas and in New Zealand,
CSCC rates are among the highest in the world [152; 151; 148; 604]. The majority
of CSCC patients have an excellent prognosis following simple excision. However, a
subset present with high-risk CSCC that are associated with high rates of recurrence,
metastasis and disease-specific death [605; 153]. The immune system plays a critical
role in limiting the development of skin cancer which is reflected by the elevated risk
and aggressiveness of CSCC in immuno-suppressed individuals [605; 606; 607; 608].
This high-risk subgroup of patients is therefore routinely targeted for increased clinical
surveillance. However, within the wider population of apparently immune competent
patients, the identification of high risk CSCC is problematic.
A number of clinical and histological characteristics of CSCC tumours are associated
with increased risk of recurrence, metastasis and death. Currently, the most effective
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predictors of high-risk tumours are tumour thickness [161; 162; 163] and the Brigham
and Women’s Hospital (BWH) tumour (T) staging system [165]. However, it is clear
that a more effective risk stratification scheme is required to accurately identify high-
risk CSCC [609; 162; 163; 610], and there is currently considerable interest in defining
additional markers of risk [165; 166].
Neutrophils are a key immunomodulatory population whose activities are thought
to predominantly promote tumour progression [72]. This concept is supported by
numerous studies that have associated increased circulating and/or tumour-infiltrating
neutrophils with poor outcome in a range of cancers types including melanoma [72; 611;
188; 612]. Studies in SCC have been limited to head and neck (HNSCC) and cervical
SCC, where both neutrophil infiltration and elevated neutrophil/lymphocyte ratio have
been associated with poor prognosis [189; 190]. However, the relative numbers of
circulating and tumor-infiltrating neutrophils in CSCC is presently unknown, as is
their prognostic significance.
Myeloperoxidase (MPO) is an enzyme found in neutrophils, which, in the presence
of halides such as chlorine, produces a number of oxidative and cytotoxic agents. HOCl
is the strongest MPO-derived oxidant released by the neutrophil and has been shown
to have both direct and indirect carcinogenic effects on host cell DNA [6; 56]. Several
studies have found associations with MPO in tumour tissue with increased risk of both
secondary, and advanced stage tumours [117; 118; 119; 120]. Furthermore, MPO is
a component of neutrophil extracellular traps (NETs), which have been associated
with facilitating tumour metastasis [382; 384]. Analysing the presence of MPO in the
tumour tissue of CSCC patients could reveal a possible mechanism for how neutrophils
contribute to tumour progression.
The significance of neutrophils in the setting of CSCC is unknown. Analysing asso-
ciations between circulating and tumour-infiltrating neutrophil numbers, the presence
of MPO in tumours and clinical markers of high risk CSCC may clarify whether neu-
trophils have a potential functional role and/or prognostic value in CSCC. 1
1Data in Table 3.2 and Figure 3.4B, were previously presented in the thesis entitled: Immune sup-
pression and cutaneous squamous cell carcinoma tumour biology written by the student and submitted
for the degree of Bachelor of Biomedical Science with Honours. These data have been included in
order to provide a framework for the data presented in this thesis.
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2 Objectives
 Perform a clinical audit of patients requiring inpatient secondary care for CSCC
treatment to determine whether circulating neutrophil counts correlate with known
clinicopathological risk factors.
 Analyse patient matched peripheral blood and CSCC tumour samples for rela-
tionships between clinicopathological risk factors, circulating neutrophils, lym-
phocytes and tumour-localised MPO positive immune cells.
3 Experimental Approach
As part of a clinical audit, a search of the Department of Plastic Surgery’s (Canterbury
District Health Board) database identified 282 cases of primary CSCC in patients
lacking exclusion criteria such as other malignancies, chemotherapy and HIV. Further
selection criteria (detailed in Chapter 2) were applied to restrict multiple tumours
occurring within a short period to a single representative tumour per patient. Patients
receiving immuno-suppressive medications were also excluded from the final cohort
because exposure to immuno-suppressive drugs is known to be associated with more
aggressive tumours [605; 613] and it is well established that corticosteroids can increase
circulating neutrophil numbers as a result of their effects on neutrophil demargination
and lifespan [180; 181; 182].
Immunohistochemical analysis of CD66b (granulocyte marker), CD8 (lymphocyte
marker) and MPO was performed on primary CSCC tumour tissue from 20 prospec-
tively collected eligible patients (selection criteria as per “Final cohort”) who also had




The clinico-pathological characteristics of the final cohort (n = 129) are provided in
Table 3.1.
Table 3.1: Clinico-pathological characteristics of the final cohort
Patient features
n 129
Median age, years (range) 81 (51 – 96)
Age ≥ 78 62%
Male gender 57%
Deaths 43%
Recurrence >3 months 14%
Tumor features2
Median thickness, mm m(r)3 5.0 (0.5 – 27)
Thickness ≥ 5 mm 54%
Median diameter, mm m(r) 24 (4.0 – 150)
Diameter ≥ 20 mm 63%
Clark level 5 60%
Poor differentiation 31%
Perineural invasion 12%
Significant lymphocyte infiltration 50%
T-stage 2b or 3 60%
Blood counts
Median neutrophils (×109/L) m(r) 4.5 (0.5 – 18)
Median lymphocytes (×109/L) m(r) 1.5 (0.4 – 5.5)
Median NLR4 3.0 (0.7 – 23)
2 tumour features as defined in references [614; 615]
3 median(range)
4 neutrophil to lymphocyte ratio
4.2 Associations between circulating immune cell populations
and tumour staging variables
There are currently no consensus cut-points for subdivision of the continuous variables
neutrophil count, NLR, and tumour thickness into “high” and “low” categories. There-
fore, median values from the current study cohort were used to define cut-point values
in all subsequent analysis (neutrophil count 4.5 × 109/L; NLR ≥ 3; tumour thickness
≥ 5 mm)(Table 3.2).
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A high neutrophil count was associated with the presence of high-risk tumour fea-
tures including thickness ≥ 5 mm, Clark level V, and T stage 2b/3 (Table 3.2). This
analysis did not include a correction for multiple comparisons and a p-value of <0.05
was considered significant.
Table 3.2: Comparison of cases subdivided on the basis of high versus low neutrophil numbers
or neutrophil to lymphocyte ratio
Neutrophils5 NLR6
High (%) Low (%) p High (%) Low (%) p
Age ≥ 78 63 61 0.910 71 53 0.039
Male gender 48 65 0.064 55 58 0.781
Death 42 44 0.800 49 36 0.127
Recurrence 12 16 0.587 20 8 0.046
Tumour features
Thickness ≥ 5 mm 65 44 0.019 58 50 0.368
Diameter ≥ 20 mm 69 57 0.176 69 57 0.176
Clark level V 70 48 0.012 64 56 0.364
Poor differentiation 33 29 0.604 31 30 0.894
Perineural invasion 16 8 0.179 11 13 0.759
High T-stage (2b&3) 69 50 0.035 65 54 0.222
5 Neutrophil counts ≥ 4.5× 109/L were considered high.
6 Neutrophil to lymphocyte ratio. NLR ≥ 3 were considered high.
Metastases developed in four patients during follow-up. Of these, 4/4 had NLR ≥
3 and tumour thickness ≥ 5 mm, 3/4 had a neutrophil count ≥4.5 × 109/L, whereas
only 2/4 had a tumour diameter ≥ 20 mm and 1/4 was staged as T2b (Table 3.3).
4.3 Survival analysis
As a group, the patient cohort had a significantly poorer survival than an age/gender
matched normal population (Figure 3.1A). Univariate and multivariate analysis demon-
strated that, of the known prognostic risk factors analysed, only age and tumour thick-
ness were significant independent predictors of poor overall survival (OS) (Figure 3.1B
and Table 3.4).
When neutrophil number and NLR were entered as continuous variables in a uni-
variate analysis only NLR was a significant predictor of overall survival. When the
90
Table 3.3: Clinical and tumour characteristics of patients who subsequently developed metas-
tasis
#1 #2 #3 #4
Gender Female Male Male Male
Age 71 63 86 72
Neutrophil count 5.0 3.3 8.7 5.9
NLR 4.5 3.3 3.6 3.7
Anatomical site limb head/neck scalp lip
Diameter (mm) 50 14 17 25
Differentiation moderate nd7 moderate moderate
Perineural Invasion no no no yes
Thickness (mm) 6 5 5 18
BWH T Stage 2a 2a 2a 2b
Significant lymphocyte
infiltration of tumor
yes no yes no
Time to metastasis (months) 8 21 37 2
7 nd, not determined
known risk factors of age and tumour thickness were included in a multivariate analy-
ses, NLR was not an independent predictor of OS (Table 3.4).
Therefore, prognostically relevant cut-points were explored for neutrophil count and
NLR using the median, lower and upper quartile values. Categorization of NLR based
on these cut-points did not result in significant groupings (data not shown). However,
categorization of neutrophils (cut-points of 3.55 vs. 4.50 vs. 5.75) showed patients with
neutrophil counts in the lowest quartile (NeutLQ) had significantly longer OS compared
to other patients (Figure 3.1C and Table 3.4). However, NeutrophilLQ did not remain
an independent predictor of OS following multivariate analysis that included age and
tumour thickness.
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Figure 3.1: Overall survival analysis. Kaplan–Meier survival curves of the overall survival of
either (A) all patients or (B,C) patients stratified into high and low groups on the basis of (B) median
thickness (<5 mm vs ≥ 5 mm) or (C) lowest quartile of neutrophil count (<3.5 vs ≥ 3.5). The OS of
a New Zealand population age/sex matched to the study cohort is shown for comparison. Significance
of survival differences is indicated on the plots and the numbers in brackets associated with each curve
detail the respective number of events/number of patients.
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Table 3.4: Analysis of overall survival
Univariate Multivariate
Model 1
Log neutrophil count 0.9 (0.6 – 1.0)
Model 2
Neutrophil (LQ)8 1.9 (1.1 – 4.6)* 1.5 (0.7 – 3.4)
Age 1.1 (1.1 – 1.1)***
Thickness 1.8 (1.1 – 3.6)*
Model 3
Log NLR 3.1 (1.1 - 8.8)* 1.8 (0.6 – 6.3)
Age 1.1 (1.1 – 1.1***
Thickness 2.1 (1.2 – 3.8)*
8Lowest quartile
Significant differences denoted by asterisks * = p <0.05, ** = p <0.01, *** = p <0.001
HR, Hazard ratio (95% CI, Confidence interval)
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4.4 Analysis of matched circulating and tumour localised im-
mune cell populations
In a separate cohort (n = 20), prospectively collected tumour tissue was available
for laboratory analyses. There were no significant differences in age, gender, tumour
diameter, T-stage, neutrophil and lymphocyte counts or NLR between patient groups
when subdivided by tumour thickness (Table 3.5).
Table 3.5: Clinical and immune cell population characteristics of immunohistochemical study




median age, years (range) 83 (68-95) 83 (73-88) 0.41
male gender % (#) 61.5 (8) 71 (5) 1
Tumour features
Diameter (mm) m(r) 21.8 (9-45) 29.6 (15-135) 0.67
Thickness (mm) m(r) 4.0 (1-4.5) 6.3 (5-33) <0.01
Stage 2b/3, % (#) 38.4 (5) 42.8 (3) 1
CBC
Neutrophil count x109/L, m(r) 4.5 (3.2-6.8) 4.6 (1.7-7) 0.64
Lymphocyte count x109/L, m(r) 2.0 (0.7-3.7) 1.9(1.1-2.1) 0.32
NLR 2.8 (1-8.3) 2.8(0.8-4.8) 0.92
m(r), median (range)
The immunohistochemical analysis of tumour-localised CD66b+ neutrophils and
CD8+ T lymphocytes showed tumours ≥ 5 mm thick had increased numbers of total
(p = 0.02) and peritumourally (p = 0.01) localised neutrophils compared with tumours
< 5 mm thick (Figure 3.2). No significant associations were observed between tumour-
localised immune cells and tumour diameter > 20mm, T-stage 2b/3 or Clark level V
(data not shown).
Adjacent sections of tumour tissue from the same patient cohort were analysed for
numbers of MPO+ immune cells. No significant relationships were observed between
numbers of MPO+ immune cells and tumour thickness ≥ 5mm, diameter >20mm or
















Figure 3.2: Analysis of tumour-localised CD66b+ neutrophils. Representative images of im-
munohistochemical double staining analysis of CD66b+ neutrophils (brown) and CD8+ lymphocytes
(pink) in (A) a tumour with a thickness of 14 mm and (B) a tumour with a thickness of 2mm (C)
numbers of total and (D) peritumoural neutrophils in tumours with a thickness of ≥ 5 mm versus




































































































































Figure 3.3: Analysis of tumour-localised MPO+ immune cells. The number of peritumoural
or intratumoural MPO+ cells per high-powered field (HPF) are on the x-axes per indicated category
of thickness, diameter or tumour stage on the y-axes. No statistical significance was found using
unpaired t-test, p-values <0.05 .
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The tumour tissue was then assessed for levels of extracellular MPO. High and low
levels of extracellular MPO were detected in both the peritumoural and intratumoural
regions of all the tumour samples (Figure 3.4). There were no significant associations
between the levels of extracellular MPO and tumour thickness ≥ 5mm, or T-stage 2b/3
(Figure 3.5).
A comparison of the numbers of MPO+ immune cells against the level of extracel-
lular MPO revealed that while smaller numbers of MPO+ cells correlated with lower
extracellular MPO diffusion in the intratumoural region (r=0.62, p <0.01), the levels
of extracellular MPO in the peritumoural region was not correlated with the amount
of MPO+ cells in the region. This indicated that the extracellular MPO observed did
not simply reflect the number of neutrophils in the vicinity.
Furthermore, although excluded from immunohistochemical analyses due to the
challenges associated with accurate quantification, it was noted that many of the tu-
mours examined displayed large necrotic cores with substantial neutrophil infiltration
(Figure 3.6). Although it was unclear if the neutrophils in these regions were viable,
they stained positively for both intracellular MPO and diffuse extracellular MPO, and
were in close contact not only with tumour cells but other tumour-infiltrating immune
cells.
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Figure 3.4: Representative images of tumour-localised MPO+ immune cells. Representative
images of (A) intratumoural immune cells showing high levels of extracellular MPO (left) and low levels
of extracellular MPO (right) (B) Representative images of peritumoural immune cells showing high
(left) and low levels (right) of extracellular MPO.
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Figure 3.5: Number of patients with high vs low extracellular MPO with respect to stage
and thickness. (A) The number of patients with high (grey) and low (black) (A) peritumoural or
(B) intratumoural diffuse extracellular MPO with respect to tumour stage or thickness. Variables






Figure 3.6: Central necrotic islands in CSCC tumours exhibiting areas of high immune
cell infiltrate (A) (1) tumour cells surrounding a necrotic island of immune infiltrate including MPO
positive neutrophils, and extracellular MPO, (2) MPO negative immune cells (possibly lymphocytes)
surrounded by MPO positive neutrophils in a necrotic tumour island, (3) peritumoural neutrophils.




It is clear from studies of immuno-suppressed individuals that the immune system plays
an important role in the development of CSCC. However, in non-suppressed patients
it is unknown what immunological mechanisms underlie the development of high risk
CSCC that are associated with increased rates of recurrence, metastasis and patient
death. The identification of such high risk tumours in these patients is problematic.
Neutrophils and polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs)
play an important role in tumour growth and have been shown to provide a useful
prognostic marker in a range of cancers. However, little is currently known concerning
the potential role and prognostic value of these cell types in CSCC.
The major strengths of this study included access to complete patient and tumour
pathology data (including tumour thickness), and the use of stringent selection criteria
to exclude patients with co-morbidities and/or medications that may affect tumour
resident and circulating leukocyte populations.
In the current study, the clinically recognised CSCC risk factors were compared us-
ing OS as the measured outcome due to the low numbers of metastatic events. Tumour
thickness ≥ 5 mm was the only independent predictor of OS, after accounting for age.
Analogous findings were presented by Brantsch et al. [610], who showed that immuno-
suppression and increased tumour thickness were the most significant prognostic factors
for CSCC metastasis.
In univariate analysis, low levels of circulating neutrophils were associated with sig-
nificantly longer OS. There is some evidence that patients with CSCC have increased
all-cause mortality [616; 617], and the patients in the current study had a significantly
poorer survival than an age and gender matched New Zealand population, despite the
stringent patient selection criteria used in this study. As there is a strong associa-
tion between CSCC and immuno-suppression, it is possible that in some apparently
immuno-competent patients, CSCC occurrence is due to a sub-clinical immune suppres-
sion that induces, and/or results from, a number of other co-morbidities. Therefore,
although few, if any, of the deaths recorded in the current study were disease specific,
it is possible that OS may also provide a broad marker of altered immune status asso-
ciated with metastatic risk. In this regard, it is notable that it has been reported that
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differences between the BWH T-stages with respect to risk were similar, irrespective of
whether overall survival or incidence of metastasis was used as the primary endpoint
[162; 165]. The finding that neutrophil number is a significant predictor of OS is there-
fore not incompatible with a role for neutrophils in CSCC development/progression,
but it is more likely that neutrophil numbers are merely a marker of unrelated co-
morbidities.
A direct analysis of the metastatic events associated with elevated neutrophil num-
bers would provide the best evidence of an association between neutrophils and metastatic
risk. However, in common with other published studies, only a low number of metastatic
events were observed. Notably, even the largest of the studies performed to date
[161; 162] reported low numbers of associated events (<30) in immunocompetent pa-
tients and did not evaluate these patients as a separate group. Although the low
numbers of events in this study did not permit statistical analysis, it is pertinent that
all four patients who developed metastasis had tumours more than 5 mm thick with
elevated neutrophil to lymphocyte ratios, and three out of the four had high circulating
neutrophil counts.
Increased tumour thickness and T-stage are currently the most discriminatory, al-
beit broad, markers of metastatic risk. In the current study, those patients with an
elevated neutrophil count had a significantly higher proportion of CSCC exhibiting the
high-risk tumour features of T-stage 2b/3, increased tumour thickness (≥ 5mm)and
Clark level V (a surrogate measure of tumour thickness). Immunohistochemical analy-
sis of tumours with thickness ≥ 5 mm had greater numbers of total and peri-tumourally
located CD66b+ leukocytes. These associations had not previously been investigated
in the setting of CSCC, and these data suggest mobilisation of CD66b+ leukocytes is
a feature in patients with high-risk CSCC tumours. This is consistent with the mo-
bilisation of neutrophils reported in other cancers, including oral SCC and HNSCC
[72; 611; 188; 612], and with accumulating scientific evidence that neutrophils play an
important role in tumour development and progression [72].
However, it must be acknowledged that the CD66b+ leukocytes identified in the tu-
mour tissue may be partly or wholly comprised of PMN-MDSC rather than neutrophils,
as these two CD66b+ cell types share many features and cannot be differentiated in
tissue sections. In contrast, circulating PMN-MDSC and neutrophil populations can
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be distinguished and circulating frequencies of PMN-MDSC are higher in patients with
high T-stage tumours [587]. PMN-MDSC are potent suppressors of anti-tumour re-
sponses [99; 618], and although high circulating PMN-MDSC frequencies correlate with
metastatic burden in a number of solid tumours [101; 100] their relationship to high-
risk CSCC in the tumour has not previously been reported. Therefore, determination
of the relative contributions of neutrophils and PMN-MDSC in the setting of CSCC
awaits development of phenotypic discriminators of these cell types.
Interestingly, the immunohistochemical analysis of the numbers of MPO+ cells
did not correspond with the numbers of CD66b+ neutrophils numbers in the tumour
tissue of the same patient cohort (Figures 3.2 and 3.3). The existence of significant
proportions of CD66b+/MPO- cells has previously been observed in cell suspensions
from colorectal cancer patients as well as HNSCC tumour tissue [73; 619]. In the current
study, it was observed that in some tumours there were low numbers of MPO+ cells,
but high amounts of extracellular MPO, raising the possibility that some neutrophils
had been activated, released their MPO and subsequently died. Another possibility
for this discrepancy could be an increased presence of MPO+ tissue macrophages in
lower CSCC stage tumours. Although not traditionally considered to be a rich source
of MPO, macrophages have been shown to contain substantial levels of active MPO
under inflammatory conditions, in some cancers, or by the phagocytosis of apoptotic
neutrophils and extracellular MPO [620; 621; 622; 623; 624]. An immunohistochemical
double staining analysis which included the macrophage surface marker CD68 alongside
MPO could be performed in order to test this theory, but was not conducted in the
current study. Although not statistically significant, it was interesting to note that the
majority of patients with higher stage CSCC had low extracellular MPO expression in
the peritumoural regions compared to lower stage patients (87.5% vs. 58.3%). There
is evidence to suggest that N2 TAN have reduced MPO expression compared to naive
and PMN-MDSC [76]. In established cancers, this is thought to contribute to the
pro-tumoural role of neutrophils as their cytotoxic capacity is reduced. In the current
study, neither higher expression of extracellular nor cell-localised MPO were associated
with tumour characteristics of increased metastatic risk. It is possible that MPO
could be immunohistochemically detectable but not active. In future studies, a protein
oxidation marker such as 3-chlorotyrosine may be a more informative biomarker. It is
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also relevant to consider the average age of the patients in this study was 83, and whilst
there have been no studies on the influence of age on tumouricidal and MPO activity
in neutrophils, several studies have shown that phagocytic and bactericidal activities
decrease with increased age [625; 626]. Importantly, extracellular MPO was detected
in the regions of high immune infiltrate in all the patient tumours analysed and could
therefore represent a potential target for therapeutic agents.
In summary, this study demonstrates that the presence of high risk CSCC is as-
sociated with increased numbers of both circulating and tumour resident populations
of neutrophils and/or PMN-MDSC. These findings demonstrate the potential for neu-
trophils and PMN-MDSC as prognostic markers in CSCC, and suggest they may play
an important functional role in CSCC progression. In the clinical setting, circulating
neutrophil counts are routinely available, and therefore merit further investigation in
studies aimed at developing more clinically useful prognostic models for identifying
high-risk CSCC in patients not receiving immuno-suppressive therapies. With respect
to development of new therapeutic options for CSCC, manipulating the functional
capacities of these cell types by targeting MPO may be a useful approach.
The observation that there was considerable neutrophil infiltration in CSCC tu-
mours, including their necrotic core regions, which stained positively for both localised
and extracellular MPO raised several questions. How are these neutrophils in their
life or in their death, impacting other cells in the tumour microenvironment? If these
neutrophils were dead, what death pathways might be triggered in a cancer setting and
how can these pathways be altered? The following chapters will explore the molecular
players involved in inflammatory death pathways of neutrophils, and the impact of
activated neutrophils on other cells.
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Chapter 4
The role of necroptosis effector
proteins in the fate and function of
activated neutrophils
1 Introduction
Neutrophils are the most abundant white blood cells in the human body, and represent
an integral part of the innate immune defence against pathogens. They are generally
thought to be short-lived cells, and in the absence of survival signals will die by apopto-
sis within 24 hours [282]. While apoptosis is the default process in mature neutrophils,
during inflammation neutrophils may become exposed to microbial constituents, pro-
survival factors and cytokines that can modify molecular death pathways and alter
normal lifespan [283].
Infection typically leads to phagocytosis of pathogens and the activation of the
NADPH oxidase complex (NOX2), which produces of a range of reactive oxygen
species including superoxide (O ·–2 ), hydrogen peroxide (H2O2) and hypochlorous acid
(HOCl)[5]. In general, the activation of phagocytosis-induced cell death pathways trig-
gers the intra- and extracellular signalling involved in an orderly neutrophil death that
does not discharge its intracellular contents [339]. The rapid clearance of neutrophil
remains by circulating macrophages results in the resolution of inflammation [203].
However, physical trauma to the cell, excessive bacterial load and exposure to cer-
tain stimuli can cause the neutrophil to die an explosive necrotic death, leading to its
pro-inflammatory and tissue-damaging contents being extruded into the extracellular
space. Circulating immune cells are attracted to damage associated molecular patterns
(DAMPS) released during necrotic death which can initiate an acute inflammatory re-
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sponse [359]. The mode of neutrophil cell death will therefore have a major impact on
whether inflammation is resolved or exacerbated.
Although cell death by necrosis appears crude, it can be a regulated process [200].
The molecular players involved in triggering and regulating necrotic death pathways
are abundant, with complex and heterogeneous roles.
Necroptosis is a caspase-independent form of regulated necrosis orchestrated by
receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3
(RIPK3), and the pseudokinase mixed lineage kinase domain-like protein (MLKL).
MLKL acts as the terminal effector protein in necroptosis, its phosphorylation and
subsequent oligimerisation contributes to pore formation, loss of membrane integrity
and ultimately necrotic death.
The necroptotic pathway can be triggered in response to numerous stimuli, the
best studied being the inflammatory cytokine tumour necrosis factor alpha (TNF-
α), due to its ubiquitous presence in the tumour microenvironment. TNF-α binds
to tumour necrosis factor receptors (TNFR) which recruit RIPK1. In the absence of
active inhibitor of apoptosis proteins (IAP), and when caspases are inactive, RIPK1 and
RIPK3 will form a protein complex called the necrosome, which in turn phosphorylates
and activates MLKL. As neutrophils are likely to come into contact with TNF-α in
the tumour microenvironment, it is important to investigate if neutrophils respond
to TNF-α by undergoing necroptosis. To date, the ability of human neutrophils to
undergo TNF-α-induced necroptosis has not been reported [417].
While MLKL pseudokinase has been shown to exist in neutrophils, it may have
functions beyond its conventional role as a necroptosis effector protein [420; 419; 273].
Recent studies have suggested that MLKL may also be involved in neutrophil extra-
cellular trap (NET) formation [420; 423; 426]. Neutrophils release NETs, in response
to chemical or pathogenic stimuli, which are composed of chromatin and citrullinated
histones as well as several bactericidal granule components including myeloperoxidase
(MPO) and neutrophil elastase (NE). NET extrusion is a process dependent on a
series of molecular events including: superoxide production, mitochondrial depolar-
ization, vacuolization, chromatin decondensation and membrane remodelling. While
some of the molecular players coordinating NET release are known, the extent of the
contribution of MLKL in this pathway remains unclear.
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The results of Chapter 3 and other published works have suggested that neu-
trophils are recruited to tumour tissue and are associated with poor patient outcomes
[587; 117; 118; 119]. The immunohistochemical analyses of tumour tissue (Chapter 3
Figure 3.6) also revealed the presence of large numbers of neutrophils in the peritu-
mour, intratumour and necrotic core regions of cutaneous squamous cell carcinomas
that were in close proximity to extracellular MPO. This raises the possibility that these
tumour associated neutrophils may have undergone lytic death. Further characterisa-
tion of neutrophil death pathways may therefore be important to enable the discovery
of therapeutic targets that control neutrophil death and regulate inflammation in a
cancer setting. The role of necroptotic effector proteins in neutrophil activation and
cell death pathways is poorly understood.
2 Objectives
This chapter has the following specific objectives:
 Determine if there is MLKL activation (phosphorylation) and cell death in neu-
trophils upon treatment with:
– necroptosis stimuli (TNF-α, SMAC mimetic and pan-caspase inhibitor)
– classical stimuli (PMA (chemical), P. aeruginosa and zymosan (phagocytic/
particulate)
 Determine if inhibition of MLKL function or activation has an impact on neu-
trophil response to stimuli by examining the oxidative burst, NET release and
degranulation
3 Experimental Approach
3.1 Neutrophil purification, inhibitors and stimuli
Neutrophils were purified from the peripheral blood of either healthy human donors
by density gradient centrifugation, or from wild type (WT) and MLKL -/- mice by
negative selection magnetic cell sorting (detailed in (Chapter 2 Section 3).
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In addition to the knock-out mice, inhibition of the necroptotic pathway was tested
by pre-incubating neutrophils with either 10µM of the RIPK1 inhibitor Necrostatin-
1 (Nec-1), or 10µM of the MLKL inhibitor necrosulfonamide (NSA) for 30 minutes
prior to exposure to stimuli. NSA inhibits MLKL translocation to the membranes and
oligomerisation by covalently binding to the Cys86 residue in MLKL’s four helix bun-
dle. Notably, this residue is not conserved in mouse cells, therefore NSA is ineffective
at inhibiting MLKL activity in murine models [239]. Nec-1 is an allosteric inhibitor of
RIPK1, therefore disabling its phosphorylation activity and ability to activate RIPK3.
To test for NADPH oxidase involvement in the necroptosis pathway, diphenyleneiodo-
nium (DPI) (10µM) was used as an inhibitor of NOX2. Control cells were treated with
the volumetric equivalent of the solvent dimethyl sulfoxide (DMSO) kept below 0.1%.
Where indicated, phorbol 12-myristate 13-acetate (PMA) was used to stimulate
NOX2 assembly and respiratory burst at either 12ng/mL (20nM) or 100ng/mL (162nM).
Phagocytic stimuli were opsonised with 50% autologous serum for 30 minutes prior to
exposure to neutrophils to enhance recognition and facilitate uptake. The fungal par-
ticle zymosan was used at a multiplicity of infection (MOI) 5 and two different strains
of Pseudomonas aeruginosa (PA01) or a clinical isolate (PAC) were used at a MOI 10.
3.2 Live cell fluorescence microscopy
Live cell fluorescence microscopy was used to visualise NET forming neutrophils. The
fluorescent dye Hoescht (0.1 µM) was used to visualise nuclear and intracellular DNA
and cell impermeable DRAQ7 (1.2µM) or Sytox Green (0.1 µM) fluorescent dyes were
used to visualise extracellular DNA.
3.3 TSZ treatment
To assess cell death with the prototypical stimuli for TNF-α-induced necroptosis (re-
ferred to as TSZ), neutrophils were pre-incubated with the pan-caspase inhibitor ZVAD-
FMK (Z) (10µM) and the IAP inhibitor SMAC mimetic (S) (BV6 (20µM) in human
cells or Birinapant (20µM) in mice), prior to stimulation with TNF-α (T) (100ng/mL).
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Figure 4.1: Graphical summary of the inhibitors used in TSZ treatment. To induce necrop-
tosis, neutrophils were pre-incubated with IAP inhibitor SMAC mimetic (S) and the pan-caspase
inhibitor ZVAD-FMK (Z) prior to stimulation with TNF-α. Pre-treatment with necrosulfonamide
(NSA) blocks the translocation of the MLKL oligomer to membranes and prevents cell lysis. Pre-
treatment with Necrostatin-1 also blocks necroptosis by inhibiting RIPK1 kinase activity. DPI in-
hibits the NADPH oxidase activity and was used to assess the involvement of its oxidants in some
experiments.
3.4 Viability assays
An optical light microscope was used to observe neutrophil morphology after treatment
and prior to viability assays.
Flow cytometry was used to assess cell surface exposure of the cell membrane phos-
pholipid phosphatidylserine (PS) using FITC conjugated Annexin V antibodies. An-
nexin V has a strong affinity for PS under high calcium conditions and can be detected
by flow cytometry. Cell death was also assessed using propidium iodide (PI) at the
indicated time points post-stimulation. However, a dramatic decrease in the rate of
cell numbers flowing through the flow cytometer was observed in stimulated cells, in-
dicating that dead cells could have been clumping or disintegrating. Therefore, this
method may have been underestimating cell death.
Neutrophil viability was also determined by colorimetric quantification of lactate
dehydrogenase (LDH) activity in the supernatant after stimulation. LDH is a cytoplas-
mic enzyme that is released from the cell when there is plasma membrane damage. In
this assay, LDH derived from the supernatants of membrane compromised neutrophils
oxidized lactate to pyruvate, which reacts with iodonitrotetrazolium chloride (INT) in
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a reaction buffer to form the colored formazan. Formazan is water-soluble and can be
readily detected colorimetrically by measuring absorbance with a spectrophotometer.
Neutrophil LDH release was calculated as a percent of maximal LDH activity values
derived from chemically induced lysis of the equivalent number of neutrophils.
3.5 Functional assays
NET formation was assessed by measuring the amount of fluorescence emitted from
Sytox Green bound to extracellular DNA using a fluorescence plate reader at 4 hours
post-stimulation. This was presented as a percentage compared to neutrophils exposed
to the stimulus without inhibitors. To measure NET formation in mice, an imaging
approach was used to quantify NETs. This method was chosen due to the low numbers
of mouse neutrophils obtained from peripheral blood, consequently providing too weak
a signal for accurate detection by the fluorescence plate reader. Mouse neutrophils were
stimulated with PMA (20nM) and the number of Sytox Green positive neutrophils
per field of view were enumerated manually and reported as a percentage of total
neutrophils per field of view hourly over the 4 hours post-stimulation.
The rate of production of extracellular O ·–2 in PMA stimulated neutrophils was
assessed using an assay that monitors the reduction and therefore change in absorbance
of cytochrome c over a 5 minute period. Catalase is added to scavenge hydrogen
peroxide thereby preventing direct oxidation of cytochrome c or downstream oxidation
by MPO reaction products. Superoxide dismutase was used a negative control as it
rapidly catalyses the dismutation of O ·–2 before it can react with cytochrome c.
A taurine chloramine assay was performed to assess extracellular HOCl release in
PMA stimulated neutrophils. This assay relies on the reaction of taurine with the chlo-
ramines produced by neutrophils to oxidise tetramethylbenzidine (TMB) to produce a
strongly absorbing blue product. The amount of extracellular HOCl produced by PMA
stimulated neutrophils can be quantified by comparing the absorbance of the product
to a standard curve generated with reagent HOCl.
Since the taurine chloramine assay can only detect levels of HOCl released from the
neutrophil, levels of HOCl produced in the phagosome as a result of phagocytosis could
not be investigated with this method. Therefore, the effect of MLKL inhibition on the
production of intracellular HOCl was explored by using the cell permeable fluorescent
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dye R19S. Upon contact with HOCl the dye will fluoresce and its intensity can be
quantified by flow cytometry.
To investigate neutrophil degranulation, the release of the azurophilic and small
granule enzyme β-glucoronidase was measured by its ability to hydrolyse phenolphthalein-
glucoronidate. Degranulation can be induced by exposure to a combination of the
chemotactic peptide formyl-Methionyl-Leucyl-Phenylalanine (fLMP) and the myco-
toxin cytochalasin B (cyto B). After stimulation, the neutrophil supernatant con-
taining β-glucoronidase is removed and added to a buffer containing the substrate
phenolphthalein-glucuronide. The liberated phenophthalein compound is coloured in
basic solutions and its concentration can be determined by its absorbance in relation
to a standard curve generated from known concentrations of phenophthalein.
4 Results
4.1 Conventional necroptotic stimuli (TSZ) induces MLKL-
and RIPK1-dependent cell death in human neutrophils
Neutrophils were incubated with TSZ, and cell morphology was observed at 4 hours
(Figure 4.2). Control neutrophils displayed intact membranes and very few signs of
blebbing or cellular debris (Figure 4.2A). In contrast, TSZ stimulated neutrophils
showed a large amount of cellular debris with many of the remaining cells display-
ing compromised and/or swelling of plasma membranes (Figure 4.2B). The majority of
both the Nec-1 and NSA pre-treated TSZ stimulated neutrophils membranes appeared
intact with only a few cells showing signs of compromised membranes and some cellular
debris, indicating protection from cell death (Figure 4.2C & D). DPI had no impact
on TSZ stimulation (Figure 4.2E). SZ stimulated neutrophils appeared similar in mor-
phology to the control group (Figure 4.2F). However, in the TS stimulated neutrophil
condition there was evidence of cellular debris with many neutrophils showing signs of
membrane blebbing or rupture (Figure 4.2G), an effect that was partially attenuated
by pre-treatment with Nec-1 (Figure 4.2H).
To quantify the observed effects, release of the intracellular enzyme LDH was mea-
sured. At both the 4 and 8 hour time points, TSZ stimulation resulted in high levels of
LDH release (approximately 75-85% of maximal LDH), an effect that was significantly
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Figure 4.2: Representative microscopic images of TSZ stimulated neutrophils. Human
neutrophils treated with necroptotic stimuli (TSZ) or indicated inhibitors for 4 hours before assessment
of cell morphology. (A) Control (B) TSZ stimulated (C) Nec-1 (10µM) pre-treated TSZ stimulated
(D) NSA (10µM) pre-treated TSZ stimulated (E) DPI (10µM) pre-treated TSZ stimulated (F) SZ
stimulated (G) TS stimulated (H) Nec-1 (10µM) pre-treated TS stimulated
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reduced by pre-treatment with both Nec-1 and NSA but not with DPI (Figure 4.3A
& B). These results suggest that human neutrophils are susceptible to TSZ induced
necroptosis. Interestingly, DPI treatment consistently but not significantly increased
LDH activity levels at both time points indicating inhibition of the NADPH oxidase
did not influence TSZ induced cell death in this model.
Neutrophils treated with only TS demonstrated comparable LDH release to the TSZ
treated neutrophils at both time points. This effect was partially reduced in neutrophils
pre-treated with Nec-1 but not with NSA or DPI, consistent with apoptotic death. As
a control, neutrophils were treated with SZ only. SZ treatment had no effect at 4 hours,
but by 8 hours significant cell death had occured (Figure 4.3A & B).
MLKL activation was assessed by quantifying the amount of phosphorylated MLKL
(MLKL-P) protein in the human neutrophil lysates from each TSZ treatment condition
by western blot. Equal volumes of lysates were run on an SDS page gel, transferred to
nitrocellulose membranes and then probed for MLKL-P. Membranes were chemically
stripped and subsequently probed with antibodies against native MLKL, and β-actin.
After numerous attempts, only two independent western blots yielded a positive signal
for MLKL-P (Figure 4.4). All treatment conditions including control appeared to
demonstrate some MLKL phosphorylation, however the results of the western blotting
were too inconsistent to quantify or draw any conclusions.
To test for potential off-target effects induced by the MLKL inhibitor NSA, cell
death was assessed using an LDH assay in TSZ stimulated mouse peripheral blood
neutrophils purified from MLKL -/- and WT mice with or without Nec-1. TSZ stimu-
lation did not appear to kill mouse neutrophils (Figure 4.5).
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Figure 4.3: Viability assays for TSZ stimulated neutrophils. Human neutrophils were stim-
ulated with necroptotic pathway stimuli (TSZ) or TS or SZ with or without inhibitors (10µM NSA
or Nec-1) and levels of LDH activity were measured in the supernatants after (A) 4 hours and (B) 8
hours. Graphs represent the relative LDH release as a percent of maximal LDH values derived from
chemically induced lysis of the equivalent number of neutrophils. Bars represent the average of 3-8
experiments and the different shapes of the data points correspond to the same experiment. Significant
differences were determined using a 1-way ANOVA and Dunnett’s multiple comparisons test ( ** =p
<0.01, *** =p <0.001, **** =p <0.0001).
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Figure 4.4: Western blotting for phosphorylated MLKL in TSZ stimulated neutrophils.
Human neutrophils were treated with necroptotic stimuli (TSZ) or inhibitors for 4 hours and whole
cell lysates probed for MLKL-P, MLKL and β-actin proteins on a western blot. Western blots are
from two independent experiments.
Figure 4.5: LDH activity assay for mouse TSZ stimulated neutrophils. MLKL -/- mouse
(white) and wild type (WT) mouse (grey) peripheral blood neutrophils were treated with necroptotic
stimuli (TSZ) Human neutrophils and pre-treated with the indicated reagents: Birinapant (20µM)(S)
and ZVAD-fmk (10µM)(Z) and/or Nec-1 (10µM) for 30 minutes prior to stimulation with TNF-α
(100ng/mL)(T). Levels of LDH activity were measured in the supernatants after 4 hours. Graph
represents the average LDH activity of the cells as a percent of maximal LDH values. Bars represent
the average 5 experiments, data point shapes correspond to the same replicate.
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4.2 MLKL inhibition does not impact cell death in neutrophils
activated by PMA or zymosan
To assess if MLKL or RIPK1 contributed to cell death when exposed to conventional
chemical or phagocytic neutrophil stimuli, human peripheral neutrophils were pre-
incubated with inhibitors Nec-1, NSA or DPI and then stimulated with either PMA
(100ng/mL), or the fungal particle zymosan (MOI 5) and analysed after 3 hours.
PMA stimulated neutrophils demonstrated significantly higher LDH release, which
was negated by pre-incubation with DPI (Figure 4.7A). Neither Nec-1 nor NSA pre-
treatment significantly reduced LDH release in PMA stimulated neutrophils. This find-
ing was consistent with microscopic analysis which demonstrated that very few intact
cells were observed in both the PMA stimulated and inhibitor pre-treated neutrophils
(Figure 4.7A &B).
To determine if RIPK1 or MLKL inhibition had an effect on PS exposure, PMA
stimulated neutrophils pre-treated with or without Nec-1 or NSA were assessed by flow
cytometry for Annexin V-FITC antibody adhesion and PI staining after 3 hours. As a
control, neutrophils stimulated with PMA and pre-treated with or without Nec-1 and
NSA inhibitors were evaluated for fluorescence without Annexin V. As expected, there
were no PMA stimulated cells emitting fluorescence in the FITC channel, whilst NSA
pre-treated cells had a strong peak in the FITC channel (despite no Annexin V being
present in either condition)(Figure 4.6B & C). This finding made the evaluation of PS
exposure with NSA in this system potentially confounding. Nec-1 did not fluoresce in
any channel (data not shown), therefore only Nec-1 was used in this system.
There was no significant difference in the percentage of cells staining positively for
PS between PMA stimulated and Nec-1 pre-incubated neutrophils (Figure 4.7C). This
indicated that RIPK1 and MLKL were not involved in cell death and that RIPK1 was
not involved in PS exposure in neutrophils stimulated with PMA (100ng/mL). Notably,
the flow cytometry analysis indicated that only ∼35% of neutrophils were membrane-
compromised after PMA stimulation, whereas the observed cell morphology and LDH
activity assay indicated that there were considerably more.
Phagocytosis generally induces non-lytic cell death in neutrophils, therefore, it was
not unexpected to observe very little LDH activity in the supernatant of zymosan
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Figure 4.6: NSA fluoresces in the FITC channel. Representative flow cytometry of (A) forward
and side scatters, (B) fluorescent profiles in the FITC channel and (C) gating strategies of the fluores-
cent channels for neutrophils stimulated with PMA or pre-incubated with NSA (10µM) and analysed
after 3 hours. Note: no Annexin V was present in either treatment
stimulated neutrophils at this time point. Zymosan stimulated neutrophils demon-
strated only an average of 10% LDH release, and Nec-1 and NSA pre-treatment had
no significant inhibitory effect (Figure 4.8A). Assessment of the cell morphology of the
different treatment conditions confirmed that the majority of neutrophils had retained
membrane integrity and there were no significant morphological differences between
zymosan stimulated neutrophils and neutrophils that had been pre-incubated with in-
hibitors of MLKL and RIPK1 (Figure 4.8B). A large proportion (75%) of zymosan
stimulated neutrophils demonstrated PS exposure consistent with apoptosis, and Nec-
1 was unable to block PS exposure (Figure 4.8C). Since there was less cell death in this
model, the results from the flow cytometry were more consistent with the LDH and






































































Figure 4.7: Viability assays for PMA stimulated neutrophils. Human neutrophils stimulated
with PMA. Human neutrophils were pre-incubated with either Nec-1 (10µM) or NSA (10µM) for 30
minutes prior to stimulation with PMA (100ng/mL). (A) Levels of LDH activity were measured in
the supernatants after 3 hours. Graph represents the relative cytotoxicity of the cells as a percentage
of maximal LDH values. Bars represent the average of at least 4 separate experiments, data point
shapes correspond to the same replicate (B) Representative images of neutrophils 3 hours post PMA
stimulation with or without indicated inhibitors (C) After 3 hours, neutrophils were stained with
Annexin V-FITC and PI to detect surface exposure of PS and to assess cell death, respectively, and
analyzed by flow cytometry.
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Figure 4.8: Viability assays for zymosan stimulated neutrophils. Human neutrophils treated
with zymosan (MOI 5). Human neutrophils were pre-treated with either Nec-1 (10µM) or NSA
(10µM) for 30 minutes prior to stimulation with zymosan (MOI 5). (A) Levels of LDH activity were
measured in the supernatants after 3 hours. Graph represents the relative cytotoxicity of the cells as
a percentage of maximal LDH values. Bars represent the average of at least 5 separate experiments,
data point shapes correspond to the same replicate. (B) Representative images of neutrophils 3 hours
post zymosan stimulation (C) After 3 hours, neutrophils were stained with Annexin V-FITC and PI
to detect surface exposure of PS and to assess membrane integrity, respectively, and analyzed by flow
cytometry.
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To investigate if MLKL becomes phosphorylated during PMA and zymosan stimu-
lation, whole neutrophil lysates were harvested at 0, 1 and 2 hours post-stimulation and
levels of MLKL-P, MLKL, and β-actin were assessed by western blot (Figure 4.9). Both
PMA stimulated and zymosan stimulated neutrophils showed some evidence of MLKL
phosphorylation, however these results were inconsistent. The colorectal cancer cell
line (HT29) is commonly used as a positive control for MLKL-P following TSZ stimu-
lation and lysates from an experiment using this system are shown in Figures 4.9B and
4.9D. This control suggested that the variable western blotting results for MLKL phos-
phorylation in both the PMA and zymosan stimulated as well as the TSZ stimulated
neutrophil lysates (Figure 4.4) may be due to specific traits of the neutrophil.
Figure 4.9: Western blotting for phosphorylated MLKL in PMA stimulated neu-
trophils.(A-B) Human neutrophils were stimulated with PMA (100ng/mL) or (C-D) zymosan (MOI
5) and harvested from 0-3 hours post-stimulation. MLKL-P, MLKL, and β-actin in whole cell lysates
were detected by western blot. Where indicated, HT29 was used as a positive control for MLKL-P
activation for unstimulated (-ve) or TSZ stimulated cells (+ve). Each western blot is from a separate
independent experiment.
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4.3 MLKL inhibition and neutrophil response to stimuli
4.3.1 The effect of MLKL inhibition on NET formation
Activated MLKL has been reported to associate with membranes and contribute to
pore formation during necroptosis. NET formation requires the breakdown of nuclear,
granular and plasma membranes and the molecular contributors to these processes re-
main unclear. Therefore, the potential contribution of MLKL to NET formation was
investigated. PMA and the Gram-negative bacterium P.aeruginosa are both potent in-
ducers of NETs, a process dependent on the activation of NOX2 [627]. To visualise and
quantify extracellular DNA release, the cell impermeable DNA binding dyes DRAQ7 or
Sytox green were used in this section. It is notable that neither of these dyes is specific
for NETs and could potentially bind to intracellular DNA in a permeabilised cell or
extracellular DNA from a dying cell that at not undergone NETosis. For simplicity,
this section will refer to any extracellular DNA bound to these dyes as an indication
of NET formation.
Live cell microscopy was used to visualise the NET formation process in neutrophils
stimulated with PMA (20 nM) and stained with Hoescht flourescent dye (blue) to vi-
sualise nuclei and cell impermeable DNA binding dye DRAQ7 (red) over 3.5 hours.
Representative images at 30 minute intervals starting from 1 hour post-stimulation are
presented in Figure 4.10. At 60 minutes post-stimulation, neutrophils are beginning to
adhere to the plate and vacuolisation is visible (Figure 4.10A). At 90 minutes, intracel-
lular DNA begins to condense and cells begin to flatten out; one neutrophil has expelled
its DNA extracellularly (red) (Figure 4.10B). At 120 minutes, the neutrophils continue
to flatten, their intracellular DNA appears diffuse within the cell and vacuoles become
more visible (Figure 4.10C). The neutrophils continue to release their DNA at 150
minutes, and one neutrophil (black arrow) starts to become enlarged (Figure 4.10D).
At 180 minutes, all but one neutrophil (black arrow) have extruded their DNA and
membrane integrity appears compromised. The membrane of the last remaining intact
neutrophil becomes more rounded (Figure 4.10E). At 210 minutes post-stimulation,
the last neutrophil extrudes its DNA (black arrow)(Figure 4.10F).
Using the same fluorescent dyes, live cell microscopy was used to visualise NET for-
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Figure 4.10: NET formation in human neutrophils after exposure to PMA over 3.5 hours.
Images from live-cell microscopy of NET formation in human neutrophils stimulated with PMA (20nM)
at the indicated time points. Hoescht (blue) and DRAQ7 (red) DRAQ7 fluorescent dyes bind to
intracellular and extracellular DNA respectively.
MOI 10 with or without pre-treatment with NSA (Figure 4.11). Both the PA01 stim-
ulated neutrophils and the neutrophils pre-treated with NSA were observed ingesting
bacteria and appeared to make NETs. Although not quantified, there appeared to be
fewer NETs released per neutrophil in the NSA pre-treated neutrophils compared to
those stimulated with PA01 without the inhibitor.
A similar result was observed when a clinical isolate of P. aeruginosa (PAC)(MOI
10) was used as a stimulus. Neutrophils were pre-treated with or without NSA and
visualised over a period of 3 hours (Figure 4.12). For this experiment, only Sytox Green
was used to visualise extracellular NETs. Again, both the PAC stimulated and the NSA
pre-treated neutrophils appeared to consume bacteria and release NETs, however, there
appeared to be fewer NETs in the NSA pre-treated neutrophils compared to those
stimulated with PAC alone.
In order to quantify NET release, the fluorescence of Sytox Green binding to ex-
tracellular DNA was measured using a plate reader. Human neutrophils were pre-
treated with or without DPI, NSA or Nec-1 prior to stimulation with PMA (20nM),
P.aeruginosa (PA01) or a P.aeruginosa clinical isolate (PAC) at MOI 10.
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60 min 120 min 180 min
PA01
PA01 + NSA
Figure 4.11: Images from live cell microscopy of NET formation in human neutrophils
stimulated with PA01 with or without NSA over 3 hours. Images from live cell microscopy of
NET formation in human neutrophils pre-treated with (bottom) or without (top) NSA (10 µM) and
stimulated with P.aeruginosa (PA01) at a MOI of 10 at 60, 120 and 180 minutes post-stimulation.
Hoescht (blue) and DRAQ7 (red) fluorescent dyes bind to intracellular and extracellular DNA respec-
tively.
60 min 120 min 180 min
PAC
PAC + NSA
Figure 4.12: Images from live-cell microscopy of NET formation in human neutrophils
stimulated with PAC with or without NSA over 3 hours. Neutrophils pre-incubated with
or without NSA, prior to stimulation with a clinical isolate of P.aeruginosa (PAC) at a MOI of 10.
Sytox Green was added immediately after stimulation with PAC and the neutrophils were observed
by live-cell microscopy over 3 hours.
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Both PA01 and PAC stimulation resulted in an increase in Sytox Green fluorescence
compared to control. There was a significant decrease in fluorescence in the NSA
(10µM) pre-treated neutrophils stimulated with both PA01 or PAC (Figure 4.13A
&B), which was consistent with observations from live cell microscopy (Figures 4.11
and 4.12), but no significant difference in NET release was observed with Nec-1 pre-
treatment. These results indicated that MLKL had a role in NET formation in this
system, but RIPK1 activity was not required.
PMA stimulation also resulted in an increase in Sytox Green fluorescence compared
to control and there was a significant decrease in fluorescence in Nec-1 pre-treated
neutrophils (Figure 4.13C). NSA pre-treated neutrophils appeared to demonstrate a
decrease in fluorescence compared to PMA alone, however this was not statistically
significant. This finding suggested a RIPK1-dependent effect, independent of MLKL.
Pre-incubation with DPI decreased the fluorescence significantly in all NET stimulating
conditions, and the addition of NSA combined with DPI did not increase the inhibitory
effect of DPI. These contrasting results suggested that phagocytic and PMA stimulation
may produce NETs through different pathways.
To control for a potential quenching or enhancement of Sytox Green fluorescence
by NSA or Nec-1, the inhibitors were also added to neutrophils with each stimulus 15
minutes prior to the measurement of fluorescence in the plate reader. There were no
significant differences observed with late administration of these inhibitors (data not
shown).
To further examine the effect of MLKL deficiency on NET formation, peripheral
blood neutrophils were purified from both MLKL -/- and WT mice and stimulated with
PMA (20nM) or pre-incubated with DPI as a control. Both the WT and MLKL -/-
appeared to make NETs and pre-treatment with DPI effectively decreased the numbers
of Sytox Green positive neutrophils at 3 and 4 hours post-stimulation in both species
(Figure 4.14 and 4.15). Consistent with the human NET experiments using NSA, there
were no significant differences in Sytox Green positive neutrophils between the MLKL
-/- and WT mice at any time point. NET formation in the mouse neutrophils as a
result of exposure to PA01 (MOI 10) was also assessed. Phagocytosis was not observed
in either species, and although several neutrophils were observed that stained positively
























































































































































































































Figure 4.13: Quantification of NET formation in human neutrophils. Neutrophils pre-
incubated with or without DPI, NSA or Nec-1 prior to stimulation with (A) P.aeruginosa (PA01),
(B) a clinical isolate of P.aeruginosa (PAC) or (C) PMA. The amount of fluorescence emitted from
Sytox Green bound to extracellular DNA was measured at 4 hours post-stimulation and normalised to
the fluorescence of neutrophils exposed to stimulus alone. Results are shown from 5-10 independent
experiments. Significant differences were determined using 1-way ANOVA with multiple comparisons
on the raw data values and are denoted with * = p= <0.05, **= p <0.01,***= p<0.001, ****=p
<0.0001
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features associated with NET release and therefore the presence of NETs in this model
could not be confirmed (data not shown).
60 min 120 min 180 min
WT
MLKL -/-
Figure 4.14: Representative microscopy images of PMA-induced NET formation in WT
and MLKL -/- mouse neutrophils. Neutrophils from WT (top) and MLKL -/- (bottom) stim-
ulated with PMA (20nM) and incubated with Sytox Green were visualised over a period of 4 hours.
Images show neutrophils at 60, 120 and 180 minutes post-stimulation.
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Figure 4.15: PMA-induced NET formation in WT and MLKL -/- mouse neutrophils.
Neutrophils from WT (black) and MLKL -/- (white) pre-incubated with or without DPI, prior to
stimulation with PMA. The percentage of Sytox Green positive neutrophils per field of view is displayed
on the y-axis and the time points are on the x-axis. Results are from 3 independent experiments, data
point shapes correspond to the same replicate.
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4.3.2 The effect of MLKL inhibition on the oxidative burst
Upon stimulation with PMA or phagocytic stimuli, NOX2 assembles and produces su-
peroxide O ·–2 , which then dismutates to hydrogen peroxide (H2O2). H2O2 is converted
to hypochlorous acid (HOCl) by myeloperoxidase (MPO). Because several published
reports had suggested MLKL involvement in the release of NETs, and because NET
formation is generally dependent on the activity of NOX2 and MPO in some mod-
els, the contribution of MLKL and RIPK1 on the production of O ·–2 and HOCl was
assessed.
4.3.3 PMA stimulation
The effect of the inhibition of either MLKL or RIPK1 on the production of extracellu-
lar O ·–2 in PMA stimulated neutrophils was investigated using an assay based on the
reduction of cytochrome c. The amount of O ·–2 produced by PMA stimulated neu-
trophils was significantly reduced by pre-treatment with NSA but not Nec-1 (Figure
4.16C).
The taurine chloramine assay was used to quantify extracellular HOCl in neutrophils
pre-treated with NSA or DPI prior to PMA stimulation. The result of this assay demon-
strated that PMA-stimulated neutrophils pre-treated with DPI produced significantly
less HOCl compared to PMA stimulated neutrophils (Figure 4.16A). Pre-treatment
with NSA resulted in a small but significant decrease in HOCl release compared to
PMA alone, but very minor in comparison to DPI. In order to control for potential
off-target effects of NSA, an MPO activity assay was performed in a cell-free system
using the same assay. MPO or MPO with NSA were pre-incubated for 30 minutes
prior to the addition of H2O2, and the amount of HOCl produced was quantified after
4 minutes. Figure 4.16B indicates that NSA did not have a direct inhibitory effect on
MPO.
To measure the effect of MLKL and RIPK1 inhibition on intracellular HOCl pro-
duction, neutrophils were incubated with the HOCl-activated R19S probe, pre-treated
with either NSA, Nec-1 or DPI and stimulated with PMA. The percentage of cells
exhibiting R19S fluorescence as well as the intensity of the fluorescence was assessed
by flow cytometry 2 hours post-stimulation.


































































































































Figure 4.16: The effect of MLKL inhibition on hypochlorous acid and superoxide pro-
duction in PMA stimulated neutrophils. (A) HOCl production as a percent of PMA (B) The
amount of HOCl produced as a result of MPO activity in a cell-free assay (C) The amount of O ·–2
produced per minute per 1 × 106 neutrophils stimulated with PMA or indicated inhibitors. Graphs
represent the results of 3 - 7 independent experiments, data point shapes correspond to the same
experiment. Significant differences were determined using a 1-way ANOVA and Dunnett’s multiple
comparisons test and are denoted with * = p <0.05 or ** p <0.01, *** p <0.001
HOCl or the intensity of their signal by either NSA or Nec-1 (Figure 4.17). DPI
significantly inhibited both the percentage of neutrophils producing HOCl as well as
the amount of HOCl produced.
To further investigate the role of MLKL in HOCl production, the R19S assay was
repeated with murine neutrophils. MLKL -/- and WT mouse neutrophils were purified
from peripheral blood and stimulated with PMA or pre-incubated with DPI as a con-
trol. R19S fluorescence was observed upon stimulation in both species albeit at a lower
intensity than with the human neutrophils. There were no significant differences in
the percentage of R19S positive neutrophils or the mean fluorescent intensity between
the MLKL -/- mice and the WT mice (Figure 4.18A-C). DPI pre-treatment effectively
abrogated the production of HOCl as a result of PMA stimulation in both species.
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Figure 4.17: Percentage and intensity of HOCl production by PMA stimulated human
neutrophils (A) The percentage of R19S positive neutrophils and (B) the intensity of the signal in
mean fluorescence units (MFU) following PMA stimulation after 3 hours. (C) A representative his-
togram of the number of cells (y-axis) and mean fluorescence intensity (x-axis), the different conditions
are noted at the top of each peak. The graphs represent results of 4 independent experiments, data
point shapes correspond to the same experiment. Significant differences were determined using raw
data values with a 1-way ANOVA and Dunnett’s multiple comparisons test and are denoted with * =








































































Control PMA + DPI
Figure 4.18: Percentage and intensity of HOCl production by PMA stimulated mouse
neutrophils. PMA stimulated MLKL -/- (white) and WT neutrophils (grey) (A) The y-axis shows
the percentage of R19S positive neutrophils for each condition (x-axis) (B) the y-axis shows the mean
fluorescence intensity units for each treatment condition (x-axis) (C) a representative histogram of the
number of cells (y-axis) and mean fluorescence intensity (x-axis), the different conditions are noted at
the top of each peak. Graphs represent the results of 3 independent experiments, data point shapes
correspond to the same experiment.
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4.3.4 Phagocytic stimuli
To visualise intracellular HOCl production, human neutrophils were pre-incubated with
the HOCl sensitive fluorescent dye R19S, with or without NSA prior to stimulation with
PA01 (MOI 10). To visualise NETs, Sytox Green was added immediately after stimu-
lation and the neutrophils were recorded with live cell microscopy over 3 hours (Figure
4.19). By 30 minutes post-stimulation, there was a rapid increase in red fluorescence
(HOCl) in the PA01 stimulated neutrophils, which was absent in the NSA pre-treated
neutrophils at the same time point. At 3 hours, there was very little red fluorescence
observed and markedly fewer Sytox Green positive NETs detected in the NSA pre-




30 mins 60 mins 120 mins 180 mins
Figure 4.19: Representative images from live cell microscopy of HOCl production and
NET formation in human neutrophils stimulated with PA01 at various time points. Neu-
trophils pre-incubated with R19S (red) and with or without NSA, prior to stimulation with PA01
(MOI 10). Sytox Green was added immediately after stimulation with PA01 and the neutrophils were
observed by live cell microscopy over 3 hours. Figure shows still images from the footage at 30, 60,
120 and 180 minutes post-stimulation for the indicated conditions.
To measure the effect observed with live cell microscopy, neutrophils were incubated
with R19S, pre-treated with either NSA, Nec-1 or DPI and stimulated with zymosan.
The percentage of cells exhibiting R19S fluorescence as well as the intensity of the
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fluorescence was assessed by flow cytometry 2 hours post-stimulation.
There was no inhibitory effect on the percentage of cells producing intracellular
HOCl by either NSA or Nec-1 (Figure 4.20A). However, there was a significant decrease
in the R19S fluorescence intensity in the zymosan stimulated neutrophils pre-treated
with Nec-1 compared to zymosan stimulated neutrophils without the inhibitor (Figure
4.20B &C). This indicated, that although similar numbers of cells were producing
HOCl, Nec-1 treatment may have been affecting the amount of HOCl produced. DPI

















































































































Figure 4.20: Percentage and intensity of HOCl production by zymosan stimulated human
neutrophils (A) The percentage of R19S positive neutrophils and (B) the intensity of the signal in
mean fluorescence units (MFU) following exposure to zymosan (MOI 5) after 3 hours. (C) A represen-
tative histogram of the number of cells (y-axis) and mean fluorescence intensity (x-axis), the different
conditions are noted at the top of each peak. The graphs represent results of 4 independent experi-
ments, data point shapes correspond to the same experiment. Significant differences were determined
using raw data values with a 1-way ANOVA and Dunnett’s multiple comparisons test and are denoted
with * = p <0.05 or ** p <0.01
To control for the potential fluorescence quenching effect of NSA or Nec-1, an
independent experiment was performed where instead of pre-incubating the neutrophils
with the inhibitors prior to stimulation, the inhibitors were added 10 minutes before
flow cytometric assessment. There was no significant difference in the percentage of
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cells fluorescing or the average fluorescence intensity (data not shown). Furthermore,
in a cell-free assay, HOCl was added to equimolar concentrations of R19S with or
without the NSA or Nec-1, and the amount of fluorescence was measured. There was no
significant decrease in fluorescence observed due to the presence of the inhibitors (data
not shown). These assessments indicated that the effects of the inhibitors observed in
the assays involving R19S were more likely to be a true biological effect rather than a
technical artefact of the inhibitors.
Several attempts were made to repeat this experiment using mouse neutrophils
with zymosan as a stimulus, however no detectable fluorescence could be observed.
A cytospin was performed for each treatment condition to visualise cell morphology
and to assess successful phagocytosis. While the zymosan particles appeared to be
inside the neutrophils, it was unclear why no fluorescence was detected in this assay
(Figure 4.21). Further experiments using mouse neutrophils with this assay were not
undertaken. Furthermore, extracellular O ·–2 release in murine neutrophils was not






Figure 4.21: Microscopic images of control, PMA or zymosan stimulated WT and MLKL
-/- mouse neutrophils Representative images of mouse neutrophil cytospins (WT or MLKL -/-)
with the indicated stimuli on the left hand side. The zymosan stimulated neutrophils appeared to
ingest the particles (photo bottom right) as indicated with black arrows.
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4.3.5 The effect of MLKL inhibition on neutrophil degranulation
The effect of MLKL inhibition on neutrophil degranulation was next assessed. Human
neutrophils were pre-incubated with or without NSA, stimulated to degranulate with
fLMP and cyto B, and the amount of extracellular β-glucuronidase in their supernatant
was measured. Pre-treatment with NSA had no significant effect on the release of β-


















































Figure 4.22: Neutrophil degranulation. The concentration of phenolphthalein produced from
β-glucuronidase activity in fLMP and cyto B stimulated neutrophils pre-incubated with or without
NSA. Results are from 3 independent experiments, data point shapes correspond to the same replicate.
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5 Discussion
Although there have been considerable advances in the understanding of cell death
pathways in recent years, the molecular intermediates and mechanisms involved in
the regulation of neutrophil cell death remain challenging to define. Many unique
features of the neutrophil can impact on standard modes of cell death, most notably, its
innate tendency to favour apoptosis, and its ability to produce strong oxidants that can
modify the activity of a number of regulatory proteins involved in cell death pathways
[295]. While apoptosis remains the default mode of cell death in the neutrophil, they
can also undergo several forms of regulated necrosis that depend on the stimulus and
activity of downstream effector proteins [628]. Given the sheer numbers of neutrophils
in circulation and the volatile nature of their contents, the characterisation of their
death pathways is vital in the understanding of inflammation and related diseases.
Furthermore, the ability to manipulate these processes may also provide therapeutic
opportunities.
Lytic death as a result of NET release (NETosis), is a relatively newly characterised
form of regulated necrosis that is caspase-independent and occurs in response to both
chemical and particulate stimuli [197]. Necroptosis is another pro-inflammatory form of
necrotic cell death that is caspase-independent, and like NETosis, requires membrane
permeabilisation by molecular mediators to occur. Furthermore, the prototypical stim-
uli of necroptosis (TNF-α binding to its death receptor) has been shown to induce NET
release [629; 630]. This raised the possibility that NETosis and necroptosis could share
effector protein intermediates. While several investigations into this hypothesis had
been previously reported, the findings were conflicting. Furthermore, whether or not
necroptosis by the conventional pathways could occur in human neutrophils had not
been established. The current study investigated the ability of neutrophils to undergo
standard TSZ-induced necroptosis as well as the role of necroptotic effector proteins in
typical neutrophil responses to PMA and phagocytic stimuli.
This is the first study to show that human neutrophils can undergo cell death
when stimulated with the protypical inducers of TNF-α-induced necroptosis, as TSZ-
stimulated neutrophils pre-incubated with inhibitors of MLKL and RIPK1 resisted cell
death. However, TSZ stimulation of mouse peripheral blood neutrophils did not result
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in cell death, making it impossible to validate the results of MLKL inhibition in human
cells. The MLKL inhibitor NSA had no effect on TNF-α-mediated apoptosis (TS
treatment), suggesting that it acts specifically on the necroptosis pathway. Inhibition
of the NADPH oxidase with DPI had no significant effect on TSZ-induced cell death
indicating that oxidants derived from NOX2 are not required for the execution of
TNF-α-induced necroptosis in neutrophils. This finding is in agreement with a report
showing that DPI had no inhibitory effect on cell death in TSZ stimulated bone marrow
derived mouse neutrophils primed with IFN-γ [423]. The effect of direct inhibition
of MLKL on PS exposure could not be assessed due to NSA’s interference with the
fluorescence assay, however, RIPK1 inhibition had no effect on PS exposure.
Pharmacological inhibition of caspases and IAPs was used to induce TNF-α-induced
necroptosis in vitro in neutrophils, however, these conditions are also likely to occur in
a pathological setting. During infection and/or inflammation, neutrophils become ex-
posed to a variety of particulate and inflammatory stimuli in combination with TNF-α,
that could activate the neutrophil to produce oxidants. Although TNF-α alone is a
weak stimulus of respiratory burst and degranulation, when presented in combination
with phagocytic stimuli, it has been shown to increase neutrophil production of H2O2,
adherence, degranulation and phagocytic uptake substantially [631]. Since caspases
are redox sensitive cysteine-dependent enzymes, their activity is susceptible to inacti-
vation through oxidants produced by the neutrophil [632; 300]. Several early reports
from our research group showed that neutrophil oxidants produced by stimulation with
PMA or Staphylococcus aureus, inactivated caspases and prevented caspase-dependent
cell death [300; 306; 307]. Caspase inhibition was also shown to be a requirement for
PS exposure [633; 306]. Moreover, the MPO-derived oxidant hypothiocyanous acid
(HOSCN) is capable of inhibiting apoptosis and inactivating caspases in endothelial
cells, suggesting that the oxidants released from neutrophils in the inflammatory envi-
ronment can impact death pathways in surrounding cells [634]. A major role of IAPs
in preventing necroptosis is to keep RIPK1, RIPK3 and MLKL ubiquitylated and in-
activated [264; 227]. However, there are seven cysteine residues in the RING domain
of IAPs, which are responsible for its ubiquitylation functions [635]. Although there
is little information in the literature about the potential redox inactivation of this en-
zyme, it is possible that oxidants produced in activated neutrophils could modify and
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inhibit its E3 ligase activity. One published report has shown that the combined effect
of TNF-α with zymosan increase LDH activity in neutrophil supernatant significantly
compared to zymosan or PMA treatment alone [631]. Future work could investigate
the effect of MLKL and RIPK1 inhibition on cell death when neutrophils are exposed
to both phagocytic stimuli and TNF-α (without a caspase inhibitor or SMAC mimetic)
to determine if the oxidants produced from NOX2 stimulation would be sufficient to
inhibit caspases and IAP and promote necroptosis.
Another aim of this study was to explore the effects of MLKL inhibition on cell
death, oxidant production and NET formation in neutrophils exposed to the soluble
stimulus PMA and various phagocytic stimuli. It is important to keep in mind that
these stimuli activate neutrophils via very different mechanisms. PMA stimulation
effectively bypasses any upstream pathway involved in the activation of the NADPH
oxidase by directly activating protein kinase C, that then phosphorylates the NOX2
component p47PHOX and promotes its activation [636]. In contrast, the presence of
particulate or bacterial stimuli will induce NADPH oxidase assembly on phagosomal
membranes as a result of phagocytosis, but will also stimulate other molecular path-
ways through the binding of PAMPS (such as LPS or flagellins) to TLR receptors on
the neutrophil cell surface. Furthermore, the amount of oxidants produced and their
localisation in the cell will be quite different between the two stimuli. PMA-induced
activation does not involve the formation of a phagosome and can be active at the
plasma membrane, granules and intracellular vesicles [637], whereas oxidant produc-
tion induced by phagocytosis will be predominantly localised to the phagosome.
The production of high levels of oxidants in neutrophils stimulated by PMA is
thought to be the main driver of NET extrusion and lytic death. Inhibition of MLKL
decreased the production of HOCl and O ·–2 , but it did not significantly decrease NET
release. This suggests that sufficient oxidant generation was still occurring to enable
NET formation. The oxidative burst and MPO activity are known to be essential for
NET formation, which was confirmed in the current study by the use of DPI.
Nonphagosomal intracellular oxidants induced by PMA and generated on granule
membranes have been shown to fuse with intracellular vesicles that were subsequently
secreted by exocytosis [638]. Recently, it was demonstrated in HT29 cells, that MLKL
facilitates the generation of extracellular vesicles and is involved in endosomal traffick-
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ing [273]. This non-lethal function of MLKL was shown to be independent of RIPK3
but dependent on the residues targeted by RIPK3 (T537 and S358), suggesting that
MLKL could be phosphorylated by other kinases [273]. Given the novel role of MLKL
in vesicle formation and release, it seems plausible that the inhibition of MLKL in
PMA-stimulated neutrophils may have decreased the efficacy of oxidant laden vesicle
release, resulting in the decreased HOCl and O ·–2 observed extracellularly. However,
this inhibition did not reduce intracellular levels of oxidants sufficiently to inhibit NET
release. It is unclear how this theory fits with the finding that inhibition of RIPK1
decreased NET release in PMA-stimulated neutrophils. It may be that Nec-1 had
off-target effects in this system by inducing apoptosis in some cells (discussed below).
Nonetheless, while this finding contrasts other studies which have shown that RIPK1
inhibition had no effect on PMA induced NET formation [639; 423], it does corroborate
several others [420; 424; 425].
The investigation into the role of necroptotic proteins in the phagocytic model pro-
duced contrasting results to those of PMA. The inhibition of necroptotic effector pro-
teins in human neutrophils ingesting zymosan particles did not appear to have an effect
on the number of neutrophils producing intracellular HOCl, however, RIPK1 inhibition
did have an effect on the amount of HOCl produced. In a model of adhesion-receptor-
induced neutrophil necroptosis, which relies on NADPH oxidase-derived oxidants and
not MLKL as the final effector for cell lysis, it was proposed that MLKL interacts with
proteins involved in the assembly and activation of the NADPH oxidase [406]. Inhibi-
tion of MLKL resulted in lower levels of intracellular oxidants and reduced cell death.
The authors used several types of MLKL inhibitors as well as NSA but interestingly,
while NSA pre-treatment saved the neutrophils from necroptotic death, it did not de-
crease oxidant levels (and in some cases increased it, although this was not statistically
significant). The report suggested that this was due to the different inhibitory targets
of the MLKL inhibitors. While NSA targets the effector domain directly, the other
MLKL inhibitors targeted the RIPK3 phosphorylation sites [406]. This suggests that
phosphorylated MLKL could be involved in NADPH oxidase assembly or activation in
models that involve cell surface receptor stimulation and signal transduction pathways.
If MLKL were involved in the assembly of the NADPH oxidase then this could explain
the effect of Nec-1 and not NSA on intracellular oxidant levels. It would be interesting
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to use these alternative MLKL inhibitors in the assays used in the current study when
they become commercially available to test this theory.
Pre-treating neutrophils with NSA inhibited NET release in both strains of P.
aeruginosa, while Nec-1 did not. MLKL involvement could not be confirmed using
MLKL -/- mice because of weak NET formation in WT mice. In the absence of a
RIPK3 inhibitor, the possibility that RIPK3 could still be actively phosphorylating
MLKL is a potential explanation for this. Other phagocytic models of neutrophil lytic
cell death have shown that RIPK3 can be activated independently of RIPK1 [412; 256],
which could explain the effect of NSA but not Nec-1. TLR-mediated necrosis through a
pathway dependent on the TLR4-adaptor protein TRIF, RIPK3 and MLKL has been
reported in mouse macrophages [640]. This pathway does not require RIPK1, but
rather TRIF, through its RHIM domain, either nucleates or promotes the formation of
RIPK3 homo-oligomers, necrosome formation and downstream MLKL activation [237].
Neutrophils express both TLR4 and TLR2 on their cell surface, which have been shown
to detect LPS from Gram-negative bacteria including P. aeruginosa, and lead to the
activation of NOX2 [641; 642]. Based on these reports and the results from this chapter
it is tempting to speculate that RIPK1 may not play a major role in P. aeruginosa-
induced NET release, and that MLKL activation is upstream of the assembly of the
NADPH oxidase perhaps involving TLR signalling and alternative activation of RIPK3.
The activity of the NADPH oxidase could be the major determinant in the mode of
cell death of P. aeruginosa stimulated neutrophils. DPI reduced NET formation in P.
aeruginosa-stimulated neutrophils but not to the same degree as observed with PMA
stimulated neutrophils. Since the method used to quantify NETs in this chapter was
limited by its ability to distinguish between modes of lytic death, it is possible that a
proportion of neutrophils that were pre-treated with DPI were undergoing pyroptosis.
Ryu and colleagues demonstrated that PA01 induces NLRC4-dependent pyroptosis in
mice and human neutrophils when NOX2 is impaired [216]. This suggests that if MLKL
is in fact involved in NADPH oxidase activation, then the possibility that its inhibition
could have also induced pyroptosis in the current study cannot be ruled out. However,
since pyroptosis is thought to occur in instances of overwhelming bacterial load, the
MOI used in the Ryu study were between 20-40 MOI, which is substantially higher
than the MOI used in the current study (10). Further research is required to define the
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diverse functions of MLKL in the neutrophil, particularly its role in vesicle trafficking,
NADPH oxidase assembly and/or activation, and in the TLR pathway.
There has been a call to standardize experimental approaches in the NET field
which will aid the ability of researchers consolidate data across studies [422]. Although
the methods used to quantify NETs in the current study have been previously pub-
lished [197; 588; 421], novel approaches have recently started to emerge that involve
more quantitative image- and antibody-based methods which enable more specific char-
acterisation of NETs while both increasing throughput and decreasing observer bias
[423; 643; 644; 422].
Previous research that has used bone marrow mouse neutrophils in models of
necroptosis and NET release have “primed” the cells with G-CSF or IFN-γ prior to
stimulation [423]. While these cytokines are likely to be in circulation during inflam-
mation and drive the release of immature neutrophils from the bone marrow, there are
numerous phenotypic and functional differences between immature bone marrow neu-
trophils and mature circulating neutrophils [645; 646]. Therefore, mouse neutrophils
were purified from venous blood in an effort to more closely mimic the human popula-
tions used in the current study. However, due to the small quantities of blood that can
be derived from a single mouse (∼1mL), combined with the fact that only 10-25% of
circulating mouse leukocytes are neutrophils, the blood from several genetically iden-
tical mice had to be pooled in order to obtain workable concentrations of neutrophils.
Aside from PMA, all other stimuli failed to induce death in mouse neutrophils under
identical conditions and time points as the human neutrophils. One study has shown
that there are not only considerable differences between mouse strains in their ability
to produce NETs, but that they require up to 16 hours in order to observe NET re-
lease in approximately 30% of a stimulated neutrophil population [647]. Furthermore,
released NETs remain in close contact with the carcass of mouse neutrophils, and are
structurally distinct from human neutrophils, with a much more compact appearance
[647]. These traits make distinguishing NET release in mice very challenging with-
out more specific markers. Therefore, the current study was limited by the use of
pharmacological inhibitors in human neutrophils.
Nec-1 has recently been shown to be chemically identical to the compound methyl-
thiohydantoin-tryptophan (MTH-Trp) [648; 412; 649; 650]. MTH-Trp is used as an in-
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hibitor of the indoleamine-2,3-dioxygenase(IDO)-kynurenine pathway, a pathway which
catabolises the amino acid tryptophan to kynurenine and has direct relevance to the
innate and adaptive immune systems [651]. The disruption of this metabolic pathway
can lead to reduced production of NAD+ and other key metabolites with potential
immunosuppressive effects [652]. In neutrophils, Nec-1 treatment has been shown to
induce apoptosis through the reduction of Mcl-1 expression and increased expression
of Bax even in the presence of survival factors [653]. There have also been reports
that Nec-1 may have direct cytotoxic effects at lower doses and that its effect on the
inhibition of necroptosis is only relevant at higher doses [649]. Currently, the preferred
inhibitor is Nec-1s which effectively inhibits RIPK1, does not interact with IDO and is
not cytotoxic at low doses [251; 650]. Therefore, the results presented in this chapter
connected to Nec-1 treatment cannot exclude the involvement of the IDO pathway
and/or alternative death pathways.
Further limitations have been reported with the use of NSA. Since NSA is a non-
specific cysteine-reactive drug, it is possible that it may cross-react with other cysteine
containing proteins [239; 654]. Indeed, the finding in the current study that NSA is
fluorescent in the FITC channel, limited its use in flow cytometry analyses in this
system. Notwithstanding this finding, NSA did not seem to have an effect on the
fluorescence of the R19S dye (which emits at a different wavelength), when added at a
time when it could permeate the cells but not have an impact on its target pathway.
It also did not appear to influence the fluorescence of extracellular Sytox Green (FITC
channel) using a similar control. Nonetheless, it may be prudent to use alternate MLKL
inhibitors where possible.
Alternative methods to flow cytometry may be useful in order to accurately quan-
tify necroptotic populations in neutrophils, particularly at later time points. Not only
are membranes compromised due to the lytic nature of necroptosis but further damage
could occur due to the oxidants and proteases released from neutrophils during the
necrotic process. The transfer of lytic cells from cell culture plates can further dam-
age cells making them difficult to detect by the flow cytometer. This was apparent
in the current study from the lack of consistency between the observed cell death by
microscopy compared to the populations of cells that were deemed viable by flow cy-
tometry. This is potentially an issue that contributes to the differing results reported
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in the literature [422; 420; 421; 411].
The oxidants and proteases released from dying neutrophils may have also con-
tributed to the failure to obtain consistent immunoblotting results. It is also possible
that neutrophils may express only small amounts of MLKL, or that only a small pro-
portion gets phosphorylated. Other studies that have shown phosphorylated MLKL in
human neutrophils by western blot have used lysates from cell concentrations of up to
5×106/mL, and still display low intensity protein bands [420; 425]. In the current study,
numerous techniques were used to lyse the cells including, different concentrations of
neutrophils, the addition of multiple protease and phosphatase inhibitors, a range of
buffers, freeze-thaw methods, lysing directly in sample buffer and boiling. Others have
reported issues with western blotting with neutrophils and have suggested the use of
Trizol [286] or RIPA buffers supplemented with diisopropyl fluorophosphate (DFP),
an irreversible inhibitor of the multiple serine proteases, for the successful blotting of
phosphorylated proteins in neutrophils [367]. These methods could be tested in future
work.
Although human neutrophils were donated by healthy volunteers in the current
study, it was notable that there was a substantial amount of variation between exper-
iments in many of the assays used. This variation could have been introduced during
the isolation procedure as there have been reports that neutrophils can occasionally
become primed or damaged during this process [277; 285]. Increased variability can
also be due to differences in drug responses between donors. Interindividual differences
in the ability of isolated neutrophils to form NETs has been previously described [655].
Moreover, the ages of the donors ranged from 22-56 years and several studies have
shown that phagocytic and bactericidal activities decrease with increased age due to
increased cytoplasmic calcium concentrations [625; 626]. Future studies could consider
limiting the age range of human donors to control for potential functional differences
between donors.
Overall, the results presented in this chapter add to the understanding of the necrop-
tosis pathway in a burgeoning field of cell death. It shows, for the first time, that TSZ
treatment can result in necroptotic cell death in human neutrophils and that P. aerug-
inosa-induced NET release can be inhibited by the MLKL inhibitor NSA. However,
further research is required to better understand the varied functions of MLKL in the
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neutrophil, its interaction partners and means of activation.
This research also highlights that there are a number of challenges associated with
the study of cell death in human neutrophils. Firstly, caution should be exercised when
using flow cytometry to quantify necrotic, membrane compromised cells, as a major
population of dead cells could be unaccounted for. Secondly, the use of inhibitors that
have off-target effects, are directly cytotoxic or interfere with standard assays limit the
interpretation of cell death pathways. Furthermore, extrapolating meaningful informa-
tion about human neutrophil fate and function using mouse models is problematic, due
to the low abundance of mature neutrophils in circulation, and significant differences
in reactivity to stimuli. Complicating matters further, is the continual expansion of
novel mechanisms that orchestrate cell death subroutines with multitudes of poten-
tially overlapping biochemical pathways. The development of more specific inhibitors
of human necroptotic effector proteins and the use of pertinent experimental models








Environmental factors can change the epigenetic landscape of DNA leading to altered
protein expression and modified cell functions [427; 428]. The methylation of cytosine
in DNA is an epigenetic mark that leads to gene silencing. DNA methylation patterns
are often modified in human cancers which can result in the silencing of tumour sup-
pressor genes and/or the activation of oncogenes [430]. In an attempt to gain insight
into how the environment may influence disease outcomes, many epigenetic studies
investigate how exposure to environmental factors can change patterns of DNA methy-
lation. However, few studies have investigated the mechanisms behind methylomic
changes and how these changes become established in the methylome. Moreover, the
dosage and exposure time required for such changes to occur remain undefined.
Predicting the consequences of changes in DNA methylation is complex, however,
epigenetic changes are observed in all forms of cancer and play a role in directing
tumour progression [431]. Many of the environmental factors associated with DNA
methylation changes, including inflammation, are also recognised as risk factors in
cancer [28]. However, a mechanistic link between inflammation and epigenetic changes
in cancer is yet to be established.
Activated neutrophils are a rich source of oxidants and excessive or prolonged oxi-
dant production can lead to tissue damage and chronic disease states [656]. Two of the
major oxidants produced by the neutrophil, hydrogen peroxide (H2O2) and hypochlor-
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ous acid (HOCl), can freely diffuse into neighbouring cells and cause membrane damage,
induce cell death and oxidise DNA and proteins.
One way in which methylation patterns can be altered by environmental stimuli
is by influencing the activity of DNA methyltransferases (DNMTs) and levels of the
methyl donor, S -adenosyl methionine (SAM) [486]. DNMTs faithfully transfer DNA
methylation to the nascent DNA strand during replication, which ensures that the
correct pattern of methylation is maintained across multiple cycles of cell division.
Therefore, cells are most susceptible to making mistakes in copying the pattern of
DNA methylation during cell replication. DNMTs contain an active site cysteine that
undertakes nucleophilic attack on cytosine [473]. Cysteine residues are sensitive to
oxidation which will inhibit catalytic activity, and in the case of structural cysteines,
block interactions with binding partners and DNA [11; 12]. Exposure to neutrophil-
derived oxidants at an inflammatory site could therefore inhibit DNMTs, altering the
efficiency with which DNA methylation patterns are transferred during replication.
Furthermore, HOCl and its downstream reaction products, chloramines, not only react
with thiols, but also oxidise methionine and could alter availability of methyl groups
to DNMT from SAM [5].
Previous work by our research group has shown that sublethal doses of both H2O2
and glycine chloramine (GlyCl) directly inhibit DNMT1 activity in vitro[585]. Further-
more, GlyCl treatment depleted intracellular methionine levels after 30 minutes and
SAM levels after 2 hours. In addition, a mass spectrometry method revealed a global
decrease in methylation in Jurkat T-lymphoma cells after exposure to GlyCl, but not
H2O2. Building on this research, it was hypothesised that epigenetic regulation is in-
fluenced by oxidative stress, due in part to the susceptibility of DNMT and SAM levels
to redox regulation. Using Jurkat T-lymphoma cells and bead chip array technology,
the impact of exposure to sublethal doses of H2O2 or GlyCl on initial and inherited
DNA methylation patterns at a nucleotide level resolution was investigated.
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2 Objectives
 Investigate the impact of exposure to neutrophil oxidants on DNA methylation
patterns in Jurkat T-lymphoma cells
 Determine if the methylation changes observed after exposure to the oxidants are
sustained in subsequent cell divisions
 Identify the potential altered molecular pathways of affected genes
3 Experimental approach
3.1 Jurkat T-lymphoma cell synchronisation and oxidant ex-
posure
To maximise the number of Jurkat cells undergoing DNA synthesis (S-phase) at any
one time, Jurkat cells were treated with thymidine for 18 hours to arrest the cells in G1
phase of the cell cycle. At 18 hours, the cells were counted and cell death and cell cycle
analysis was assessed by flow cytometry to ensure successful blocking. The cells were
washed twice in PBS and resuspended in fresh media with cytidine to promote release
into S-phase. The cells were then split into either a treatment or control flask. The
treatment cells received the oxidant bolus and the control cells received the equivalent
volume of PBS. At each time point, 5×106 cells were centrifuged, supernatant discarded
and DNA stored at -20◦C for future extractions. A graphical representation of the tissue
culture model applied in this chapter is presented in Figure 5.1.
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supplemented with cytidine
Split cells into control 
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Figure 5.1: Graphical summary of Jurkat T-lymphoma cell synchronisation and oxidant
exposure. Figure shows the experimental model utilised for three different oxidant treatment condi-
tions. This was repeated for four independent experiments per treatment type.
3.2 Cell viability, proliferation and cell cycle progression
Viability, cell proliferation and cell cycle progression at all major time points were
observed by flow cytometry and detailed methods are presented in Methods section 4.
Briefly, the percentage of viable cells at each major time point was assessed by the
exclusion of propidium iodide (PI). Cell cycle transitions were observed by fixation
with ethanol followed by incubation with PI for 30 minutes. PI enters the cells and
binds to DNA, and the amount of fluorescence is indicative of the amount of DNA
contained in each cell. As cells progress through the cell cycle, DNA is duplicated
with the highest levels coinciding with G2/M phase. Cell proliferation was observed
by labelling cells with carboxyfluorescein succinimidyl ester (CFSE), and monitoring
the dilution of CFSE over 72 hours. CFSE is a cell permeable fluorescent dye which
covalently binds intracellular amines such as lysine residues. At each cell division, the
fluorescence detected is roughly halved, enabling the visualisation of the proliferation of
labelled cell populations over time. This experiment was done at the same time as the
other replicates, however CFSE labelled cells were not sent for methylation analysis.
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3.3 DNA extraction and sodium bisulfite conversion
For each replicate, from each experimental condition, DNA was extracted from treat-
ment and control at the 4 and 72 hour time points and treated with the sodium bisul-
fite. Under acidic conditions, sodium bisulfite will react with unmethylated cytosines
converting them to uracils (and substituted for thymines during amplification by Poly-
merase Chain Reaction), but will not react with methylated cytosines. Therefore,
methylated cytosines are protected and remain as cytosines (Figure 5.2).
Whole genomic bisulfite converted DNA was sent for processing on the Illumina
Infinium MethylationEPIC 850K array (Illumina Inc.) by Agresearch (Invermay Agri-
cultural Centre, Mosgiel 9092).
Figure 5.2: Bisulfite conversion Figure shows the steps involved in converting unmethylated cy-
tosines from extracted DNA samples to uracils using sodium bisulfite (bisulfite conversion). Repro-
duced from [657]
3.4 Principles of the Illumina Infinium MethylationEPIC 850K
array
The array uses bead chip technology to measure DNA methylation using 850,000 indi-
vidual probes. Beads are assembled in microwells on a silica slide, and contain hundreds
of thousands of copies of a single oligonucleotide corresponding to a specific CpG site.
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Bisulfite converted DNA is added to the slide, hybridizes with the beads and the slide
is subsequently scanned for signal intensity. The array contains several different types
of beads which are described in Figure 5.3.
3.5 Bioinformatic analysis
Agresearch performed the array analysis and returned raw unprocessed intensity data
as .idat files for bioinformatic analysis.
3.5.1 Identification of differentially methylated CpGs
The methylation status of each CpG site was calculated using normalised CpG site
signals represented as methylation values (M-values) and β-values. M-values were gen-
erated as the log2 ratio of the signal intensities of methylated CpG site divided by the





Unless stated otherwise, statistical analyses were performed using the M-values.
A M-value of 0 means the intensity between the methylated and unmethylated CpG
sites is similar, indicating the CpG site is about 50% methylated. Positive M-values
indicates that more molecules are methylated than unmethylated, while the opposite
is true of negative M-values [600].
β-values (average DNA methylation level for each CpG site) were used for data
visualization and range from 0 (unmethylated) to 1 (methylated). β-values were gen-
erated by dividing the methylated CpG site intensities with the sum of the methylated














































































































Figure 5.3: Infinium Methylation Assay probe types (A) The Infinium I assay contains two
bead types, one bead type corresponds directly to the methylated CpG and one bead type that
corresponds to the unmethylated sequence. Both bead types for the same CpG will have the same
labelled nucleotide incorporated directly adjacent to the CpG site and will be detected in the same
colour channel. (B) With the Infinium II bead type, the methylation status is determined by single-
base extension of labelled nucleotides in different channels. If “A” is incorporated then the site is
unmethylated and if “G” is incorporated then the site is methylated. Based on the intensities of the
methylated probe and the unmethylated probe, the array can estimate the methylation status of the
specific CpG site. Figure adapted from [658]
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A β-value of one indicates that every copy of the CpG site was methylated and a
β-value of zero means that all CpG sites were unmethylated.
3.5.2 Principal component analysis and hierarchical clustering
Unsupervised assessment is a valuable technique to discover groupings and subgroup-
ings within large datasets without any preconceived target values [593]. For each exper-
iment, the data were first evaluated by principal component analysis and hierarchical
clustering in order to observe data variability on a more tangible scale and enable the
identification of potential trends, clusters and outliers.
In order to reduce the number of dimensions in the dataset, principal component
analysis (PCA) was used to find the most correlated set of variables that explain the
maximum variance and combine these variables linearly into a single variable called a
principal component. Principal component one represents the highest variance in the
dataset and principal component two, although unrelated to principal component one,
represents the second highest variance across the dataset.
Hierarchical clustering was performed on a distance (or similarity) matrix calculated
using the β-values for all probes, regardless of significance. This technique groups the
data into clusters where each cluster is distinct from the other clusters, and the groups
within the cluster are more similar to each other.
3.5.3 Identification of differentially methylated CpGs
Differences in methylation were first assessed by looking at the average relative methy-
lation levels of all probes for each group at each time point. The individual CpG’s
that demonstrated significant changes between treatment and control in methylation
(differentially methylated CpG sites) were also identified.
In the context of cancer, epigenetic heterogeneity in response to an environmental
stress enables a range of transcriptional states across a population, some of which might
confer resistance [659; 660]. This has been observed in acute myeloid leukemia and head
and neck squamous cell carcinoma where epigenetic heterogeneity has been correlated
with poorer outcomes and a shorter time to relapse [661; 662].Differential variability is
a measure of epigenetic instability that when compared across separate populations can
help identify biological pathways that may be affected by a particular treatment [598].
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Therefore, the heterogeneity (differentially variable CpG sites between treatment and
control) were also assessed.
In order to identify differentially methylated regions, the data was analysed for
consistent methylation changes across multiple adjacent probes. These regions were
then tested for potential biological relevance by interrogating the Kyoto Encyclopedia
of Genes and Genomes (KEGG) [602] and gene ontology databases (GO) [603].
The workflow used in this study for the analysis and interpretation of DNA methy-
lation data is presented in Figure 5.4.
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Bisulfite conversion of extracted DNA 
DNA methylation microarray assay




Data visualisation and statistical analysis
• Clustering analysis assessments of global similarities 
and differences in sample datasets
• Global visualisation of DNA methylation distribution 
Identification of differentially methylated regions
• Statistical testing for differential DNA methylation at 
single CpGs
• Ranking based on statistical significance and effect 
size
• List of statistically significant differentially 
methylated regions (DMR) with correction for 
multiple hypothesis testing (FDR)
Interpretation of differences in DNA methylation
• Integrative analysis in the context of other genomic 
datasets
• Search for significant enrichment of gene functions 
and regulatory elements among the DMR
Figure 5.4: Workflow for the analysis and interpretation of microarray DNA methylation
data. Bisulfite converted DNA from each replicate and treatment condition is sent for processing on
the bead-chip array. Genome-wide methylation is mapped using microarray data. The raw data is
processed and quality control performed using specific algorithms and software. The resulting CpG
methylation data (β-values) is used for data visualisation and statistical analysis that identifies global
and site specific changes ultimately allowing for biological interpretation. Figure adapted from [663]
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4 Results
4.1 Determination of the timing of S-phase in synchronised
Jurkat cells
Cell cycle transitions over a period of 24 hours were observed by flow cytometry to
determine how long after release from thymidine block, the cells started to replicate
their DNA. Representative histograms from two flow cytometry analyses are shown in
Figure 5.5. The asynchronous population of Jurkat cells shows the majority of cells in
the G0/G1 phase, ∼20% of cells in S-phase and ∼14% of cells in G2/M phase which
displays a small characteristic peak just before cell division. Immediately after being
released from the thymidine block (thymidine released 0h), the number of cells in S-
and G2/M phase is reduced. At 5 hours post release, the peak shifts to the right as
∼60% of cells are replicating their DNA. At 10 hours post release the largest peak
is shifted maximally to the right (G2/M phase) immediately before cells undergo cell
division and halve their DNA content.
Figure 5.5: Representative flow cytometry histograms of Jurkat cell cycle. Figure shows
representative histograms with the number of cells on the y-axis and the mean fluorescence from PI
staining (DNA content) on the x-axis. The number of cells as a percent, in each phase of the cell
cycle are shown for asynchronous cells, 0, 5 and 10 hours post release from thymidine block for two
representative experiments. Note: this analysis was completed by Dr. Paul Pace, Research Fellow,
Centre for Free Radical Research, Otago University.
The average percentage of cells in each phase of the cell cycle for each hour post-
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release from thymidine block over a period of 24 hours is shown in Figure 5.6. Based
on this data, it was determined that the majority of the cells entered S-phase between























Figure 5.6: Hourly Jurkat cell cycle analysis over the 24 hours post-release from thymidine
block. Hours post release are represented on the x-axis and DNA content, as a percentage for G1
(green), G2/M (blue) and S-phase (red) is represented on the y-axis. Error bars represent standard
deviation from three individual experiments. DNA content was assessed using PI staining, followed
by flow cytometry analysis. Note: this analysis was completed by Dr. Paul Pace, Research Fellow,
Centre for Free Radical Research, Otago University.
4.2 Hydrogen peroxide treatment
Under similar conditions, previous work by our research group showed that there was
no significant difference in global methylation in Jurkat cells treated with 50-100 µM
H2O2 immediately after release from thymidine block [585]. Therefore, the dose and
the timing of exposure was altered in the current study. Because H2O2 has been shown
to be consumed by Jurkat cells and media constituents within ∼30 minutes of exposure
[664; 632], the Jurkat cells were exposed to two doses of H2O2 at 2 and 3 hours post
synchronization release. This maximised cell exposure to H2O2 during the expected
period of DNA replication (Figure 5.6). H2O2 treatment was performed on released
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synchronised Jurkat cells as per the method described in section 3.1 (Figure 5.1).
4.2.1 Determination of sublethal H2O2 concentrations
To determine the dose of H2O2 that would result in minimal cell death, synchronised
cells were exposed to a range of concentrations and toxicity assessed after 24 hours
(Figure 5.7). Subsequent analyses were performed on synchronized cells at a final con-
centration of 10µM, which was associated with an average of 15% decrease in viability
at 24 hours compared with the control samples (Figure 5.7).















Figure 5.7: Influence of hydrogen peroxide exposure on cell viability of synchronised
Jurkat cells. Cells (1 × 106/mL) were exposed to varying doses of H2O2 at both 2 and 3 hours
post-release, each dose was at the stated concentration on the x-axis and viability was assessed by
flow cytometry based on the exclusion of PI after 24 hours. Data are means of three independent
experiments +/- SEM.
4.2.2 Hydrogen peroxide sensitivity and cell cycle progression
At 4 hours post-release, there was minimal cell death and no significant differences in
viability between the treatment and control groups. However, there was a significant
decrease in viability in the treatment group compared to control at 24 hours (p = 0.02)
and at 48 hours (p = 0.04) which was no longer observed at 72 hours (p = 0.25)(Figure
5.8A).
Live cell counts indicated that only the control cells doubled in cell density after 24
hours, whereas the treated cells had significantly lower fold growth compared to control
(p = 0.02) (Figure 5.8B). Cells were split to a concentration of 2.5×105 cells/mL at 24
hours, and the decrease in fold growth for the treatment samples compared to control
156














































Figure 5.8: Viability and percentage growth for the H2O2 treated Jurkat cells at each
major time point. (A) Viability was assessed by flow cytometry based on the exclusion of PI at
preblock, postblock and 4, 24, 48 and 72 hours post-release. (B) The percentage growth (y-axis) for
each replicate at 24, 48 and 72 hours post release (x-axis). Live cell counts conducted at 24, 48 and 72
hours post release were compared to the previous day’s counts and the percentage growth calculated
((current day count - previous day count)/previous day count x100). The different colours represent the
different replicates, treatment and control that originated from the same stock. Significant differences
are denoted with asterisks * = p <0.05
The decrease in proliferation observed in live cell counts by the treatment group was
confirmed by the analysis of CFSE dilution by flow cytometry (Figure 5.9). At 24, 48
and 72 hours the control cells had less CFSE content at consistent intervals suggesting
they had undergone cell division and thus diluted the CFSE signal. The treatment
cells also had less CFSE at 24 hours but not to the same extent as the control cells. At
48 hours, a population of cells from the treatment group had undergone cell division in
line with the control cells, however another peak was observed at 24 hours suggesting
that these cells had stalled at that time point. At 72 hours, there was a population
of cells that had a similar CFSE content to the control cells, but a population of cells
at this time point still had relatively high CFSE content and had not divided. These
delayed cells likely represented an apoptotic population. This assay indicated that
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while there were fewer cells replicating at each time point compared to the control
















Figure 5.9: CFSE dilution of H2O2 treated cells at 24, 48 and 72 hours post-release
The number of cells is displayed on the y-axis and the concentration of CFSE is on the x-axis. The
black peak shows the CFSE concentration immediately post release from thymidine block. The peaks
generated by CFSE dilution in the control cells are shown in blue and the treatment cells are shown
in green.
Cell cycle progression was monitored during the course of the experiment, which
confirmed the success of the cell synchronization procedure by the absence of an asyn-
chronous population after thymidine block. Figure 5.10 shows the flow cytometry
histograms of the cell cycle analysis for each major time point. Immediately post
thymidine block the cells in the stock flask showed minimal cells in S-phase and G2/M.
There was no obvious differences between treatment and control at 4 hours post re-
lease, but at 24 hours the control cells had completed cell division while the treatment
cells were still in S-phase and G2/M. At 48 hours, both treatment and control cells
appeared to recover from the block and by 72 hours, the distribution of cells in each









Figure 5.10: Representative cell cycle analysis at major time points for H2O2 treated
Jurkat cells. Figure shows the flow cytometry cell cycle analysis for each indicated time point with
the DNA content on the x-axis and the number of cells on the y-axis.
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4.2.3 DNA methylation analysis
DNA was extracted from either H2O2 treated cells or control cells at 4 and 72 hours
post synchronization release from 4 independent experiments. Extracted DNA was
then bisulfite converted and sent to the genomic service provider (AgResearch) for
analysis of DNA methylation profiles using the Illumina Infinium MethylationEPIC
850K array. Agresearch returned raw unprocessed intensity signal data for each probe
as .idat files. The data underwent quality control and was normalised as described in
the Methods prior to data exploration (Chapter 2).
4.2.4 Unsupervised assessment of data variability in H2O2 treated cells.
When multidimensional scaling was used to assess the top contributing factors in data
variability in the samples, these corresponded with treatment, and to a lesser extent
time (Figure 5.11A). Overall, the control samples grouped distinctively from treatment
samples. However, the treatment samples from the 72 hour time point more closely
represented the control samples than the treatment samples from the 4 hour time
point (Figure 5.11A). As expected, there was no separation between time points for
the control samples.
Except for one sample which incorrectly grouped within the treatment, hierarchical
clustering successfully differentiated between the control and treatment groups (Figure
5.11B). A single sample originating from the 4 hour control group (black) appeared
to be an outlier, however, inclusion of this sample did not substantially influence the
results (data not shown). In the control group cluster, samples from the same replicate
were identified as being more closely “related”, which reinforced that the effect of
biological replicate should be accounted for in subsequent statistical designs.
4.2.5 Average relative methylation analyses
Average relative DNA methylation for each group was calculated using the mean β-
values from all probes for each sample. The mean difference in methylation between
treatment and control groups was then calculated using paired t-test.
At the 4 hour time point, the mean methylation level of the treatment group was
3.33% less than the control group (p= 0.013, t(5) = 3.72) (Figure 5.12A), however, at 72
hours this significant difference was no longer observed (p= 0.10, t(4) = 2.2). There was
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Figure 5.11: Unsupervised assessment of data variability in H2O2 treated cells. (A) Mul-
tidimensional scaling of β-values, with the distances for leading Log2FC in dimension 1 represented
on the x axis and the leading Log2FC in dimension 2 are represented on the y-axis. Dots represent
the control group, and triangles represent the treatment group. Black represents samples collected
at the 4 hour time point and light grey represents samples collected at the 72 hour time point. (B)
Hierarchical clustering of β-values for all CpG sites. The relative change in β-values is represented on
the y axis and individual samples are represented on the x-axis. Samples are coloured according to
the replicate (four in total), where cells from each replicate originated from the same stock.
no significant difference between the 4 hour and 72 hour time points within each group,
however, the treatment group demonstrated a minor increase, and had substantially
reduced variability (Figure 5.12A).
Plotting the individual probe-wise comparisons of significance versus effect size
change, confirmed there was a substantial decrease in methylation after H2O2 treatment
compared to control, with several CpG sites from the 4 hour time point demonstrating
a significant log2FC greater than ∼1. However, there was a comparative reduction
in the effect size and significance at the 72 hour time point, which indicates that the
treatment and control samples were more similar to each other than at the 4 hour time
point (Figures 5.12B & C). Taken together, these observations indicate a significant
decrease in DNA methylation in the treatment group compared to the control group
at 4 hours, which was largely restored by 72 hours (Figure 5.12).
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Figure 5.12: Analysis of average relative DNA methylation. (A) Mean methylation levels in
each group. Mean methylation levels for β-values are presented as percentages on the y-axis, and each
group is represented on x-axis. (B) Volcano plot displaying log fold changes on the x-axis versus a
measure of statistical significance on the y-axis log10(p-value) for the 4 hour time point (C) Volcano
plot displaying log fold changes on the x-axis versus a measure of statistical significance on the y-axis
log10(p-value) for the 72 hour time point.
4.2.6 Analysis of variability in DNA methylation after H2O2 exposure
Principal component analysis and average relative methylation change suggested that
there was a higher level of heterogeneity in the DNA methylation profiles after H2O2
treatment. CpG methylation heterogeneity is a proposed mechanism that enables can-
cer cells to adapt to environmental stress [665], therefore, CpG methylation hetero-
geneity was further investigated by assessing the differential variability at individual
CpG positions (DVPs).
At the 4 hour time point, 1035 DVPs demonstrated a significant increase in vari-
ability in the treatment group compared to the control, and 286 demonstrated a sig-
nificant decrease in variability. At the 72 hour time point only 41 DVPs demonstrated
an increase in variability and 115 demonstrated a decrease (Table 5.1). 46 DVPs were
common between the two time points, however, only 18% (7 DVPs) showed a consis-
tent direction of change (Figure 5.13). This increase in variability suggested that H2O2
exposure may not have had an effect on the same CpGs in all cells.
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Figure 5.13: Box plots showing representative β-values of a subset of the top differentially
variable CpG sites. CpG sites were selected that demonstrated a consistent effect at both the 4
hour and 72 hour time points. β-values are represented on the y-axis and group on the x-axis. The
CpG sites are marked with an orange dot in the representative gene scheme placed on top of each
graph. The transcriptional start site is marked by a red arrow. (A) chr1:165265507 (B) chr3:15058168
(C) chr14:38727024 (D) chr10:79789707 (E) chr14:93415143 (F) chr3:130236522
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Table 5.1: Summary of DVPs (treatment compared to control) observed at each time point
Direction of change DVPs at 4 hours DVPs at 72 hours
Decreased 286 115
Increased 1035 41
DVP, differentially variable position
4.2.7 Differentially methylated CpGs at the 4 hour time point
To identify changes that associated with H2O2 treatment, DNA methylation levels at
each individual CpG site were assessed. To summarize the results, each CpG site
was mapped to the corresponding genomic region and unadjusted significance was
plotted across the whole genome as a Manhattan plot (Figure 5.14). This analysis
demonstrated that significant differentially methylated CpGs were observed across the
genome, however, certain loci also demonstrated an enrichment for closely located








Figure 5.14: Manhattan plot of all CpG sites –log10(p values based on M-Values at the 4
hour time point. All CpG sites are ordered per chromosome position along the x-axis, and p-values
as the –log10(p values) are presented on the y-axis. Genome-wide significance was determined using
the “Benjamini, Hochberg” method within Limma and is represented by the horizontal black line.
Analyses to determine the direction of change of the top most significant differen-
tially methylated CpG sites at the 4 hour time point were next assessed. To enrich for
biologically relevant changes the top most significant sites that demonstrated a change
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in methylation were filtered to only detect CpGs which demonstrated a differential
change in methylation greater than a Log2FC of 1. For this analysis, significant CpG
sites that had a methylation value above 90% and less than 10% in the control samples
were also excluded. This approach increased the likelihood of selecting for biologically
relevant changes by excluding CpG sites demonstrating, for example, a decrease in
methylation from 10% to 5%, which although is a large fold change, is unlikely to have
a biological effect.
When using a Log2FC cutoff of 1, there were 1162 CpG sites that demonstrated a
significant decrease in methylation and 89 CpG sites that demonstrated a significant
increase in methylation (adj. p <0.05). Increasing the Log2FC cutoff to 1.2 identified
87 CpG sites that demonstrated a significant decrease in methylation and 3 CpG sites
that demonstrated a significant increase (Table 5.2).
Table 5.2: Summary table of top most significant differentially methylated CpG sites at the
4 hour time-point.




The top 20 most significant positions when using a Log2FC cutoff of 1 all demon-
strated a decrease in DNA methylation (Table 5.3). This corresponded with ∼50%
decrease in methylation in the treatment samples compared to control samples. Be-
cause each original strand of DNA acts as a template for the transfer of methylation
during replication, a 50% reduction in methylation is equivalent to a complete loss of
methylation on the nascent DNA strand.
In general, the top most significant CpG sites had an initial methylation value of
20-25% in the control group, and a value of 10-15% in the treatment group (Figure
5.15A), however, the raw data for the top six most significant CpG sites that did not
conform to this general trend are presented in Figure 5.15 (including the three CpG
sites that demonstrated increased methylation).
165
Figure 5.15: Box plots showing representative β-values at the 4 hour time point for
selected CpG sites with a Log2FC >1.2. Box plots showing representative β-values at the 4
hour time point for selected CpG sites with a Log2FC >1.2. β-values are represented on the y-axis
and group on the x-axis. The CpG sites are marked with an orange dot in the gene scheme placed
on top of each graph, with the TSS is marked by a red arrow (A) chr15:41794412 (B) chr13:96367153
(C) chr5:14108721 (D) chr1:183846009 (E) chrX:106061616 (F) chr13:52637074
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Table 5.3: The top 20 most significant differentially methylated genes at the 4 hour time-
point as assessed using Limma’s “treat” statistic
(4hr) (72hr)
Probe ID Log2FC Adj P -Val Log2FC CHR Basepair Gene
cg21195920 -1.62 0.001 -0.09 15 90944458 IQGAP1
cg09333215 -1.84 0.01 -0.17 1 88475866
cg00192946 -2.19 0.01 -0.98 X 32430274 DMD
cg24024260 -2.29 0.01 -0.40 2 182174340 LOC101927156
cg20576896 -1.01 0.01 -0.52 12 64521378 SRGAP1
cg04254259 -1.6 0.01 -0.47 4 68996281 TMPRSS11F
cg11372135 -2.05 0.01 -0.53 10 18629284 CACNB2
cg11544398 -1.19 0.02 -0.70 18 25955245
cg20700869 -1.39 0.02 -0.79 8 141775220 PTK2
cg06403830 -1.5 0.02 -0.36 2 202279205 TRAK2
cg10792660 -1.52 0.02 -0.35 4 125369980
cg18949056 -1.62 0.02 -0.66 10 97317243 SORBS1
cg05577994 -1.45 0.02 -1.21 10 119254968 EMX2OS
cg03550208 -1.44 0.02 -0.41 5 6582193 LOC255167
cg01492091 -1.81 0.02 -0.83 7 31460998
cg00440859 -1.23 0.02 -0.57 X 115028898 DANT2
cg03719252 -1.43 0.02 -0.43 6 140529431
cg04362419 -1.6 0.02 -0.58 3 138297086 CEP70
cg06812574 -1.56 0.02 -1.02 10 18331664 SLC39A12
cg00196810 -1.34 0.02 -0.58 3 53925267 SELK
CHR, chromosome
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4.2.8 Differentially methylated CpGs at the 72 hour time point
At the 72 hour time point, 19 CpG sites demonstrated a significant decrease in methy-
lation and one CpG site demonstrated a significant increase in methylation (adj. p
<0.05), when assessed using a log2FC cutoff of 1 (Table 5.4). The magnitude of these
changes was less than 10%, therefore there were no significant CpG sites detected at
a Log2FC cutoff of 1.2 at the 72 hour time point. Fifteen of the 20 significant CpG
sites detected at the 72 hour time point were also detected in the 4 hour time point
when a Log2FC of >1 was used (Table 5.4). One of these CpG sites was also de-
tected in the 4 hour time point when a Log2FC >1.2 was used (cg05577994 mapping
to gene: EMX2OS at chr10:119254968, adj. p <0.05), with one CpG site approaching
significance (cg18363176 mapping to gene: FLI1 at chr11:128606110, adj. p = 0.054).
The CpG sites corresponding to the EMX2OS gene had a smaller Log2FC at 72 hours
than at 4 hours, however, all other significant CpG sites showed a substantially larger
Log2FC at 72 hours than at 4 hours (Table 5.4).
4.2.9 Differentially methylated gene regions
Analyses to determine if multiple CpG sites mapping to the same genomic loci demon-
strated consistent methylation changes were next assessed. This analysis was limited to
differentially methylated regions (DMRS) that contained 5 or more adjacent significant
CpGs, with an average change in methylation larger than 5%. Under these parameters,
70 significant DMRs at the 4 hour time point and 5 significant DMRs at the 72 hour
time point were detected (Supplementary tables B.1 and B.2). Two significant DMRs
were consistent between the 4 hour and 72 hour time points (Table 5.5 and Figure 5.17)
4.2.10 Pathway analysis
The genes corresponding to the top most significant CpG sites that demonstrated
decreased methylation at 4 hours compared to controls, were assessed for significant
biological relevance by pathway analysis within the GO and KEGG databases. This
analysis identifies significant enrichment of multiple genes that relate to the same bi-
ological pathway. Neither comparison identified significantly enriched pathways, after
correction for multiple testing (Table 4.2.10).
Figure 5.16: Box plots showing representative β-values at the 72 hour time point.β-values
are represented on the y-axis and group on the x-axis. The CpG sites are marked with an orange
dot in the gene scheme placed on top of each graph, with the TSS is marked by a red arrow. (A)
chr2:160224706 (B) chr10:119254968 (C) chr103:40996323 (D) chr8:118145984 (E) chr13:88794067 (F)
chr4:115580778
Table 5.4: Top 20 differentially methylated probes ordered by t-statistic significance for the
72 hour time point assessed using Limma’s toptreat function with a logFC>1
(4hr) (72hr)
Probe ID Log2FC Log2FC Adj P -Val Gene Chr Basepair
cg22181263 -0.23 -1.31 0.02 6 63922844
ch.2.3268406F -0.67 -1.15 0.02 BAZ2B* 2 160224706
cg14490945 -0.68 -1.14 0.02 LINC00598* 13 40996323
cg05655613 -0.59 -1.42 0.02 * 11 105101601
cg10578504 -1.02 -1.54 0.04 SLC30A8* 8 118145984
cg08223309 -0.98 -1.41 0.04 * 4 14390632
cg18216587 -0.79 -1.09 0.04 CNTNAP2 * 7 146019420
cg25329318 -0.37 -0.58 0.04 * 5 38253946
cg25479340 0.45 1.1 0.04 LOC105370306 13 88794067
cg17347305 -0.47 -1.09 0.04 * 5 102803554
cg24707035 -0.73 -1.17 0.04 IGF1 * 12 102868087
cg22962811 -0.44 -1.06 0.04 4 181868775
cg11424548 -0.8 -1.22 0.04 * 10 120000847
cg14699663 -0.92 -1.18 0.04 GPR1 * 2 207082644
cg21998794 -0.78 -1.72 0.04 ELP4;IMMP1L * 11 31530551
cg26627970 -0.45 -1.64 0.04 KHDRBS2 6 62993589
cg27374159 -0.75 -1.04 0.04 UGT8 * 4 115580778
cg22383292 -0.43 -1.18 0.04 THSD7A 7 11412105
cg05577994 -1.45 -1.25 0.04 EMX2OS** 10 119254968
cg15864256 -0.85 -1 0.05 12 91755828
* Probes displayed a significant adj P -value at 4 hours (Log2FC >1).
** Probes displayed a significant adj P -value at 4 hours (Log2FC >1.2).
Table 5.5: Significant DMRs that were observed at both the 4 hour and 72 hour time points.
4 hours 72 hours
Max Mean Max Mean
Promoter FDR βFC βFC FDR βFC βFC
snoU13.410-201 8× 10−5 -0.1 -0.05 5× 10−8 -0.08 -0.05
RP11-322J23.1-001 0.012 -0.1 -0.05 2× 10−4 -0.1 -0.05
A B
Figure 5.17: Differentially methylated gene regions. DMRs that displayed a significant change
in methylation (y-axis represents β-values) across five CpGs (x-axis) between the treatment (grey) and
control (black) for both 4 hour and 72 hour time points. Gene structure is placed on top of each graph,
with the TSS is marked by a red arrow, grey lines represent non-coding RNA. (A) chr3:172693052-

































































































































































































































































































































































































































































































































































4.3 Glycine Chloramine treatment
It had been previously reported that synchronised Jurkat cells treated with either
200µM or 500µM GlyCl immediately after release from thymidine blocking exhibited
a 20-40% decrease in global methylation with minimal impact to cell viability after 24
hours [585]. Based on the results from the H2O2 exposure in the previous section, it
was proposed that exposure to GlyCl during S-phase could result in a similar if not
more substantial decrease in methylation compared to control.
The following sections present the results from two separate experiments. The first
dataset comprises four experimental replicates of Jurkat cells treated with a single bolus
of 200µM GlyCl (treatment) or control at 2 hours post-release which is referred to as the
S-phase exposure. The second dataset comprises three experimental replicates of Jurkat
cells exposed to a single bolus of 200µM GlyCl (treatment) or control immediately post-
release from thymidine block, referred to as the pre-replication-phase exposure.
4.3.1 Glycine Chloramine sensitivity and cell cycle progression
At the 24 hour time point, both the S-phase and pre-replication-phase treatment groups
experienced a significant decrease in viability compared to control (p = 0.01 and 0.02
respectively), and they were consistently less viable compared to controls at the 48
hour time point (p = 0.001 and 0.01 respectively). At the 72 hour time point, there
was no significant difference in viability in the treatment group compared to control
in the S-phase exposure cells. However at the same time point, the pre-replication
phase GlyCl exposed cells were significantly less viable compared to control (p = 0.03)
(Figure 5.18A & B).
The percentage growth of the S-phase GlyCl treatment cells were not negatively
affected at 24 and 72 hours but did experience a significant decrease in growth com-
pared to controls at 48 hours (p = 0.03)(Figure 5.18C). In contrast, the pre-replication
phase treatment cells displayed significantly decreased percent growth compared to
controls at the 24 and 48 hour time points (p = 0.02 and 0.01), but not at the 72
hour time point (Figure 5.18D). Overall, the replicates that were exposed to GlyCl
during pre-replication phase appeared to be more sensitive compared to the GlyCl
exposure replicates at S-phase, with larger differences in both viability and percent
growth compared to controls at all major time points (Figure 5.18).
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The GlyCl treated cells also experienced slowed cell proliferation compared to con-
trol demonstrated by CFSE dilution analysis (Figure 5.19). At 24, 48 and 72 hours
the control cells had less CFSE content at consistent intervals suggesting they had
undergone cell division and thus diluted the CFSE signal. The treatment cells also
had less CFSE at 24 hours keeping in line with control cells. However, at 48 hours
there was a distinct lag in proliferation compared to control cells, suggesting slower
proliferation. This lag was also observed at 72 hours, where the treatment cells had

































































































Figure 5.18: Viability and percentage growth for the GlyCl treated Jurkat cells at each
major time point. Viability was assessed by flow cytometry based on the exclusion of PI at pre-
block, post-block and 4, 24, 48 and 72 hours post-release for (A) the S-phase exposure and the (B)
pre-replication exposure. For the both the (C) S-phase exposure and the (D) pre-replication phase
exposure, live cell counts for treatment and control were conducted at 24, 48 and 72 hours post release,
and the percentage growth calculated. Significant differences are denoted by asterisks * = p <0.05,
** = p <0.01
Regardless of the timing of treatment, the GlyCl treated cells experienced a delay
in their progression through the cell cycle, as evidenced by the flow cytometry cell cycle
































Figure 5.19: CFSE dilution of GlyCl treated cells at 24, 48 and 72 hours post-release.
CFSE dilution assay of the (A) S-phase GlyCl and (B) Pre-replication phase GlyCl treatment and
control replicates. The black peak shows the CFSE concentration immediately post release from
thymidine block. The peaks generated by CFSE dilution in the control cells are shown in blue and the
treatment cells are shown in green.The number of cells is displayed on the y-axis and the concentration
of CFSE is on the x-axis.
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4.4 Glycine Chloramine exposure during S-phase
Cells were harvested at 4 and 72 hours post-release from four independent replicates,
DNA extracted and bisulfite converted and sent for analysis of DNA methylation pro-
files using the Illumina Infinium MethylationEPIC 850K array.
4.4.1 Principle component analysis of DNA methylation and hierarchical
clustering
Multidimensional scaling was used to assess the top contributing factors in data vari-
ability, however, no distinctive groupings were observed in principal component analysis
(Figure 5.20A). Furthermore, hierarchical clustering analysis revealed a total lack of
clustering in the treatment or the control samples, and groupings appeared random
between replicates (Figure 5.20B).
A B
Figure 5.20: Unsupervised assessment of data variability in cells treated with GlyCl
during S-phase compared to controls (A) Multidimensional scaling of β-values, with the distances
for leading Log2FC in dimension 1 represented on the x axis and the leading Log2FC in dimension 2
are represented on the y-axis. Dots represent the control group, and triangles represent the treatment
group. Samples are coloured according to the replicate (four in total), where cells from each replicate
originated from the same stock.(B) Hierarchical clustering of β-values for all CpG sites. The relative
change in β-values is represented on the y-axis and individual samples are represented on the x-
axis. Samples are coloured according to the replicate (four in total), where cells from each replicate
originated from the same stock.
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4.4.2 Average relative methylation analyses
There were no significant differences in average relative methylation levels between
treatment and control at either the 4 and 72 hour time points (Figure 5.21A). Probe-
wise comparisons of significance, versus effect size change demonstrated that there were
no substantial changes in methylation after GlyCl treatment compared to control at










Figure 5.21: Analysis of average relative DNA methylation of S-phase GlyCl exposure
cells (A) Mean methylation levels in each group. Mean methylation levels for β-values are presented
as percentages on the y-axis, and each group is represented on x-axis.(B) Volcano plot displaying log
fold changes on the x-axis versus a measure of statistical significance on the y-axis log10(p-value) for
the 4 hour time point (C) Volcano plot displaying log fold changes on the x-axis versus a measure of
statistical significance on the y-axis log10(p-value) for the 72 hour time point.
Analysis of the top differentially methylated CpGs between treatment and control
at the 4 and 72 hour time points failed to detect any significant changes after correcting
for genome wide significance (Tables 5.7 and 5.8).
These analyses indicated that treatment with GlyCl during S-phase did not have a
significant effect on DNA methylation compared to control and therefore the data was
not investigated further.
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Table 5.7: Top 20 most significant differentially methylated CpGs at the 4 hour time point
for S-phase GlyCl exposure.
Probe name LogFC adj.p.Val Direction Gene Chr Basepair
cg01617955 -1.129 0.488 Down LRBA chr4 151667406
cg17578309 -0.820 0.999 Down TBC1D16 chr17 77964703
cg03791426 -0.504 0.999 Down OLFML2B chr1 161955224
cg21781319 0.827 0.999 Up MIR633;MIR548W chr17 61020813
cg00010266 -0.841 0.999 Down MFSD3 chr8 145734519
cg22627029 0.761 0.999 Up HLA-DRB6 chr6 32520615
cg20325092 -0.882 0.999 Down CAPS2 chr12 75699992
cg22410262 0.715 0.999 Up chr11 64198213
cg08743671 -0.619 0.999 Down NDUFV1; chr11 67378570
cg08596797 0.628 0.999 Up SMAD6; chr15 66994027
cg06096382 0.629 0.999 Up HECW1 chr7 43151725
cg12650153 0.740 0.999 Up IKBKAP chr9 111646993
cg22842599 -0.428 0.999 Down LMTK2 chr7 97749133
cg24454158 0.541 0.999 Up FMN2;FMN2 chr1 240476462
cg07173352 1.163 0.999 Up TAGLN; chr11 117070856
cg22423294 -0.6931 0.999 Down TFDP1; chr13 114286133
cg04513006 -0.6221 0.999 Down ESRP2 chr16 68270252
cg21620282 -0.726 0.999 Down CHGA chr14 93389628
cg17786993 1.145 0.999 Up chr4 175340268
cg22075325 -0.511 0.999 Down chr14 100484602
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Table 5.8: Top 20 most significant differentially methylated CpGs at the 72 hour time point
for S-phase GlyCl exposure.
Probe name LogFC p.Value adj.p.Val Direction Gene Chr Basepair
cg24328079 2.056 4.87× 10−6 0.9999 Up NMI chr2 152146531
cg16582649 -0.952 5.01× 10−6 0.9999 Down FTHL17 chrX 31090073
cg08039116 0.633 5.38× 10−6 0.9999 Up HECW1 chr7 43152254
cg24044884 -1.042 1.03× 10−5 0.9999 Down NSG1 chr4 4387109
cg02252248 -0.697 1.09× 10−5 0.9999 Down chr17 47073164
cg17403512 0.533 1.24× 10−5 0.9999 Up chr15 28700396
cg11781282 -1.075 1.27× 10−5 0.9999 Down UBXN4 chr2 136505575
cg15094236 -0.508 1.27× 10−5 0.9999 Down LOC285768 chr6 1070389
cg15798516 0.567 1.28× 10−5 0.9999 Up LOC647288 chr13 75814711
cg21970086 -3.350 1.37× 10−5 0.9999 Down PRUNE2 chr9 79318390
cg16983152 0.503 1.50× 10−5 0.9999 Up BAT2 chr6 31592053
cg19063654 -0.601 1.87× 10−5 0.9999 Down HAVCR2 chr5 156516798
cg12041841 0.404 1.90× 10−5 0.9999 Up chr1 115347822
cg16712664 0.501 2.09× 10−5 0.9999 Up chr16 30787355
cg12348202 0.820 2.13× 10−5 0.9999 Up PTPRN2 chr7 158381023
cg18363721 0.690 2.14× 10−5 0.9999 Up SLC25A38 chr3 39424765
cg06658404 0.618 2.16× 10−5 0.9999 Up chr16 54408014
cg13420422 -0.721 2.30× 10−5 0.9999 Down chr7 140770260
cg25637520 0.621 2.36× 10−5 0.9999 Up KDM4B chr19 5043247
cg19030994 -1.047 2.57× 10−5 0.9999 Down PDCD6 chr5 273394
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4.5 Glycine chloramine exposure during pre-replication phase
In a new set of experiments, synchronised Jurkat cells were treated with a single bolus
of GlyCl (200µM) during the pre-replication phase (immediately after release from
thymidine block).
Cell preparation for analysis on the Illumina Infinium MethylationEPIC 850K array
was carried out as described for all previous experiments.
The genomic service provider (AgResearch) signaled the presence of two samples
that demonstrated an abnormal fluorescent profile and low data quality. Therefore,
an independent assessment of data variability was performed to investigate how their
inclusion would influence the results, and is presented in Appendix A. Because these
two samples originated from the same replicate, it was concluded that the best approach
was to remove the whole replicate which allowed for paired analysis. Therefore, the
pre-replication phase GlyCl exposure dataset analysis contains only three replicates,
instead of four.
4.5.1 Principle component analysis of DNA methylation and hierarchical
clustering
Principal component analysis demonstrated that treatment corresponded with the most
significant source of variation, and the 4 hour treatment group clustered separately from
all the other groups (Figure 5.22A).
In the hierarchical clustering analysis, the 4 hour treatment replicates also clustered
distinctly from all the other replicates (Figure 5.22B).
Data variability between exposure times was then investigated by including the
replicates from the S-phase GlyCl dataset in the principal component analysis. Figure
5.23 shows that all the S-phase GlyCl exposure replicates (treatment and control)
from all time points clustered distinctly from the pre-replication phase replicates in the
first dimension indicating that they are very different from the pre-replication phase
exposure but not very different from each other.
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A B
Figure 5.22: Unsupervised assessment of data variability in pre-replication phase GlyCl
exposure dataset. (A) Multidimensional scaling of β-values, with the distances for leading Log2FC
in dimension 1 represented on the x-axis and the leading Log2FC in dimension 2 are represented on
the y-axis. Dots represent the control group, and triangles represent the treatment group. Samples are
coloured according to the replicate (three in total), where cells from each replicate originated from the
same stock.(B) Hierarchical clustering of β-values for all CpG sites. The relative change in β-values is
represented on the y-axis and individual samples are represented on the x-axis. Samples are coloured
according to the replicate (three in total), where cells from each replicate originated from the same
stock.
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Figure 5.23: PCA of data variability in pre-replication phase and S-phase GlyCl exposure
datasets. Multidimensional scaling of β-values, with the distances for leading Log2FC in dimension
1 represented on the x-axis and the leading Log2FC in dimension 2 are represented on the y-axis.
Dots represent the GlyCl pre-replication-phase exposure group, and triangles represent the S-phase
exposure group. Samples are coloured according to the time and treatment/control (three replicates
in total for each exposure time point.)
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4.5.2 Average relative methylation analyses
At the 4 hour time point, there was a 0.01% increase in average relative methylation
levels in the treatment group compared to the control group (p= 0.04, t(3) = -3.2).
However at 72 hours, there was no significant difference (p= 0.89, t(2) = 0.15) (Figure
5.24).
Figure 5.24: Analysis of average relative DNA methylation for the pre-replication phase
GlyCl exposure. Mean methylation levels in each group. Mean methylation levels for β-values are
presented as percentages on the y-axis, and each group is represented on x-axis.
Plotting the individual probe-wise comparisons of significance versus effect size
change confirmed there was a substantial decrease in methylation after GlyCl treatment
compared to control, with many CpG sites from the 4 hour time point demonstrating
a significant log2FC greater than ∼1. However, there was a dramatic reduction in the
effect size and significance at the 72 hour time point, indicating that the significant
changes in DNA methylation in the treatment group compared to the control group
observed at 4 hours, was largely restored by 72 hours (Figures 5.25A & B).
Comparing the effect size versus significance from the pre-replication phase (Fig-
ure 5.25A & B) and S-phase datasets (Figure 5.25C & D) demonstrated substantial
methylomic changes were observed during the pre-replication phase experiment that
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Figure 5.25: Volcano plots of the GlyCl pre-replication phase exposure dataset compared
to the S-phase exposure dataset. Volcano plots showing log fold changes on the x-axis versus a
measure of statistical significance on the y-axis -log10(p-value) for (A) the 4 hour time point for the
GlyCl pre-replication phase exposure (B) the 72 hour time point for the GlyCl pre-replication phase
exposure (C) the 4 hour time point for the S-phase GlyCl exposure (D) the 72 hour time point for the
S-phase GlyCl exposure
4.5.3 Analysis of variability in DNA methylation after GlyCl exposure
The variability in the level of methylation at each CpG (DVP) across replicates in the
treatment group compared to control was next assessed. At the 4 hour time point, the
treatment group demonstrated an increase in differential variability at 5910 positions
compared to control, and a decrease at 13769 positions. At the 72 hour time point,
1892 positions demonstrated an increase and 2743 demonstrated a decrease (Table 5.9).
Twenty-three DVPs were common between the 4 and 72 hour time points, however only
6 DVPs (26%) demonstrated a consistent direction of change (Table 5.10).
Table 5.9: Summary of DVPs (treatment compared to control) observed at each time point




Table 5.10: Differentially variable probes (DVPs) ordered by t-statistic significance that were
common at both the 4 and 72 hour time points.
(4hr) (72hr)
Probe ID LVR t adj.p LVR t adj.p Gene
cg06521531 6.72 7.73 0.009 -5.85 -8.259 0.0091 FHL1
cg13981054 6.07 7.61 0.009 6.47 7.661 0.0122
cg10568558 -3.31 -7.03 0.012 -3.63 -5.561 0.0337 UBE4B
cg14612785 -7.3 -6.51 0.015 -4.41 -5.34 0.0369 EIF4E3
cg27445386 2.30 6.25 0.015 -3.98 -5.100 0.0407 CNPY3
cg13835576 5.83 6.25 0.015 -6.09 -6.500 0.0236 BLK
cg00276792 -8.35 -6.21 0.015 6.87 5.18 0.039
cg27560282 -2.85 -5.90 0.016 -6.10 -5.109 0.0405 ICK
cg24598449 3.63 5.86 0.017 -3.24 -4.98 0.0431 FBXO6
cg09016212 4.50 5.86 0.017 -2.84 -8.408 0.0091 GRASP
cg03913456 4.70 5.83 0.017 -5.15 -6.213 0.0260 NCAPH
cg00360072 2.16 5.77 0.017 -2.28 -5.35 0.036 HDAC4
cg21267439 -3.67 -5.73 0.018 5.24 5.484 0.035 NT5DC1
cg15372625 -2.91 -5.72 0.018 -3.02 -5.189 0.0392
cg05352535 4.95 5.67 0.018 -3.59 -6.355 0.024 PVRL3
cg23161691 7.55 5.66 0.018 -3.58 -5.552 0.033 BAHCC1
cg21388527 -2.68 -5.63 0.018 3.25 8.479 0.009 EPHA6
cg18558388 5.21 5.62 0.019 -6.73 -5.225 0.0385 SAP30L
cg00823357 4.97 5.59 0.019 -3.25 -5.10 0.040 EFNB1
cg23444251 3.01 5.49 0.019 -3.43 -5.043 0.0416 FGFR2
cg16688031 3.69 5.39 0.020 -2.11 -5.664 0.0318
cg20898865 -2.17 -5.27 0.022 -3.09 -8.177 0.0091
cg03324815 -1.84 -5.25 0.022 2.33 5.202 0.0390 MZF1
*LVR, Log Variance Ratio
**Probes that demonstrated a consistent direction of change are in bold typeface.
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4.5.4 Differentially methylated CpGs at the 4 hour time point
To identify changes that were associated with GlyCl treatment at the 4 hour time point,
DNA methylation levels at each individual CpG site were assessed. To summarize the
results, each CpG site was mapped to the corresponding genomic region and unadjusted








Figure 5.26: Manhattan plot of all CpG sites –log10(p values based on M-Values in the
4 hour time point for the GlyCl pre-replication phase exposure. All CpG sites are ordered
per chromosome position along the x-axis, and p-values as the –log10(p values) are presented on the
y-axis. Genome-wide significance was determined using the “Benjamini, Hochberg” method within
Limma and is represented by the horizontal black line.
This analysis confirmed that methylation changes were spread out across the genome,
however, it appeared that many significant probes were concentrated to specific gene
loci, indicating that genetic regions, as well as individual probes may have been particu-
larly susceptible to GlyCl treatment. Additionally, it appeared that significant changes
were concentrated towards the ends of the chromosomes.
Using a Log2FC cutoff of 1, there were 92665 the CpG sites that displayed a sig-
nificant decreased methylation compared to control and 66403 that demonstrated an
increase at 4 hours. At 72 hours, there were only 4 that demonstrated a decrease and
6 showed an increase. When the Log2FC was increased to 2, there were 124 CpG sites
that demonstrated decreased methylation compared to control at the 4 hour time point
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and no CpG sites demonstrated an increase. At the 72 hour time point, no differentially
methylated CpG sites were observed (Table 5.11).
Table 5.11: Summary table of the significant differentially methylated CpG sites at the 4 and
72 hour time points using cut offs of Log2FC >1 and Log2FC >2
Log2FC>1 Log2FC>2
Direction of change 4 hr 72 hr 4 hr 72 hr
Decreased 92665 4 124 0
Increased 66403 6 0 0
This analysis indicated that the largest fold changes in differentially methylated
CpGs in the treatment group at the 4 hour time point were all decreases. The data
was then filtered to include CpG sites that demonstrated both a Log2FC >2 and a
minimum of 20% mean change between treatment and control. The largest fold changes
at the 4 hour time point, ordered by significance, are presented in Table 5.12.
A subset of the top significant CpG sites that demonstrated the largest fold changes

















Figure 5.27: Box plots showing β-values of a subset of the top differentially methylated
CpG sites.CpG sites were selected that demonstrated the largest, significant fold changes at the 4
hour time point. β-values are represented on the y-axis and group on the x-axis. (A) chr1:59043255
(B) chr17:62131780 (C) chr14:103150012 (D) chr1:36056577 (E) chr1:17265457 (F) chr11:61314936
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Table 5.12: Top most significant differentially methylated probes with a Log2FC >2 and
a 20% change between treatment and control at the 4 hour time point for the GlyCl pre-
replication phase exposure dataset.
Log2FC adj.p.Val Direction Gene Chr Basepair
cg10553894 -1.802 0.002 Down CPT1A 11 68550534
cg13782884 -1.830 0.002 Down FAM46B 1 27339287
cg05372828 -1.821 0.003 Down KCNAB2 1 6111632
cg16852704 -1.749 0.005 Down TLX2 2 74743243
cg04946721 -2.198 0.012 Down ERN1 17 62131780
cg18862597 -2.037 0.012 Down CROCC 1 17265457
cg06830450 -1.964 0.015 Down LOC100130776;AGAP2 12 58121004
cg12873037 -1.839 0.018 Down C17orf56 17 79205369
cg19635533 -1.911 0.018 Down NACC1 19 13249050
cg17049621 -1.772 0.019 Down FZD2 17 42635778
cg21871608 -2.028 0.02 Down ITPK1 14 93409468
cg07149030 -1.900 0.021 Down ABR 17 982503
cg02080909 -1.937 0.021 Down BAIAP2 17 79058333
cg23120934 -1.829 0.022 Down SCRIB 8 144887083
cg10692302 -2.011 0.022 Down GRM2 3 51747227
cg27182230 -4.667 0.023 Down ZFHX3 16 72882824
cg08130783 -2.083 0.023 Down TFAP2E 1 36056577
cg14899522 -1.982 0.024 Down PRKCQ 10 6472750
cg15474728 -1.927 0.025 Down ABR 17 982497
cg04801085 -2.135 0.025 Down RCOR1 14 103150012
cg10068222 -1.585 0.026 Down 16 899108
cg08925720 -2.004 0.027 Down SYT7 11 61314936
cg16699148 -2.331 0.028 Down TACSTD2 1 59043255
cg00015930 -2.222 0.033 Down 1 46921746
cg26924445 -1.622 0.039 Down ACRC X 70824102
cg15002761 -1.870 0.04 Down IGSF9B 11 133816097
cg09400123 -1.720 0.044 Down RUNDC2C 16 29324046
cg10040530 -2.094 0.044 Down 14 104010839
cg08298555 -2.167 0.049 Down CACNA1H 16 1260656
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4.5.5 Differentially methylated CpGs at the 72 hour time point
At the 72 hour time point, 4 CpG sites demonstrated a significant decrease in differential
methylation and 6 CpG sites demonstrated a significant increase (adj. p <0.05), when
assessed using a Log2FC cutoff of 1 (Table 5.13). The magnitude of these changes
was less than 10%, therefore there were no significant CpG sites detected at a Log2FC
cutoff of 2 at the 72 hour time point.
Table 5.13: Top 20 most significant differentially methylated CpGs at the 72 hour time point
using a Log2FC cutoff of 1 for the GlyCl pre-replication phase exposure.
Probe name log2FC adj.p.Val Direction Gene Chr Basepair
cg00297451 1.352 0.0113 Up ARHGAP11A 15 32908400
cg16381597 1.533 0.0224 Up ZNF142;BCS1L 2 219524462
cg27633753 1.320 0.0224 Up OCRL X 128674222
cg03343631 -0.910 0.0224 Down RASA3 13 114764489
cg18538954 -0.854 0.0224 Down 16 56511477
cg14058432 0.972 0.0232 Up PELI2 14 56584702
cg13722120 0.918 0.0245 Up ERC2 3 56487225
cg07171505 1.150 0.0471 Up C16orf70 16 67144003
cg07934941 -0.886 0.0471 Down MLF1IP 4 185654596
cg06851253 -0.909 0.0486 Down CHCHD4;TMEM43 3 14166363
cg21975824 -1.119 0.0562 Down RBM26 13 79980660
cg13055288 0.897 0.0565 Up SLC7A2 8 17396259
cg13953717 0.694 0.0565 Up MIR99AHG 21 17657943
cg08046288 1.144 0.0565 Up 1 199082308
cg11216153 -0.964 0.0565 Down HADH 4 108921304
cg02768742 1.084 0.0565 Up LARS 5 145562530
cg19407454 -0.688 0.0565 Down IQCE 7 2643258
cg03050188 1.206 0.0565 Up 2 11531606
cg11979743 -0.978 0.0595 Down FAM110A 20 814510
cg16603817 0.769 0.0595 Up 5 148827511
Two of the 10 top significantly differentially methylated CpG sites detected at the
72 hour time point were also significant in the 4 hour time point when a Log2FC of
>1 was used. The CpG sites corresponding to both the ERC2 and the MLF1IP genes
had a smaller Log2FC at 4 hours than at 72 hours, but neither was consistent in the
direction of change (Figure 5.28).
4.5.6 Differentially methylated gene regions
An analysis to determine if multiple CpG sites mapping to the same genomic loci




Figure 5.28: Box plots showing representative β-values of the two differentially methylated
CpG sites at both the 4 hour and 72 hour time points in the GlyCl pre-replication phase
exposure β-values are represented on the y-axis and group on the x-axis. (A) ERC2 (B) MLF1IP
undertaken. To identify differentially methylated regions, this analysis was limited to
loci consisting of five or more consecutive probes that displayed significant average
change in differential methylation larger than 10%. Under these parameters, 85 sig-
nificant DMRs were detected at the 4 hour time point but no significant DMRs were
observed at the 72 hour time point (Supplementary Table B.3). When the parame-
ters were relaxed to investigate changes in methylation greater than 5%, there were
5 significant DMRs at the 72 hour time point (Supplementary Table B.4). No DMRs
demonstrated a consistent change between the 4 and 72 hour time points.
Of the 85 significant DMRs at the 4 hour time point, 14 had 10 or more adjacent
significant CpGs. The top two DMRs with the highest number of significant adjacent
CpGs mapped to the MAPK8IP3 gene region (18 CpGs)(Figure 5.29) and the TFAP2E




Figure 5.29: Differentially methylated MAPK8IP3 gene region. DMR corresponding to the
MAPK8IP3 gene (chromosome 16:1813796-1818819, width:5024 bp) that displayed a significant change
in methylation (β-values (y-axis)) across 18 CpGs (x-axis) between the treatment (grey) and control
(black) for the 4 hour time point. Gene structure is placed on top of each graph, exons are shown as
black bars, and the transcriptional start site is marked by a red arrow.
TFAP2E
chr1:36037583-36039885
Figure 5.30: Differentially methylated TFAP2E gene region. DMR corresponding to TFAP2E
gene (chromosome 1:36037583-36039885, width:2303 bp) that displayed a significant change in methy-
lation (β-values (y-axis)) across 16 CpGs (x-axis) between the treatment (grey) and control (black)
for the 4 hour time point. Gene structure is placed on top of each graph, exons are shown as black
bars, and the transcriptional start site is marked by a red arrow.
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4.5.7 Pathway analysis
To investigate potential enrichment of multiple genes that relate to the same biological
pathway, the genes corresponding to the top most significant CpG sites that demon-
strated decreased methylation at 4 hours compared to controls, were analysed within
the KEGG database. Fifty-two significant pathways were identified that had a FDR
<0.05 and the top 40 with a FDR ≤ 0.04 are presented in Table 5.14.
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Table 5.14: Results from KEGG pathway analysis containing top hits with a FDR of ≤ 0.04
KEGG Pathway Description n* DM* FDR
hsa04910 Insulin signaling pathway 137 107 0.000
hsa04144 Endocytosis 249 178 0.000
hsa05170 Human immunodeficiency virus 1 infection 212 146 0.000
hsa04370 VEGF signaling pathway 59 51 0.001
hsa04722 Neurotrophin signaling pathway 119 92 0.001
hsa04660 T cell receptor signaling pathway 104 80 0.001
hsa05131 Shigellosis 236 161 0.002
hsa04666 Fc gamma R-mediated phagocytosis 93 72 0.002
hsa05235 PD-L1 expression and PD-1 checkpoint cancer 89 68 0.002
hsa01100 Metabolic pathways 1489 875 0.002
hsa04150 mTOR signaling pathway 153 111 0.003
hsa04071 Sphingolipid signaling pathway 119 88 0.003
hsa04664 Fc epsilon RI signaling pathway 68 54 0.003
hsa04210 Apoptosis 136 97 0.003
hsa04010 MAPK signaling pathway 295 199 0.005
hsa05215 Prostate cancer 97 73 0.005
hsa05231 Choline metabolism in cancer 98 75 0.005
hsa05221 Acute myeloid leukemia 67 53 0.007
hsa04925 Aldosterone synthesis and secretion 98 72 0.012
hsa04070 Phosphatidylinositol signaling system 99 74 0.014
hsa04931 Insulin resistance 108 78 0.019
hsa04072 Phospholipase D signaling pathway 148 104 0.019
hsa05132 Salmonella infection 214 143 0.021
hsa05225 Hepatocellular carcinoma 168 115 0.022
hsa01230 Biosynthesis of amino acids 75 53 0.023
hsa00564 Glycerophospholipid metabolism 98 70 0.027
hsa04062 Chemokine signaling pathway 189 119 0.034
hsa04152 AMPK signaling pathway 120 84 0.034
hsa04218 Cellular senescence 160 108 0.038
hsa04912 GnRH signaling pathway 93 66 0.040
hsa04744 Phototransduction 28 22 0.040
hsa04810 Regulation of actin cytoskeleton 213 141 0.040
hsa05214 Glioma 75 55 0.040
hsa05220 Chronic myeloid leukemia 76 56 0.040
hsa04919 Thyroid hormone signaling pathway 119 84 0.040
hsa01521 EGFR tyrosine kinase inhibitor resistance 79 59 0.040
hsa04935 Growth hormone synthesis, secretion, action 119 84 0.040
hsa05135 Yersinia infection 120 84 0.040
hsa05211 Renal cell carcinoma 69 52 0.040
hsa04625 C-type lectin receptor signaling pathway 104 72 0.040
* number of genes in the pathway
**number of genes that were differentially methylated
FDR, false discovery rate
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5 Discussion
Epigenetic modification of DNA is a way in which environmental stimuli can modulate
human gene activity. Changes in the pattern of epigenetic marks on the DNA, such as
the methylation of cytosine, have been widely implicated in the development of diseases,
including cancer, cardiovascular disease and obesity [666; 667], but the mechanisms
by which the environment can influence epigenetic regulation are unclear. Many of
these diseases are associated with an excessive inflammatory response, resulting in
oxidative stress and disease progression [429; 668; 669]. Activated neutrophils produce
substantial amounts of cell permeable oxidants and thus contribute to the oxidative
burden at inflammatory sites. Neutrophil oxidants, in particular GlyCl, has been
shown to inactivate DNMTs and deplete SAM levels in proliferating cells [585], but
the impacts of these oxidants on epigenetic patterns of cells and whether these changes
are maintained in subsequent generations of cells is not known.
The current study investigated whether neutrophil-derived oxidants (H2O2 or GlyCl)
could alter DNA methylation patterns in synchronized Jurkat cells. Since a previous
report did not see an effect with H2O2 exposure at the time of the release of the block,
the effect of H2O2 was assessed by treating cells with two boluses of H2O2 during the
S-phase of DNA replication. The effect of GlyCl was investigated by treating cells once
with 200µM GlyCl during either S-phase or immediately after release from cell cycle
block. For each treatment, genomic changes in 5-methylcytosine (5-mC) were analysed
at 4 hours and 72 hours after the replication block was released. For each time point,
the change in methylation was assessed using the Illumina MethylationEPIC850K ar-
ray, by comparing the treatment and control samples from the same time point.
Because the treatment and control samples were split from the same synchronised
stock immediately prior to oxidant exposure, methylomic changes relating to cell cycle
were controlled for in the study design. The design of these experiments was such that
DNA methylation was assessed immediately after the majority of replication was com-
pleted (4 hours), thus comparing the efficiency of nascent DNA methylation between
the control and treatment samples. DNA methylation was assessed again after several
cycles of cell division (72 hours) to establish if the observed changes were corrected, or
were inherited into the methylome of subsequent cell generations.
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The main findings of this study were that both oxidant treatments resulted in sub-
stantial genome-wide decreases in methylation, the majority of which reverted during
subsequent rounds of cell division. However, some smaller changes were conserved and
many of the genes that demonstrated altered methylation patterns were involved in
cancer-associated pathways. These results suggest that sequence-specific alterations in
methylation can occur through interference in a pathway that acts on molecular methy-
lation machinery. How exactly this could occur remains to be shown, and suggests the
involvement of molecular players that are yet to be defined.
5.1 Methylomic changes associated with exposure to H2O2
Analysis of average relative DNA methylation levels indicated that H2O2 exposure
corresponds with a significant decrease of ∼3.3% in the average methylation level at
the 4 hour time point, however, there was no significant change between the 72 hour
time points. This change was driven by the combined effect of many CpG sites with a
log2FC approximately equal to one, however, at 72 hours the effect sizes (and therefore
significance) were substantially reduced.
There was a considerable increase in differential variability associated with H2O2
treatment at 4 hours (1035 CpG sites), which was reduced (41 CpG sites) by 72 hours.
This increased variability indicates that the same positions were not necessarily influ-
enced in all cells, which suggests that H2O2 treatment has a random or non-specific
effect on DNA methylation at many sites. There was little consistency in the direc-
tion of change between the two time points, where 82% of the CpG sites that were
significant at both time points showed contrasting results. This could suggest that
once exposed to H2O2, methylation levels at these sites struggle to re-establish. Only
seven sites displayed a consistent direction of change between these time points, three
of which showed a decrease in variability (which was opposite to the general trend).
The corresponding genes included several important DNA-binding transcription factors
which are involved in many biological processes, including insulin gene transcription
(LMX1A and NR2C2) [670; 671], and central nervous system development (LMX1A
and ITPK1) [672; 673]. Epigenetic variability is considered to be a hallmark of can-
cer, and the LMX1A has also been identified to be more frequently methylated (and
epigenetically inactivated) in cervical cancer [674; 675] and gastric cancer [676]. In
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the control samples, this site displayed highly variable methylation levels which ranged
from 23%-40%, however, in the treatment samples DNA methylation was reduced to
20% and remained low.
The observed changes from the H2O2 treatment 4 hour time point were spread across
the genome, and appeared to be non-specific, with no strong evidence for enrichment
of specific gene pathways. However, many of these changes were consistent across
multiple adjacent CpG sites, and this would suggest that the effects of H2O2 treatment
relate to the positioning of DNMT1 at the time of exposure. Because the cells were
released from synchronization at the same time, it is expected they would progress
through replication at a similar rate. Furthermore, although not statistically tested,
it appeared that there was a substantial enrichment in DNA methylation changes at
chromosomal ends. Further analysis is required to determine if this was simply due to
the array containing a higher proportion of probes (and therefore CpG sites) located at
the ends of chromosomes, or that the chromosomal ends were somehow more susceptible
to methylation changes due to oxidative stress during replication.
This study aimed to identify key methylomic changes due to oxidant exposure that
are sustained across multiple cell generations. The majority of the significant CpG
sites at the 72 hour time point originated from a smaller effect size at 4 hours (Log2FC
∼1), which suggests that they are likely to represent a delayed effect.
Although no significant enrichment of gene pathways were observed with H2O2
treatment, several of the top most significant genes were related to diabetes and can-
cer, many reporting links with oxidative stress. The BAZ2B and CNTNAP2 genes have
been identified to be differentially methylated in conjunction with air pollution-related
disease [677] and smoking [678], which are both associated with increased oxidative
stress [679]. The SLC30A8 and ELP4 genes have been associated with an increased
risk of developing type 2 diabetes [680; 681; 682; 683] including the involvement of
increased DNA methylation [684; 685]. Similarly, the IGF1 differential gene methyla-
tion has been identified in relation to both obesity [686] and to smoke exposure [687].
Decreased expression of EMX2OS was linked to decreased survival in thyroid cancer
[688], a cancer which is associated with oxidative stress [689]. Two gene regions cor-
responding to the SPATA16 gene and LOC100506102 (also overlapping with the small
nuclear RNA: snoU13.410-201, and the miRNA: RP11-322J23.1-001) demonstrated sig-
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nificant differential methylation at both 4 hours and 72 hours. The potential results
of these changes are unclear; however, the SPATA16 gene is related with sperm count
and motility. Extensive research has suggested that reactive oxygen species are a con-
tributing factor to male infertility [690], with oxidative stress identified as a common
pathology in approximately half of all infertile men [691]. Deregulation of snoRNA has
been observed in several different cancer types including chronic lymphocytic leukemia
[692], hepatocellular carcinoma [693], colorectal cancer [694] and endometrial cancer
[695], and also metabolic stress disorder [696].
These findings contrast previous work which showed that whilst H2O2 has an in-
hibitory effect on DNMT, H2O2 exposure had no effect on methylation levels in synchro-
nised Jurkat cells under similar conditions [585]. However, the current study differs in
that the Jurkat cells were treated twice during S-phase, as opposed to once immediately
following the release of thymidine block, in order to maximise H2O2 exposure during
the time period where DNMTs are most active. Furthermore, previous work utilised
a mass spectrometry approach which analysed the methylation of incorporated heavy
deoxycytidine in the nascent strand relative to total cytosine content. The cutting-edge
array technology used in the current study increased both the magnitude of the effect
size and sensitivity, which enabled detection of very small changes that were not previ-
ously possible using traditional methods. This study also highlighted the importance
of nucleotide resolution, which enabled the detection of both increased and decreased
methylation.
5.2 Methylomic changes associated with exposure to GlyCl
The average relative methylation analysis of the GlyCl treated cells during the S-phase
of DNA replication demonstrated no significant differences in average relative methyla-
tion levels at either time point. Additionally, probe-wise comparisons of the treatment
CpG sites compared to control at both the 4 and 72 hour time points indicated that
there were no Log2FC greater than 1 that achieved genome-wide significance.
These results were interesting, as previous work had shown that Jurkat cell treat-
ment with 500µM GlyCl directly inhibited DNMT activity, and therefore GlyCl ex-
posure during S-phase appeared to be a logical treatment time to observe maximal
methylation change [585]. It is possible the concentration used in the current study
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(200µM) was not high enough to inhibit DNMT activity directly, as it has been shown
that different thiol-containing enzymes have different susceptibilities to HOCl and chlo-
ramine inactivation [697]. However, since it had also been shown that GlyCl treatment
can deplete SAM levels by up to 90% two hours after treatment [585], the impact of
GlyCl exposure on DNA methylation after treatment two hours prior to replication
(immediately post-release) was also investigated.
Global DNA methylation analysis of the GlyCl treated cells during pre-replication
phase indicated a small, but significant ∼0.01% increase in the average methylation
levels at the 4 hour time point, however, there was no significant difference at the 72
hour time point. Assessing differential variability of CpG sites gives an indication of the
level of epigenetic dysregulation that could contribute to abnormal cell function and
tumourigenesis [659; 698], and there was a marked increase in differential variability
associated with GlyCl treatment at 4 hours (5910 CpG sites), which was roughly halved
(2743 CpG sites) by 72 hours. Three of the 6 genes that maintained a consistent
direction of change in differential variability at both time points are involved with
tumour suppressor gene activity and cell proliferation (EIF4E3 [699], UBE4B [700],
ICK [701]). Several studies have demonstrated that the most differentially variable CpG
sites in cancer cells compared to control had little overlap with the most differentially
methylated CpGs [702; 598]. It has also been suggested that differential variability
can provide insights into molecular pathway signatures in tumours caused by specific
carcinogens [598]. The results from the current study suggest that GlyCl treatment
may have an arbitrary effect on DNA methylation patterns as not all cells were affected
in the same way by treatment, but GlyCl exposure could contribute to epigenetic
heterogeneity longer term and eventual tumour progression.
Two CpG sites demonstrated a significant change in differential methylation at both
4 and 72 hours but were not consistent in the direction of change. The ERC2 gene is
a gene active in the brain that encodes for matrix proteins at presynaptic active zones
[703]. In the current study, differential methylation at this CpG site was decreased at 4
hours and increased at 72 hours. Epigenetic modifications, predominantly hypomethy-
lation, of ERC2 can lead to developmental disorders such as attention deficit disorder
(ADHD) [704]. The other CpG site, mapping to the MLF1IP gene, showed increased
differential methylation at 4 hours which decreased at the 72 hour time point. MLF1IP
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codes for myeloid leukemia factor 1-interacting protein which is involved in cell prolif-
eration. Overexpression of MLF1IP has been linked to progression and metastasis in
breast and colorectal cancers [705; 706].
Exposure to GlyCl during the pre-replication phase of the cell cycle impacted a
large number of CpG sites, but when the results were filtered to include only large fold
changes (Log2FC >2) that demonstrated at least a 20% change the most significant
CpG sites all demonstrated decreases in differential methylation. Many of the CpG
sites in this group corresponded to genes involved in cancer progression, proliferation
and transformation. Upregulation of proteins encoded by TACSTD2(TROP-2), SYT7,
CROCC and TFAP2E have had negative impacts on tumour progression in several
different types of cancer [707; 708; 709; 710; 711; 712; 713]. ERN1(IRE1α) is involved
in the inhibition of normal T-cell responses to cancer, as blocking its expression can
restore an anti-tumour T-lymphocyte phenotype [714]. Several of these genes are also
associated with regulated cell death (TACSTD2 [707], and TFAP2E [715]) and differ-
entiation (RCOR1, [716]).
The differentially methylated genes resulting from GlyCl treatment at the 4 hour
time point contributed to the significant enrichment of 52 gene pathways. Most notably,
some of these enriched pathways included VEGF signalling (86%), Mitogen-activated
protein kinases (MAPKs) (71%) and apoptosis (67%).
Furthermore, many of the changes in methylation at the 4 hour time point were con-
sistent across relatively large numbers of adjacent CpGs mapped to the same gene re-
gion. There were 18 adjacent CpGs that demonstrated a significant decrease in methy-
lation mapping to the MAPK8IP3 gene. The MAPK8IP3 gene encodes the MAPK 8
interacting protein 3 also known as JNK/stress-activated protein kinase-associated pro-
tein 1 (JSAP1). MAPK8IP3 is a scaffolding protein for the mitogen-activated protein
kinase (MAPK)/c-Jun N-terminal kinases (JNK). MAPKs are involved in a broad range
of signalling pathways including proliferation, differentiation, autophagy and apoptosis
[717; 718]. MAPKs positively regulate key angiogenic factors MMP [719] and VEGF
[720] which are pivotal for tumour invasiveness and progression [721]. Oxidative stress
has been shown to activate MAPK pathways which can either promote a protective
effect against oxidation [722; 723] or trigger apoptosis [724].
The TFAP2E gene region was also affected by GlyCl exposure in this study, with
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16 CpGs demonstrating significant decreased methylation. TFAP2E encodes the reg-
ulatory transcription factor AP-2. AP-2 is involved in cell cycle arrest by activating
cell cycle inhibitor p21 and has been shown to suppress proliferation in several can-
cers [725; 726]. On the other hand, overexpression of AP-2 can lead to the activation
of oncogenes associated with malignant transformation in breast and prostate cancer
[727; 728; 729; 715].
GlyCl exposure did not significantly enrich any gene pathways at the 72 hour time
point, however, many of the genes that demonstrated significant differential methyla-
tion were related to cell death (ARHGAP11A, RASA3, PELI2), mitochondrial func-
tion (CHCHD4,BCS1L) or membrane and endosomal transport of nutrients (SLC7A2,
ERC2, OCRL, TMEM43). Only two of these genes were significantly differentially
methylated at 4 hours and therefore the changes observed at 72 hours may be either
unrelated to GlyCl treatment or represent a delayed effect of treatment.
The dramatic difference in significant genome-wide methylation levels between ex-
posure to 200µM GlyCl prior to replication compared to exposure during S-phase
suggests that the effect of GlyCl on SAM and/or methionine levels is the main driver
of methylation changes rather than its potential direct inhibitory effect on DNMT.
Treatment during S-phase would not have depleted SAM levels sufficiently to disturb
DNMT activity until 4 hours post release, the time at which the majority of replication
would have been completed.
Overall, it appeared that GlyCl treatment had less of an effect on average rela-
tive methylation levels compared to H2O2. This may have been due, in part, to the
large number of CpG sites (66403) that demonstrated increased methylation at 4 hours
compared to controls. Because SAM would be depleted in the media due to GlyCl treat-
ment, it is unclear what could have contributed to this increase. One possibility could
be the formation of 5-chlorocytosine (5-cC). If 5-cC were formed, the bisulfite treat-
ment may not have converted this modified cytosine to uracil, and therefore 5-cC sites
would have been recognised as methylated on the array. However, the reaction of GlyCl
with DNA is not highly favourable, and under the current experimental conditions, the
majority of GlyCl is more likely to have reacted with methionine. Furthermore, the
formation of 5-cC appears to be a rare event with numbers of 1 per 1× 104 nucleosides
and 30 per 1×108 nucleotides being reported after treatment with HOCl or chloramines
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respectively [730; 731].
Alternatively, it has been shown that oxidative stress can promote the formation of a
complex that includes DNMT1 and DNMT3B and members of the methylation complex
called polycomb repressive complex 4 [569]. This complex is stimulated by oxidative
damage to bind to DNA at CpG islands and methylate promoters of low-expression
genes. Work was carried out using 1mM H2O2 and quantifying the methylation status
and expression of specific genes 30 minutes after exposure [569]. One could speculate
that this complex could have assembled and been responsible for the increased differ-
ential methylation in the current study due to GlyCl exposure, as early after exposure
SAM levels would have been sufficient to carry out methylation activity. Currently, no
studies have explored the effect of GlyCl or HOCl treatment on the recruitment and
activity of this complex.
While an intriguing observation, these increases in differential methylation were
not likely of major biological significance as the filtering for both larger fold changes
and percentage change identified that the largest, most significant changes were all
decreases in methylation.
These results suggest that a single exposure of GlyCl on Jurkat cells has a significant
initial impact on important gene pathways that can either confer a survival advantage or
induce cell death. These enriched pathways were not observed at the 72 hour time point,
indicating that the replenishment of methionine/SAM levels allowed for restoration of
methylation by active DNMT.
5.3 The overall effect of oxidant exposure on DNA methyla-
tion
In both oxidant treatments the large changes observed at the 4 hour time point were
likely sufficient to halt DNA replication until they were repaired, or the cell died.
The results from the 4 hour time point provide a snapshot of the genes and gene
pathways that could be more susceptible to alterations in activation due to oxidative
stress. It is unclear if the magnitude of these changes would continue to increase beyond
4 hours if repeated exposure events were encountered.
It is not entirely unexpected that the majority of methylomic changes due to oxidant
exposure were reversible, and highlights the resilience of the cell to oxidative stress.
202
It makes evolutionary sense for this to occur, otherwise every oxidative insult a cell
encountered would induce a major cellular transformation. However, it is possible that
more subtle changes in DNA methylation are more likely to be inherited by subsequent
cellular generations, and may lead to larger changes. This could be an important pro-
cess in understanding the epigenetic contributions of oxidative stress towards diseases
including diabetes and cancer.
Taken together, these results show that GlyCl and H2O2 may have different mech-
anisms of action on maintenance methylation. GlyCl treatment was unlikely to be
effectively inhibiting DNMT1 based on the lack of methylation changes when exposure
occurred during DNA replication (S-phase). Rather, the substantial changes in methy-
lation observed when GlyCl exposure occurred during pre-replication phase shows that
GlyCl indirectly influences DNMT by decreasing the availability of a methyl donor.
The increased number of differentially methylated CpG sites at the 72 hour time point
in the cells treated with H2O2 compared to GlyCl treatment, may also suggest that in-
activation of DNMT1 through oxidation may take longer to reverse, whereas under the
GlyCl treatment conditions, SAM levels would have been replenished from the addition
of fresh media at 24 and 48 hours post release, and DNMT activity could resume.
Whether the CpG sites that were affected by oxidant exposure at each time point
were common between the two treatments was not assessed in the current study. It
would be interesting to explore the nature of the affected CpG sites to ascertain if its
position on the chromosome rendered it more susceptible to oxidant treatment or other
factors such as DNAase hypersensitivity.
In summary, 4 hours after exposure both GlyCl and H2O2 were associated with
substantial genome wide decreases in methylation, which was mostly corrected during
subsequent cycles of cell division.
5.4 Limitations
This exploratory analysis is subject to limitations that may have influenced the find-
ings. Because oxidant treatment has a cytotoxic effect, it is difficult to separate the
methylation changes that were associated with cell death from those resulting from
oxidant treatment. In order to minimize this effect, relatively low concentrations of
oxidants were used which corresponded to approximately 25% decrease in cell viability
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compared to the controls. To control for the inclusion of dead cells in the final DNA
extract, samples were centrifuged at a slow speed prior to DNA extraction, which al-
lowed for removal of dead cells in the supernatant. Future studies could consider the
assessment of phosphatidylserine exposure alongside PI exclusion by flow cytometry to
control for cells in the early stages of apoptosis.
The observed methylation changes in this study are reflective of genomic DNA iso-
lated from Jurkat cells that were subject to an artificial block of cellular replication.
Jurkat cells have a highly mutated and duplicated genome compared to normal T-
lymphocytes [732]. DNMTs are often overexpressed in many cancer types [733; 734],
including Jurkat cells [735], a trait that may have favoured the reversible effect of
oxidant-induced decreases in methylation observed in the current study. However, Ju-
rkat cells were considered a suitable model due to their non-adherent nature and rapid
replication rate. Jurkat cells may also represent a physiologically relevant model as
neutrophils circulating in patients with chronic lymphocytic leukemia show a chroni-
cally activated phenotype producing elevated levels of oxidants compared to healthy
controls [579].
In order to control for methylation changes that result from cell division, the cell
cycle of the control and treatment cells was closely monitored, and DNA methylation
was only assessed when the cells were either synchronous (4 hours) or had returned to
an asynchronous population (72 hours). Oxidant treatment delayed cellular replication,
and therefore DNA methylation changes at the 24 hour and 48 hour time-point were
not assessed, due to the differing state of replication. Although it is unlikely that a large
population of cells would exist in S-phase at any one time point in vivo, in the situation
of prolonged inflammation, it is likely that a large proportion of cells will be exposed
to high oxidant levels during cellular replication. Furthermore, while DNMT activity
is widely regarded to be most active in S-phase [468; 736], there is also evidence that
it is active during G2/M and in G1 [736; 496; 737; 586]. Therefore, oxidant induced
inhibition of DNMT could also occur in an asynchronous population. Nonetheless,
in the context of cancer, an effect on a small number of cells in a population could
still have a major biological effect, although this would be challenging to study in an
experimental setting.
The short oxidant exposure period was a further limitation, especially as most
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of the large epigenetic changes reported are associated with long term exposure to
environmental stressors, such as smoking [738; 739; 740] or chronic inflammatory disease
states [741; 742]. However, the findings from the current study have a substantial
effect size, and the oxidant concentration used in this analysis is similar to in vivo
concentrations observed during chronic infection [743; 744; 745; 746].
llumina methylation EPIC bead chip arrays provide the most comprehensive cov-
erage at single-base level of differential methylation levels across the human genome.
However, a potentially confounding factor with the use of bisulfite sequencing is that
it cannot distinguish between 5-mC and 5-hydroxymethylcytosine (5-hmC) [747; 448].
5-hmC is in itself its own epigenetic mark, and can lead to demethylation (described
in detail in section 4.3.4). Furthermore, the poor reliability of a number of probes
in similar bead chip arrays has been highlighted in a recent review, suggesting that
reproducibility could be a major issue in the long-term as these arrays become more
accessible and larger volumes of data are generated [748]. However, bead chip arrays,
such as the ones utilised in the current study, do provide clues into which CpG sites
could be effected by treatment, which can then be validated using alternative methods.
Although the results of this study are yet to be independently validated, a subset
of the differentially methylated CpG sites discovered in this thesis are currently being
assessed using bisulfite amplicon sequencing (BSAS). This method uses PCR to amplify
the target gene, which is subsequently sequenced and the methylation pattern assessed.




These data provide supporting evidence for a mechanistic link between inflammation
and cancer. It shows that oxidative stress can influence methylation, causing a small
number of heritable changes in cytosine methylation patterns, which could result in
tumour formation and progression. Although it is accepted that environmental fac-
tors can influence the epigenome, few studies have investigated the pathways through
which this can occur and the effect in subsequent cell generations. These data demon-
strate that exposure to oxidative stress corresponds with substantial decreases in DNA
methylation, but the majority of these larger changes are subsequently corrected. How-
ever, some changes were conserved, suggesting that more subtle modifications in DNA
methylation can be inherited by successive cell generations. Furthermore, several of
the genes with sustained methylation changes have been implicated in cancer.
H2O2 and GlyCl appear to exert their inhibitory effects on DNMT by complemen-
tary mechanisms. H2O2 likely inactivates DNMT directly, through inactivation of its
cysteine active site whereas DNMT inactivation by GlyCl exposure may be contingent
on the availability of SAM. (Figure 5.31).
Future studies should consider the effect of continuous and/or the combined effect
of H2O2 and GlyCl on methylation levels, to more closely mimic chronic inflammation
states. In addition, it would be interesting to explore the effect of these oxidants on























Figure 5.31: Glycine chloramine and hydrogen peroxide inhibit methylation of cytosine on
newly replicated DNA. Activated neutrophils produce H2O2 which can either diffuse extracellularly
or be used as a substrate for MPO to produce HOCl. HOCl reacts readily with amines, such as glycine,
to produce chloramines (ex. GlyCl) GlyCl reacts with methionine and depletes its availability for the
DNMT methyl donor SAM. DNMTs contain cysteine residues in their active site that are susceptible
to inactivation through oxidation. H2O2, by its direct inhibition of DNMT, and GlyCl, by its depletion





Tumour associated inflammation and genomic instability are two enabling character-
istics of cancer, and the neutrophil has the capacity to contribute to both of these
hallmarks. The overarching goal of this thesis was to investigate how the activation
and death of neutrophils can influence epigenetic pathways and promote inflammation.
1 Summary of findings
Increased neutrophil numbers in the blood and tumour tissue of patients with cutaneous
squamous cell carcinoma (CSCC) were associated with increased risk of metastasis and
death. The presence of neutrophil-associated and extracellular myeloperoxidase (MPO)
in the tumour infiltrate indicates the capacity for increased levels of oxidative stress in
the tumour microenvironment. The cell death pathways that result in MPO release,
in particular the release of neutrophil extracellular traps (NETs) that contain active
MPO, were explored.
TNF-α is an important inflammatory cytokine present in the tumour microenvi-
ronment and can have a range of effects on neutrophil lifespan. Upon exposure to
TNF-α, and in the presence of a SMAC mimetic and a caspase inhibitor, human neu-
trophils underwent MLKL-RIPK1 dependent necroptosis. MLKL inhibition impeded
the release of NETs triggered by P. aeruginosa, but not PMA. MLKL could, however,
be involved in the trafficking of extracellular vesicles in PMA-stimulated neutrophils,
as the extracellular release of HOCl and O ·–2 was reduced by its inhibition. Intra-
cellular HOCl production in P. aeruginosa-stimulated neutrophils was also reduced
by preventing phosphorylation of MLKL by inhibiting RIPK1, suggesting that MLKL
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could be involved in NADPH oxidase assembly at the phagosome. Furthermore, this
study highlighted a number of challenges associated with researching cell death in neu-
trophils, such as the use of flow cytometry to quantify necrotic neutrophils, non-specific
inhibitors of death pathways, and mouse models. All of these issues may contribute to
the conflicting literature in this field.
The impact of neutrophil-derived oxidants on the patterns of DNA methylation in
cancer cells was also assessed. Methylation arrays were examined in T-lymphoma cells
after exposure to hydrogen peroxide (H2O2) and glycine chloramine (GlyCl). Both ox-
idants were shown to interfere with the maintenance methylation of 5-methylcytosine
(5-mC) in the cells immediately after replication, consistent with their ability to in-
hibit DNA methyltransferase (DNMT) enzymes and/or deplete S -adenosyl methionine
(SAM) levels in the short-term. Many of the large methylation changes occurred at
CpG sites of genes involved in tumour-promoting pathways. The changes in methy-
lation patterns observed were largely corrected in subsequent cycles of cell division,
however, some smaller changes were conserved, and could potentially be amplified un-
der conditions of chronic inflammation.
Overall, this work provides evidence for a mechanistic links between neutrophils







































Figure 6.1: Graphical summary of main findings. The tumour microenvironment is made up of
blood vessels, immune infiltrate and a plethora of cytokines and signalling molecules. (A) Neutrophils
and/or granulocytic myeloid derived suppressor cells (PMN-MDSC) accumulate in the tumour tissue of
CSCC and are associated with markers of increased metastatic risk and high circulating populations of
neutrophils are associated with poor overall survival. MPO is present in CSCC tumours, both localised
to neutrophils but also in the extracellular space. (B) Neutrophils are likely to come into contact with
TNF-α secreted by tumours and macrophages, and can undergo necroptosis when IAPs and caspases
are inhibited. Neutrophil oxidants H2O2 and HOSCN can inhibit caspases and drive alternate death
pathways in neutrophils or surrounding cells. The necroptotic effector protein MLKL may be involved
in NET production by influencing oxidant production or release. Lytic neutrophils release tissue-
damaging oxidants and proteases, many of which can penetrate cancer cells and other immune cells
(C) Oxidants produced by neutrophils such as H2O2 and GlyCl can freely diffuse into cells and disrupt
the molecular machinery (DNA methyltransferase (DNMT) and/or S -adenosyl methionine (SAM))
involved in the methylation of DNA. Modification of methylation patterns, particularly in promotor
regions, can lead to the aberrant transcription of genes, and to altered cell behaviour, phenotype and
function. 210
2 Neutrophils as biomarkers of CSCC progression
Non-melanoma skin cancers, although rarely fatal in the general population, have been
associated with increased risk of all-cause mortality and in the case of CSCC, increased
risk of other malignancies [749; 156]. Not only is CSCC associated with eventual cancer-
specific death but has also been linked to mortality as a result of cardiovascular and
pulmonary diseases, acute infection and pneumonia, suggesting the involvement of
underlying immune dysfunction [750]. There is therefore much interest in discovering
accurate biomarkers to help in identifying the tumour and patient characteristics that
increase the risk of metastatic CSCC [155]. Some potential biomarkers have been
reported that are related to inflammation, but none are currently routinely used in a
clinical setting [751; 752].
The current study showed that circulating neutrophil counts or neutrophil to lym-
phocyte ratio were associated with poor outcomes, however, these findings were limited
by the size of the cohort and the number metastatic events. Obtaining a complete blood
cell count from patients with CSCC is a routinely available procedure that could pro-
vide important information about the immune cell populations in circulation in patients
that have poor outcomes due to CSCC-specific, or CSCC-related diseases. It would
be interesting to examine circulating immune cell populations in a much larger group
of CSCC patients, to potentially reveal an immune phenotype that could predispose
individuals to the progression of CSCC and/or secondary cancers.
The results of this chapter also showed that neutrophils in tumour tissue may be
associated with factors of increased metastatic risk, which is in agreement with the
only other study that has investigated the role of neutrophils in CSCC tumours [123].
The authors showed that MPO+ neutrophils could contribute to CSCC progression
through the production of Oncostatin M, a cytokine that promotes proliferation and
polarises circulating macrophages to a pro-tumoural phenotype. The current study
did not investigate cytokine production in the tumour tissue, but did demonstrate
that MPO positive neutrophils and extracellular MPO was present in all the tumour
samples regardless of the stage. MPO was not significantly associated with high-risk
tumour characteristics in CSCC, and therefore it remains unclear what role it plays
in cancer progression. MPO in tumour tissue has been associated with both good
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and poor outcomes in a range of other cancers and may depend on the cancer type
[119; 120; 73; 79].
While there has been much research into the negative effects of prolonged neutrophil
infiltration in cancer, fewer studies have explored ways in which neutrophil infiltrate
could be exploited or manipulated to improve patient outcomes. However, interest in
using neutrophils for nanoparticle drug delivery to tumours is starting to emerge, espe-
cially to areas of the body that are difficult to treat, such as the brain [753; 754; 755].
Several studies have investigated the use of MPO and its downstream oxidants to com-
plement chemotherapy treatment and activate prodrugs [756; 757]. Pertinently, some
topical treatments for precancerous skin lesions rely on a swift neutrophil-mediated
response. Ingenol-3-angelate (otherwise known as I3A, ingenol mebutate, PEP005 or
Picato), is a diterpene ester extracted from Euphorbia peplus or milkweed. I3A has
been approved in the United States and New Zealand for clinical use in a gel form as a
topical treatment for actinic keratoses (pre-cancerous skin lesions), and is currently in
clinical trials for use in cutaneous squamous cell carcinoma and basal cell carcinoma.
I3A differs from other anti-cancer drugs in that it has been shown to not only directly
kill tumour cells but also induce a strong inflammatory response, followed by rapid
healing, good cosmetic outcomes and low recurrence [758]. Furthermore, the ability
of I3A-primed immune cells to eradicate tumours in mice lacking T-cells implies that
lymphocytes are not key mediators in this process. I3A was shown to stimulate oxidant
production in neutrophils, and upon co-culture with a melanoma cell line, neutrophils
were able to kill cancer cells only after being stimulated with I3A [759]. Similarly
to PMA, I3A also targets protein kinase C, but at present the potential of this drug
as a stimulator of NET formation has not been assessed. It would be interesting to
determine if I3A could induce NET formation in neutrophils. Since MPO is found
on NETs and has been shown to be catalytically active [369], this could represent a
novel therapeutic approach involving stimulation of NET formation combined with a
cell impermeable pro-drug that can be oxidized by extracellular NET-bound MPO into
a cytotoxic agent.
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3 Neutrophil oxidants and tumour genomic insta-
bility
A major issue confronting cancer treatment is the acquired tumour resistance to cyto-
toxic chemotherapeutics and other targeted drugs [760]. Underlying this problem is the
genetic diversity frequently observed in tumours, that allows for the selection of cells
that express genes that confer a survival advantage which can circumvent treatment.
Although this genetic diversity is due in part to the mutational load of cancer cells,
there is also evidence that mutation alone cannot account for drug-resistance in all
cases [761]. The observations that tumour drug-resistance can be reversible and that
some drug-resistant tumours are not in fact mutated at the drug target site, suggest
that dynamic epigenetic modifications could be involved [762].
Several studies have now shown that epigenetic modifications facilitate drug-resistance
by silencing apoptotic genes, hindering DNA repair and influencing drug efflux activity
[763; 764; 765]. In light of this, drug therapy accompanied by epigenetic modulators
is an area of continued research. Pertinently, DNMT inhibitors have shown promise in
increasing drug response, with some already in clinical use [766; 767].
One of the main findings of this thesis was that not only did exposure to oxidants
influence the methylation patterns of Jurkat cells, but also influenced the variability
of methylation of the cell population. Numerous studies have highlighted that the
differential variability in methylation between cancer cells and normal tissue may be
equally important as the differential methylation in identifying cancer phenotypes and
predicting disease progression [768; 769; 770; 598]. It has also been proposed that the
differential variability at CpG sites between patients could enable groupings based on
the altered biological pathways that led to tumorigenesis due to specific mechanisms
[598]. This suggests that differential variability could provide an epigenetic signature
to enable the identification of cancers that occurred due to similar molecular events,
perhaps even certain environmental stimuli (such as oxidative stress). It would be
interesting to explore both differential methylation and variability in different cell types
exposed to H2O2 and GlyCl to see if similar patterns are observed. While the current
study showed that there were differences in methylation after oxidant exposure, some of
which were heritable, it is unclear if these changes resulted in the silencing or activation
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of transcription of those genes. Once these sites are validated with bisulfite amplicon
sequencing (BSAS), RNA sequencing could be used on the cell samples harvested at
the 24 and 48 hour time points to determine if the methylation changes observed had
an impact on gene expression.
The current study shows that neutrophil oxidants can impact methylation patterns
in lymphoma cells but it remains to be shown if they could also influence the cells of the
tumour immune contexture in a similar way. The engagement of the adaptive immune
system in the tumour remains the strongest predictor of good outcomes in many can-
cer types [145; 146; 147]. Previous research from our laboratory has shown that H2O2
from activated neutrophils inhibits proliferation and contributes to T-lymphocyte death
[134]. Since H2O2 inactivates neutrophil caspases, it is possible that H2O2 released from
neutrophils also inactivates caspases in lymphocytes. Lymphocytes require caspase ac-
tivation for proliferation [771; 772], and their inhibition could block T-lymphocyte
death by apoptosis and steer the cells towards alternate forms of cell death. Therefore,
inhibition of caspases by neutrophil oxidants could represent another way in which
neutrophil oxidants could promote cancer progression. It would be interesting to co-
culture lymphocytes with activated neutrophils, NETs or individual oxidants and then
expose them to apoptotic stimuli and determine the mode of death. In parallel, the
lymphocytes could be stimulated to proliferate after treatment and changes in methy-
lation patterns could be assessed, to see if neutrophil oxidants could promote altered
methylation, gene expression and phenotype in T-lymphocytes.
4 Implications of neutrophil cell death in cancer
and inflammatory disease
Dying neutrophils, particularly NETs in the context of cancer and inflammatory dis-
ease are currently a subject of significant interest. There is mounting evidence that
dead neutrophils, particularly neutrophils that have released NETs, can sequester can-
cer cells and deliver them to distal sites, particularly the liver and the lung [773; 384].
Additionally, preliminary studies in patients with coronavirus disease 2019 (COVID-
19), have shown that high neutrophil infiltrate [774] and high neutrophil to lymphocyte
ratio (NLR)[775] are accurate markers of patients who succumb to infection. Moreover,
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it has been proposed that NET release is a key driver of the organ damage and dispro-
portionate systemic inflammation that defines the poor prognosis associated with this
novel disease [377]. Now more than ever, studies aimed at untangling the molecular
pathways involved in neutrophil death are urgently required.
The field of NET release is burgeoning, with many new mechanisms and stimuli
regularly emerging. However, there are many fundamental aspects of NET research
that remain undefined, and have lead to much confusion in the field. A recent review
presented the current opinions of expert researchers in the NET field and summarised
the areas of consensus and controversy [776]. Experts generally agree that NETs are
involved in immune defense and inflammation and that there is a need for standard-
ization in NET research. Areas where there was less consensus included, the source of
NETs (nuclear or mitochondrial), demarcation of NETs from other forms of cell death
and that NET formation involves multiple pathways [776]. NET-related research is
also challenging with respect to the materials and methods used. Many widely used
methods such as anti-coagulants in the extraction process, type and content of buffers
and culture media, purity of neutrophils as well as the pH balance of the assay have
all been shown to influence NET formation [655; 777; 778; 779]. Furthermore, there
is evidence that NET release may be involved the neutrophil tissue response called
“swarming”, which involves highly coordinated neutrophil chemotaxis, accumulation
and intracellular communication at sites of infection or inflammation [780; 781]. This
suggests that the concentration of neutrophils used in NET formation assays may also
have a bearing on experimental results. These issues were reflected in the range of
methodologies used between the reports that have investigated the role of necroptosis
pathway in NET formation [420; 421; 423]. These studies all differed on the timing and
quantification of NET release, as well as the concentration of neutrophils used, con-
stitution of plating surfaces and isolation techniques. The methods used in this thesis
to investigate NET release have also been used in the current literature, and would
likewise be subject to scrutiny for the same reasons discussed here. In future work, the
use of markers of granule proteins and citrullinated histones on extruded DNA will be
helpful to distinguish NETs between other forms of lytic death.
It remains unresolved as to whether necroptosis and NETosis share the same molec-
ular pathway. The current study showed that human neutrophils have the machinery
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to undergo cell death in vitro in response to the canonical necroptosis stimuli, which
was reversed by the most widely used inhibitors of this process. Although MLKL in-
hibition appeared to have a role in P. aeruginosa-induced NET release, it is difficult
make definitive conclusions.
Given the importance of NOX2-derived oxidants in NET release, it will be im-
portant to explore the impact of oxidants in greater detail when investigating overlap
between necroptosis and NET release pathways. The requirement of oxidants in the
execution of necroptosis has been demonstrated in some cell types, mainly by showing
that cell death could be avoided through the use of oxidant scavengers [236]. The
finding in the current study that the inhibition of the NADPH oxidase did not block
TNF-α induced cell death, indicates that if oxidants are essential in conventional neu-
trophil necroptosis, then they would be derived from other sources. In other cell types,
RIPK1 has demonstrated sensitivity to oxidation, as exposure to mitochondrial oxi-
dants stimulates its autophosphorylation [236]. MLKL is also sensitive to the redox
status of the cell as the reductant thioredoxin-1 (Trx1) prevents MLKL oligomer for-
mation under normal conditions [268]. One report has shown that a positive feedback
loop exists between cellular oxidant production and necrosome stabilisation [782]. Since
neutrophils have relatively few and arguably re-purposed mitochondria (evidenced by
low expression and alternative functionalities of cytochrome c), it remains unclear how
oxidants contribute to TNF-α-induced necroptosis in neutrophils. Low-level exposure
to the neutrophil oxidant HOSCN has been shown to block apoptosis in endothelial
cells, an effect that was dependent on the timing and duration of exposure [634]. It
could be that necroptosis protein activities operate at an optimal threshold of oxida-
tion, and the location and intensity of the oxidants produced by the NADPH oxidase
could dictate their involvement in the NET pathway. NOX2 activity was essential for
NET release in PMA stimulated neutrophils as DPI effectively abrogated NET release.
However, DPI was less effective at reducing NET formation in P. aeruginosa perhaps
indicating involvement from other pathways. Many questions remain about the alter-
nate activation pathways and functionalities of MLKL, and further research is required
particularly with regard to its role in endosomal protein and vesicle trafficking and how
these functionalities could impact its role in cell death.
The study of cell death is complex, and improved methodologies will greatly enhance
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research outcomes. Neutrophils are notoriously difficult to work with in the laboratory
due to their propensity to activate, and the reactive nature of their cell contents that
include high levels of proteases. Because neutrophils are terminally differentiated and
have low transcriptional activity, conventional molecular approaches to knockout spe-
cific proteins are not applicable to this cell type and the use of mouse models also has
considerable drawbacks. Interestingly, while many studies have used flow cytometry
to quantify necrotic death in the past, more recent reports have preferred the use of
the lactate dehydrogenase assay (LDH) [224; 419; 412; 415], indicating that others may
have encountered similar difficulties in quantifying death in significantly membrane
compromised cells.
5 Conclusions
Neutrophils appear to have a role in cancer development and progression through their
ability to promote oxidative stress and influence the function of neighbouring cells.
However, the mechanisms behind this involvement still requires more research. The
work in this thesis has shown, that neutrophil numbers are associated with high-risk
features and overall survival in CSCC, a common form of cancer with a strong links
to immune dysregulation. Neutrophils can undergo the pro-inflammatory cell death
necroptosis in response to stimuli likely encountered in the tumour microenvironment,
and oxidants produced by activated neutrophils were shown to modulate the epigenome
of proliferating T-lymphoma cells which could contribute to the non-genomic hetero-
geneity of cancer cells that is so detrimental to the development of cancer therapies.
Taken together, this work adds to the current understanding of neutrophils in can-
cer and at inflammatory sites and highlights the need for further research into the





Independent assessment of data
variability in the pre-replication
phase GlyCl exposure dataset
1 Introduction
Chapter 5 explored the effect of exposure to Glycine Chloramine (GlyCl) on DNA
methylation patterns in Jurkat cells. Synchronised Jurkat cells were treated with a
single bolus of GlyCl (200µM) during the pre-replication phase (immediately after
release from thymidine block). DNA extracted from either GlyCl treated cells or control
at 4 and 72 hours post synchronization release were bisulfite converted and sent for
analysis of DNA methylation profiles using the Illumina Infinium MethylationEPIC
850K array from 4 independent experiments.
The genomic service provider (AgResearch) advised that two samples demonstrated
an abnormal fluorescent profile and low data quality.
In order to determine how the inclusion of these samples would influence the results,
an independent assessment of data variability was undertaken. The results of these
assessments and the resulting conclusions are presented in the following sections.
2 Results
2.1 Quality control
The data processed from the array was first evaluated for signal quality. This is assessed
by calculating a detection p-value for each probe in the dataset. The detection p-value
is equal to the sum of the methylated signal and the unmethylated signal compared
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to the negative control signal. The smaller the p-value, the more accurate the signal.
CpG sites containing detection p-values >0.05 for 1% or more samples, were to be
excluded from further analysis.
However, all the samples in the initial dataset passed quality control.
2.2 Density plots and normalisation
In order to reduce technical variation between and within samples, the Subset-quantile
Within Array Normalisation (SWAN) method was applied to the dataset. Normalisa-
tion is required because the Illumina Infinium MethylationEPIC 850K array uses two
different probe types, which exhibit large differences in their β value distributions [658].
When the normalised density plots of the initial dataset were plotted, two of the
samples did not align with the rest of the samples. The raw and normalised dataset
density plots are presented in Figure A.1.
A
B
Figure A.1: Assessment of raw versus normalized β-values and M-values for the
GlyCl pre-replication phase initial dataset. Control samples are represented in dark
grey and treatment samples are represented in light grey. The bump observed at 50%
methylation is characteristic of Jurkat cells, which have a highly duplicated genome.(A) Raw
data density plot (B) Normalised data density plot
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2.2.1 Unsupervised assessment of data variability and average relative
methylation analyses of the initial dataset
Principal component analysis showed distinct clustering of the 4 hour treatment group,
and the majority of both treatment and controls from the 4 and 72 hour replicates
clustering together. However, two outliers clustering separately from all other groups
were also observed (circled in red in Figure A.2A). These outliers corresponded to a
control and a treatment sample from the 4 hour time point from the same replicate.
Hierarchical clustering analysis also isolated these outliers in one branch, but also
clustered the 4 hour treatment group separately from the rest of the samples. All other
treatment and controls from each time point across replicates grouped together (Figure
A.2B).
A B
Figure A.2: Unsupervised assessment of data variability in pre-replication-phase
GlyCl exposure cells compared to controls. (A) Multidimensional scaling of β-values,
with the distances for leading Log2FC in dimension 1 represented on the x axis and the leading
Log2FC in dimension 2 are represented on the y-axis. Dots represent the control group, and
triangles represent the treatment group. Samples are coloured according to the replicate
(four in total), where cells from each replicate originated from the same stock. Outliers are
circled in red.(B) Hierarchical clustering of β-values for all CpG sites. The relative change
in β-values is represented on the y-axis and individual samples are represented on the x-axis.
Samples are coloured according to the replicate (four in total), where cells from each replicate
originated from the same stock.
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Plotting the individual probe-wise comparisons of significance versus effect size
change, demonstrated that multiple CpG sites from the 4 hour time point displayed a
significant Log2FC greater than 1. However, there was a reduction in the effect size
and significance at the 72 hour time point compared to the 4 hour time point (Figure
A.3A & B).
There was a significant change in average relative methylation observed at the 4
hour time point (p = 0.01), t(4) = -4.1) but not at the 72 hour time point (p = 0.96),
t(5) = 0.05)(Figures A.3C).
The number of CpGs that demonstrated differential methylation (DMP) in the
treatment group compared to control were next assessed. At the 4 hour time point,
the treatment group demonstrated an increase in differential methylation at 13769













Figure A.3: Analysis of average relative DNA methylation change and probe-wise
variability in the pre-replication-phase GlyCl exposure cells initial dataset (A) Vol-
cano plot displaying log fold changes on the x-axis versus a measure of statistical significance
on the y-axis log10(p-value) for the 4 hour time point (B) Volcano plot displaying log fold
changes on the x-axis versus a measure of statistical significance on the y-axis log10(p-value)
for the 72 hour time point.(C) Mean methylation levels in each group. Mean methylation
levels for β-values are presented as percentages on the y-axis, and each group is represented
on x-axis. (D) Summary table of the differentially methylated probes (DMPs) and the direc-
tion of their change at the 4 and 72 hour time points
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2.3 Unsupervised assessment of data variability and average
relative methylation analyses with outliers excluded (re-
duced dataset)
Figure A.2A highlighted the presence of two large outliers in the dataset which cor-
responded to the samples signaled by the genomic service provider (AgResearch) as
having low data quality. Therefore, the dataset was analysed with these two samples
excluded and is referred to as the “reduced” GlyCl dataset.
Both the PCA plot and the hierarchical clustering analysis demonstrated the 4 hour
treatment group clustered separately from the rest of the samples.
A B
Figure A.4: Unsupervised assessment of data variability in pre-replication-phase
GlyCl exposure cells compared to controls “reduced” dataset. (A) Combined re-
duced dataset with the S-phase dataset. Multidimensional scaling of β-values, with the dis-
tances for leading Log2FC in dimension 1 represented on the x axis and the leading Log2FC
in dimension 2 are represented on the y-axis. Dots represent the pre-replicaion phase group,
and triangles represent the S-phase exposure group. Samples are coloured according to the
replicate, where cells from each replicate originated from the same stock.(B) Hierarchical
clustering of β-values for all CpG sites. The relative change in β-values is represented on the
y-axis and individual samples are represented on the x-axis. Samples are coloured according
to the replicate, where cells from each replicate originated from the same stock.
Probe-wise comparisons of significance versus effect size change, demonstrated that
many CpG sites from the reduced GlyCl dataset displayed significant Log2FC greater
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than 1 at 4 the hour time point (Figure A.5A), with significantly increased -log10(p-
values) compared to the initial dataset (Figure A.3A). The reduced dataset displayed
a similar trend to the initial dataset, in that there was a reduction in the effect size
and significance at the 72 hour time point (Figure A.5B).
There was a significant average relative methylation change observed at the 4 hour
time point (p = 0.002), t(4) = -4.1) but not at the 72 hour time point (p = 0.96))(Figure
A.5C).
In contrast to the initial dataset, the reduced dataset did show significant differen-
tially methylated CpG sites (DMP) at both the 4 hour and the 72 hour time points
(Figure A.5D). At the 4 hour time point, 75848 DMPs demonstrated a significant
increase in methylation in the treatment group compared to the control, and 98782
demonstrated a significant decrease. At the 72 hour time point, there were 20 differ-
entially methylated CpG sites with 5 showing decreased methylation and 15 showing
increases (Figure A.5D). Nine of the differentially methylated CpG sites were common













Figure A.5: Analysis of average relative DNA methylation and probe-wise vari-
ability in the pre-replication-phase GlyCl exposure reduced dataset (A) Volcano
plot of the 4 hour time point displaying log fold changes on the x-axis versus a measure of
statistical significance on the y-axis -log10(p-value) (B) Volcano plot of the 72 hour time point
displaying log fold changes on the x-axis versus a measure of statistical significance on the
y-axis -log10(p-value) (C) Mean methylation levels in each group. Mean methylation levels
for β-values are presented as percentages on the y-axis, and each group is represented on
x-axis. (D) Summary table of the differentially methylated probes (DMPs) and the direction
of their change at the 4 and 72 hour time points
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2.4 Data assessment with replicate four removed (final dataset)
In order to enable further paired analyses between the 4 hour and 72 hour time points
within replicates, and since both outliers were from the same replicate, the entire repli-
cate (replicate four) was removed from the dataset.
This dataset (the final dataset) was used for all subsequent analyses in Chapter 5.
At the 4 hour time point, the final GlyCl dataset had a largely equivalent number of
significant differentially methylated CpG sites compared to the reduced GlyCl dataset.
There was however, a small loss of power with removing the entire replicate four,
which was most noticeable at the 72 hour time point where significant differentially
methylated CpG sites dropped from 20 to 10 (Table A.1). Furthermore, only 5 of the
10 CpG sites were the same as the reduced dataset and the order of their significance
had changed.
Table A.1: Summary table of top most significant differentially methylated probes at the 4
and 72 hour time points for final GlyCl pre-replication phase exposure compared to reduced
GlyCl pre-replication phase exposure.
Pre-rep final Pre-rep red.
Direction of change 4 hr 72 hr 4 hr 72 hr
Decreased 92665 4 98782 5
Increased 66403 6 75848 15
3 Discussion
This independent assessment of the data variability in the pre-replication phase GlyCl
exposure dataset aimed to determine if the inclusion of samples that were identified as
abnormal by the genomic service provider should be included in the final analysis.
Although all the samples passed quality control, the normalised density plots demon-
strated the presence of two samples which were substantial outliers. These samples
corresponded to a treatment and control from the 4 hour time point from the same
replicate. Furthermore, the PCA plot and hierarchical clustering of the initial dataset
confirmed the existence of two outliers clustering distinctly from the other samples.
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There was a significant difference in average relative methylation at the 4 hour time
point which was reversed at 72 hours. Probe-wise comparison showed that there were
large fold changes in the treatment group compared to control at 4 hours which de-
creased substantially at 72 hours. There were several differentially methylated CpG
sites at 4 hours and none at 72 hours.
When the two outliers were removed from the initial dataset, the PCA plot and
hierarchical clustering analyses were both successful at grouping the 4 hour treatment
group separately from the other samples. The reduced dataset demonstrated a similar
trend to the initial dataset in that there was a significant average relative methylation
change at 4 hours and not at 72 hours. Furthermore, the probe-wise analysis showed
that there were large fold changes in the treatment group compared to control at 4
hours which decreased at 72 hours, however, there was a substantial increase in power
compared to the reduced dataset analysis. There were many differentially methylated
CpGs at the 4 hour time point, but there were also several significant differentially
methylated CpG sites at the 72 hour time point (which were not observed in the initial
dataset).
When the entire replicate was removed, the analyses of the data variation in the
final dataset were largely equivalent to the reduced dataset analyses with the exception
of a decrease in the number of significant differentially methylated CpG sites at the 72
hour time point.
In conclusion, it was determined that the inclusion of the two outlier samples in-
troduced substantial variation in the dataset and was biasing the results. The samples
were removed from the analysis because the origin of this variation was not biologically
meaningful, but rather it was derived from variability in the bead chip array. The
source of this technical variation was likely the result of low or inaccurate DNA yields.
For simplicity, and to allow for a balanced statistical analysis with paired samples, the
entire replicate was therefore removed.
Furthermore, the removal of this replicate did not impact the overall conclusions of










Figure B.1: Representative cell cycle analysis at major time points for GlyCl S-phase
treated Jurkat cells. Flow cytometry cell cycle analysis shows the DNA content on the x-axis and
the number of cells on the y-axis. Post thymidine block, the cells in the stock flask showed minimal
cells in S-phase and G2/M. There was no major difference between treatment and control at 4 hours
post release, but at 24 hours the control cells had completed cell division while the treatment cells
were just starting to divide. At 48 hours, both treatment and control cells appeared to recover from
the block and by 72 hours, the distribution of cells in each phase of the cell cycle was consistent with








Figure B.2: Representative cell cycle analysis at major time points for GlyCl pre-
replication phase treated Jurkat cells. Flow cytometry cell cycle analysis shows the DNA content
on the x-axis and the number of cells on the y-axis. Post thymidine block the cells in the stock flask
showed minimal cells in S-phase and G2/M. There was no major difference between treatment and
control at 4 hours post release, but at 24 hours the control cells had completed cell division while the
treatment cells were just starting to divide. At 48 hours, both treatment and control cells appeared
to recover from the block and by 72 hours, the distribution of cells in each phase of the cell cycle was
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Nanoparticles size-dependently initiate self-limiting NETosis-driven inflamma-
tion. Proceedings of the National Academy of Sciences of the United States
of America. 2016;113(40):E5856–E5865.
[375] Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Neutrophil extracellular
traps license macrophages for cytokine production in atherosclerosis. Science.
2015;349(6245):316–320.
[376] Berger-Achituv S, Brinkmann V, Abed UA, Kühn LI, Ben-Ezra J, Elhasid R,
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et al. Dynamics of Dnmt1 interaction with the replication machinery and its role
in postreplicative maintenance of DNA methylation. Nucleic Acids Research.
2007;35(13):4301–4312.
[466] Hashimoto H, Horton JR, Zhang X, Bostick M, Jacobsen SE, Cheng X. The
SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature.
2008;455(7214):826–829.
[467] Avvakumov GV, Walker JR, Xue S, Li Y, Duan S, Bronner C, et al. Structural
basis for recognition of hemi-methylated DNA by the SRA domain of human
UHRF1. Nature. 2008;455(7214):822–825.
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[508] Sánchez-Góngora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM. Inter-
action of liver methionine adenosyltransferase with hydroxyl radical. The FASEB
Journal. 1997;11(12):1013–1019.
[509] Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid
cells and reactive oxygen species in regulation of tumor microenviron-
ment. Clinical cancer research : an official journal of the American
Association for Cancer Research. 2012 sep;18(18):4877–82. Available
from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
3445728{\&}tool=pmcentrez{\&}rendertype=abstract.
[510] Sanchez-Gongora E, Mato JM, Farber JL. Increased sensitivity to oxida-
tive injury in Chinese hamster ovary cells stably transfected with rat liver S-
adenosylmethionine synthetase cDNA. Biochem J. 1996;773(319):767–773.
[511] Alvarez L, Corrales F, Martin-Duce A, Mato JM. Characterization of a full-
length cDNA encoding human liver S-adenosylmethionine synthetase: Tissue-
specific gene expression and mRNA levels in hepatopathies. Biochemical Journal.
1993;293(2):481–486.
[512] Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models:
Implications for early intervention in human beings. In: Alcohol. vol. 27; 2002.
p. 173–177.
289
[513] Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, et al. Hypoxia induces ge-
nomic DNA demethylation through the activation of HIF-1α and transcriptional
upregulation of MAT2A in hepatoma cells. Molecular Cancer Therapeutics.
2011;10(6):1113–1123.
[514] Lu SC, Huang ZZ, Yang H, Mato JM, Avila MA, Tsukamoto H. Changes in me-
thionine adenosyltransferase and S-adenosylmethionine homeostasis in alcoholic
rat liver. American Journal of Physiology - Gastrointestinal and Liver Physiology.
2000;279(1 42-1):178–185.
[515] Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, et al.
Recognition and potential mechanisms for replication and erasure of cytosine
hydroxymethylation. Nucleic Acids Research. 2012;40(11):4841–4849.
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